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ABSTRACT 
Propolis is a traditional value-added product from beekeeping, and bas been widely used in medicine and 
the chemical industry because of its extensive biological activities. In this dissertation some pharmacological 
properties of propolis extracted by ethanol (EEP) and water (WSP) were studied by means of modem 
pharmacological methods. The results of the experiments show the following: 
1. Both EEP and WSD led to decreased levels of fasting blood glucose (FBG), glycosylated 
haemoglobin (HBAlc), Fructosamine (FRU), blood urea nitrogen (BUN), uric acid (UA), 
malonaldehyde (MDA), nitric oxide (NO), nitric oxide synthetase (NOS), total cholesterol (TC), 
triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and very-low density lipoprotein 
cholesterol (VLDL-C) in the serum of fasting rats; and, to increased serum levels of high-density 
lipoprotein cholesterol (HDL-C) and superoxide dismutase (SOD) in rats with diabetes mellitus. This 
suggests that propolis can control blood glucose and modulate the metabolism of glucose, blood lipid 
and protein, leading to decreased outputs of lipid peroxidation and scavenging free radicals in rats with 
diabetes mellitus. 
2. Both EEP and WSD showed inhibitory effects on swelling induced by Freund's complete 
adjuvant and decreased the degree of local inflammatory responses; significantly inhibited the increase 
of interleukin-6 (lL-6) in inflamed tissues, but had no significant effect on levels of interleukin-2 (IL-2) 
and interferon-y (IFN-y). The results are consistent with the interpretation that EEP and WSD may exert 
these effects by inhibiting the activation and differentiation of mononuclear macrophages. 
3. Both EEP and WSD exhibited significant anti-inflammatory effects in animal models with 
respect to thoracic capillary vessel leakage in mice, Carrageenan-induced oedema, Carrageenan-
induced pleurisy and acute lung damage in rats. The mechanisms for the anti-inflammatory effects 
probably involve decreasing prostaglandin and NO levels. 
4. Both EEP and WSD had an inhibitory effect on the level of TG, TC, LDL-C, glutamic-pyruvic 
transaminase (GPT) and glutamic-oxalacetic transaminase (GOT) in serum, and TC, TG and MDA in liver 
of hyperlipidemic SD rats; but were without effects on HDL-C, MDA, SOD and NO in serum. EEP also 
reduced body weight, liver weight and liver index, but WSD did not reduce those indexes. The results 
showed that the two extracts contribute to the improvement of lipid metabolism in hyperlipidemic rats and 
provide them with the required anti-oxidative activity. 
5. The 80% ethanol extracts of propolis had the highest flavonoid content. The flavone content of 
water extracts of propolis were obtained with a natural surface-active agent, under ultrasonic 
perturbation at 80·C, for 12 h and was 6.7 times greater than that of propolis extracted with water at 
room temperature. Compared to EEP, WSD has the same or a greater anti-tumor or anti-inflammation 
effect at the same dosage, and shows considerable pharmacological potential especially because of its 
low side effects and ease of preparation. 
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CHAPTERl 
1. INTRODUCTION 
1.1 The chemistry and plant origins of propolis 
Propolis is a resinous material that honeybees (Apis melli/era L.) collect from various plants, 
and mix with wax and other secretions. Propolis has been widely used in medicine and the 
chemical industry because of its extensive biological activities, including anti-bacterial, 
anti-ftmgal, anti-viral, anti-protozoan, anti-inflammatory, anti-ulcer, anti-tumor, hepatoprotective, 
local anaesthetic, immunomodulation and free radical scavenging properties (Ghisalberti, 1978; 
Marcucci, 1995; Marcucci et al., 2001; Basnet et al., 2002). Unlike traditional Chinese herbal 
medicines, the components of propolis significantly differ from source to source and this is 
reflected in their biological activities. Thus it is necessary to study the chemical composition of 
propolis in relation to plant sources to provide a foundation for the standardization of propolis. 
1.1.1 Plant sources of propolis 
The issue about plant sources and the formation of propolis has long been a matter of 
scientific debate. Meyer (1956) recorded the whole process of bee collecting and 
processing propolis in detail by camera, which provided proof for some of the sources and 
formation of propolis. 
Botanical sources of propolis in temperate areas such as Europe, North America and 
North Africa are mainly Populus species and their hybrids; in New Zealand, introduced 
poplar species are the main source; in Australia however the main botanical source is 
Xanthorrhoea spp., in South America Clusia major and Clusia minor, and in Asia the 
botanical sources of propolis are poplar (Populus), birch (Betula), elm (Ulmus), alder 
(Alnus), beech (Fagus), conifers and the horse-chestnut (Aesculus). Botanical sources of 
propolis in the world are shown in table 1.1 (Burdock, 1998). 
Table 1.1 Botanical sources of propolis in the world 
Genus and species Geographic location 
Populus nigra, P. italica, P. tremula Belgium 
Populus nigra Albania 
Populus suaveolens Mongolia 
America (mainland, Hawaiian 
Populus euramericana, P. cuminata, P. aculi/olia 
islands) 
Populus euramericana England 
Betula, Populus, Pinus, Prunus and Acacia spp. 
Hungary 
Aesculus hypocastane 
Betula, Alnus spp. Poland 
Delchampia spp., Clusia major Tropical zone areas 
Clusia spp. Venezuela 
Xanthorrhoea Australia 
Populus, Betula, Ulmus, Alnus, Fagus, Aesculus, 
North temperate zone, 
conifers 
1.1.2 Studies on the history of the chemical composition of propolis 
Studies on the composition of propolis began in Germany, when Kustenmacher (I 911) 
identified cinnamic acid and cinnamon. Limited by the then available methods of analysis, 
few components of propolis were identified for a long time. After the 1950s', with the 
development of analytical methods such as TLC, HPLC and GC, more and more 
2 
components of propolis were identifed. Ghisalberti (1978) published the first review on 
propolis, which included more than 200 components of propolis, and more compounds are 
reported every year. The new components reported in recent years are shown in table 1.2. 
Table 1.2 Recently identified components of propolis 
Source of 
Composition of propolis References 
propolis 
3-caffeoylquinic acid; 4-caffeoylquinic acid; 
5-caffeoylquinic acid; 3,5-dicaffeoylquinic acid; 
3,4-dicaffeoylquinic acid; 4,5-dicaffeoylquinic acid methyl ester; 
Tatefuji et aI., 1996 
3,4-dicaffeoylquinic acid methyl ester; 
3-[ 4-hydroxy-3-(3-oxobut-l-enyl)-phenyl]acrylic acid; 
(+ )-treo-l-C-quayacylglycerol 
Flavonoid: 
5,7,4' -trihydroxy-6,8-dimethoxyflavone; 
5,6,7 - trihydroxy-3,4'-dihymethoxyflavone; 
Brazil aromadendrine-4'-methyl ether; 
3,5,7 -trihydroxy-6,4' -dimethoxyflavone 
Acetophenonederivatives: 
2-[ I-methyl]-vinyl-5-acetylcumarane; 
Bankova et al., 1998 
2-[ l-hydroxymethyl]-vinyl-6-acetyl-5 -hydroxycumarane; 
2-[ I-acetoxymethly ]-vinyl-6-acetyl-5-hydroxycumarane 
Diterpeneic acid: 
8(17), 13E-labdadien-15, 19-dioic acid; 
8(17), 13E-labdadien-15, 19-dioci acid-15-methyl ester; 
19-oxo-8(17), 13E-labdadien-15-oic acid; 
13-hydroxy-8(17),14-labdadien-19-oic acid 
3 
Brazil Prenylated p-coumaric acid: 
3,5-diprenyl-4-hydroxycinnamic acid; 
3-prenyl-4-dihydro-cinnamoyloxycinnamic acid; 
2,2-dimethyl-6-carboxyethenyl-2-2H -I-benzopyra; 
9-E-2-dimethyl-6-carboxyethenyl-8-prenyl-2H-I-benzopyran; 
3-prenyl-4-(2-methoxypropionyl)-cinnamic acid; 
(E)-3-[2,3-2H-2-( l-hydroxy-I-methylethyl)-prenyl-benzofuran-5-yl]-
2-propenoic acid 
Sonoran Desert Flavonoid: 5,7,4'-trihydroxy-6,8-dimethoxy flavone; sideritiflavone 
Tunisia 
Chile 
Canary Islands 
Myricetin 3,7,4',5'-tetramethyl ether; 
quercetin3,7,3'-trimethyl ether 
1-( 4-hydrox y-3 -methox yphen yl) I ,2-bis[ 4-[ (E)-3 -acetox ypropen-I 
-yl]-2 -methoxyphenoxy-]-propan-3-ol; 
1-( 4-hydroxy-3-methoxyphenyl)-2-[ 4-[(E)-3-acetoxypropen-I-yl]-
2- methoxyphenoxy] propan-I ,3-diol-3-acetate; 
3 -acetoxymethyl-5 -[ (E)-2-formylethen -1-yl]-2-( 4-hydroxy-3 -meth 
oxyphenyl)-7 -methoxy-2,3 -dihydrobenzofuran 
Ent-17 -hydroxy-3, 13Z-clerodadien-15-oic acid; communic acid; 
I 5-oxo-3,13Z-kolavadiene-17-oic acid and its E-isomer; 
imbricatoloic acid; isocupressic acid; acetylisocupressic acid 
Furofuran Jignas: 
sesamin; aschantin; sesartenin; yangambin 
Sesquiterpenes: 
ledol; spatulenol; germacrene 
Sugars and sugar alcohols: 
melibiose; maltose; galactose; gluuronic acid; lactose; 
xylitol; mannose; erytritol; xylose; inositol 
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Boudourova-Krasteva 
et al., 1997 
Wollenweber & 
Buchmann, 1997 
Valcic el aI., 1998 
Bankova et ai., 
1996, 1998 
1.1.3 Local differences in the chemical composition of propolis 
The chemical composition of propolis is very complex and depends on the flora in the 
areas where it is collected. The composition of propolis in Europe, North America, South 
America, and Asia is different, and these are related to the local climate and botanical 
sources. The precise composition of raw propolis varies with the source. In general, it is 
composed of 50% resin and vegetable balsam, 30% wax, 10% essential and aromatic oils, 
5% pollen and 5% various other substances including organic debris. Propolis has been 
widely used in folk medicine, the food and chemical industries of Asia because of its 
extensive biological proper ties. 
In the temperate zone, including Europe, Asia and North America, the composition of 
propolis samples originating from these regions are characterized by similar chemical 
composition, the main constituents being phenolics: flavonoid aglycones, aromatic acids 
and their esters. Samples originating from tropical areas are quite different. 
Markham et al. (1996) identified in samples from New Zealand the unusual "poplar" 
phenolics, together with two new compounds: 5-phenyl-trans, trans-2, 4-penadienoic acid 
and 5-phenyl-trans-pentenoic acid. In a sample from Egypt, along with poplar bud 
constituents, esters of caffeic acid with long-chain fatty alcohols (dodecanol, tetradecanol, 
tetradecenol and hexadecanol) were identified (Christov et al., 1998). Marcucci et al. (1998) 
identified triterpenes, il -amyrin and cycloartenol in samples from Egypt. 
In South America, the chemical composition of propolis is significantly different from 
other continents. Propolis samples with new chemical components having important 
biological properties have been found in recent years especially in Brazil. The new 
chemical components that have been recently identified are shown in table 1.2. 
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1.2 The biological properties and toxic allergic reactions 
1.2.1 Biological activity of propolis 
Propolis has extensive biological activity and has anti-oxidative, anti-viral and 
anti-bacterial properties. It can also be used to scavenge free radicals, improve immunity, 
and ameliorate afflictions such as colds and sore throats, skin problems, stomach ulcers, 
burns, hemorrhoids, gum diseases, wounds, tumors and diabetes mellitus (Burdock, 1998). 
1.2.1.1 Anti-tumor activity of propolis 
There are some components of propolis, which have cytotoxic and chemopreventive 
effects including artepillin C, clerodane diterpenoids, propolis benzofuranes, and other yet 
to be defined methanol-, ethanol- and water extracts (Banskota et al., 2000a). Specifically, 
caffeic acid phenethyl ester (CAPE) may be involved in restoring intercellular gap junction 
communication, induction of natural cell death (apoptosis), growth inhibition, and exerting 
a cytotoxic effect on malign tissues. CAPE can ameliorate inflammation caused by the 
tumour-promoter (12-0-tetradecanoylphorbol-13-aacetate), indicating that CAPE may be 
acting by interfering with the oxidative capacities of the cells rather than by being 
anti-oxidants (Jeng et al., 2000). 
Animal studies showed that CAPE, artepillin C, and the clerodane diterpenoid 
prevented cancers of the breast, skin, kidney, and the colon (Mitamura et al., 1996; Kimoto 
et ai., 1998, 2000). In addition, studies have shown that a combination of propolis and a 
chemotherapeutic drug (blemoycin) showed no synergistic effects. On the contrary, 
propolis reduced the activity of bleomycin (Scheller et ai., 1989). 
Ghazaly and Khayyal (1995) found that aqueous and ethanol extracts of propolis 
prevent radiation-induced damage during treatment by preventing inflammatory responses 
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such as edema. Velikov and Zanev (1989) showed that the application of ethanol-extracts 
of propolis minimized the probability of treatment delays due to side effects of radiation of 
the pharynx, and is thus believed to reduce the probability of metastasis and relapse 
(Velikov & Zanev, 1989). The origins and methods of preparation of propolis are very 
important. Kawabe et at. (2000) reported that propolis from Uruguay was found to be an 
inhibitor of mammary gland carcinogenesis in comparison to water-extracted propolis and 
water- and ethanol-extracted propolis from Brazil (Kawabe et al., 2000). 
The activation of all chemical carcinogens relies on cytochrome 450 in the body. 
Studies have shown that quercetin (one of the flavonoids) can inhibit the activity of 
cytochrome 450. Besides these, some flavonoids can inhibit the growth of tumor cells, 
antagonize carcinogens or modulate the enzyme system to inhibit chemical toxicity and 
carcinogenicity. The enzymes of flavonoids include hydro lases and alkaline phosphatase. 
Propolis has exhibited similar effects inhibiting glycosyltransferases of cariogenic 
Streptococci, myeloperoxidase activity of inflammation, ornithine decarboxylase, 
lipooxygenase, tyrosine protein kinase and arachidonic acid metabolism (Havsteen, 1983) . 
1.2.1.2 Anti-oxidative activity of propolis 
Propolis has little effect on benign tissue and has a protective effect because of its 
anti-oxidative properties (Matsuno et al., 1997). Some metabolic oxygen is converted to 
peroxides, superoxide anions and hydroxide free radicals during oxidation reactions with 
age and growth. The accumulation of the products of oxidation such as active oxygen and 
free radicals are positively associated with ageing. Besides these, the reaction of active 
oxygen and unsaturated fatty acids produce over-oxidation lipidemia and protein, and 
over-oxidation lipidemia is the main material that causes the atherosclerotic condition. 
Lin et al. (1999) studied the protective function of water- and ethanol-extracts of 
propolis, and the experiments showed that liver cells (hepatocytes) were protected against 
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several toxic substances like ethanol, carbon tetrachloride, galactosamine and allyl alcohol 
in the presence of propolis extracts. Dicaffeoyl quinic acid derivatives from 
water-extracted propolis were found to be especially protective. Gonzalez et al. (1995) 
found propolis had the ability of protecting the liver because of the anti-oxidative effects 
during his study on the toxicity of paracetamol. However, the protective effects of propolis 
form different sources and by different extraction methods vary (Banskota et ai., 2000b). 
These effects include protection of pancreatic beta-cells against streptozotocin and the 
heart muscle against doxorubicin, which are very important in preventing diabetes mellitus 
and myocarditis caused by chemical treatments (Chopra et aI., 1995). 
The cause of anti-oxidative activity of some components in propolis is due to the 
reaction between flavonoids and superoxide anions that inhibit the initiation of free 
radicals, binding heavy metal ions, or reacting with lipid peroxide to prevent the process of 
lipid peroxidation. Furthermore, propolis absorbed in the body obviates the need for 
Vitamin C and other hydrophilic oxidants (Fang et aI., 2000). 
1.2.1.3 Anti-viral properties of propolis 
There has been a long history of research on the anti-viral properties of propolis. 
Besides herpes virus, which can be inhibited by CAPE, other viruses, adenoviruses and 
influenza, are also inhibited by components of propolis (Kujumgiev et al., 1999). Amoros 
et al. studied the effects of propolis on the viruses including HSV-l, HSV-2, 
adenoviruses-2, VSV and poliomyelitis-2, and found that propolis could inhibit the activity 
of enzymes such as It' -ATP and phosphodiesterase and so influence phosphorylation of 
virus transfer genes, and inhibit synthesis of DNA and RNA (Luo, 1997). Propolis could 
also inhibit the replication of influenza A and influenza B, vaccinia virus, newcastle virus; 
furthermore, propolis could eliminate the enveloped viruses such as HSV and VSV. Some 
recent studies also indicated activity against the human immunodeficiency virus (HIV) 
(Harish et aI., 1997). 
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Although the components of propolis, flavonoids and CAPE, were from vanous 
sources, the anti-viral activity was common to all of them. Vynograd et al. (2000) studied 
the efficacy of ointments prepared from Canadian propolis versus acyclovir and a placebo 
in patients with confirmed genital herpes infection. The study reported a significantly faster 
and a higher percentage of healing in the propolis group within 10 days after the beginning 
of therapy (propolis 80%; 24/30 versus acyclovir 47%; 14/30 versus placebo 40; 12/30; P 
= 0.0015). In the propolis group, bacterial super-infections in the vagnia were eliminated in 
55% of cases, while patients in the group of acyclovir and placebo showed no 
improvement effect. 
1.2.1.4 Anti-bacterial activity of propolis 
The anti-bacterial and anti-inflammatory properties of propolis and its positive 
influences on wound healing and in the treatment of infections contribute to the favorable 
properties of propolis, which have been reported in China since ancient times. Experiments 
showed that propolis not only had direct bacteriostatic and mycostatic effects on a variety 
of bacteria (especially to Gl and fungi (Candida albicans), but also inhibited the adhesion 
of bacteria to the cell. Metesta tested the sensitivity of 75 bacterial strains, 69 strains 
belonged to Staphylococcus and Streptococcus. All the strains were sensitive to propolis 
extracts. The minimal inhibitory concentration (MIC) and minimum bactericidal 
concentration (MBC) of propolis to Staphylococcus aureus respectively were 10 and 120 
mglkg (Liang & Gao, 1997). In contrast to its anti-viral properties, the activity of propolis 
against certain types of bacteria varies with its origin; likewise, propolis and anti-biotic 
(tuberculostatic) drugs are synergistic (Scheller et al., 1999). 
Ear infections of dogs (canine otitis extema) were successfully treated with a 70% 
propolis-castor oil or a propolis-glycerol mixture (Heinze et al., 1996). Recent reports from 
Turkey investigated the effects of propolis extracts on wounds and infections of the eye in 
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rodents. These studies demonstrated that water extracts of propolis facilitate corneal 
epithelial wound healing and inhibit unfavorable neovascularization (Hepsen et aI. , 1999). 
Ozturk et al. (1999) found that propolis had the same efficacy as corticosteroids 
(methylprednisolone) in endotoxin induced uveitis and arthritis. 
The active anti-bacterial components of propolis are mainly flavonoids and aromatic 
acids and esters, and among these, the anti-bacterial activity of galangin, pinocebrin and 
pinobanksin are strongest. Besides these, benzyl ferulate and caffeic acid are also 
anti-bacterial components of propolis and flavonoids can inhibit the formation of free 
radicals (Burdock, 1998). 
1.2.1.5 Other properties of propolis 
Animal experiments showed that bee pollen and propolis as additive reagents can 
improve body weight, the utilization of iron ions and the regeneration of hemoglobin in 
animals (Haro, 2000). CAPE can prevent local ischemia caused by higher NO in injuries of 
the testis (Koltuksuz et aI., 2000); furthermore, propolis also has the activity of protecting 
spinal cord damage (Ilhan et al., 1999). Przybylski and Scheller found that water-soluble 
propolis and ethanol extracts of propolis can improve femur gangrene by arthrotic injection 
(Przybylski & Scheller, 1985). 
Mahmoud et al. found that propolis had significant effects on teeth allergy in a study 
on 26 Sudanese women, and propolis had significant anti-hyperalgesic effects, and could 
improve dental rigidity (Mahmoud et aI., 1999). In addition, ethanol extracts of propolis 
could act independently to release or activate the opioid system (De Campos et aI. , 1998). 
Propolis has no activity against eukaryotic parasites like Entamoeba histolytica, 
Toxoplasma gonii, Trichomonas vaginalis or Trypanosoma cruzi in situ, but in healthy 
volunteers it led to an enhancement of immune reactivity (Burdock, 1998). 
10 
1.2.2 Toxicity and allergic reactions to pro polis 
1.2.2.1 Toxicity of propolis 
Because extraction methods for propolis have not been standardized, varIOus 
published results on propolis toxicity are significantly different. Arvouet-Grand (1993) 
reported the oral LDso of propolis extract in the mouse to be greater than 7340 mglkg 
(Arvouet-Grand, 1993), while Hrytsenko (1997) reported the oral LDso of 2050 mglkg and 
an LDlOo of 2750 mglkg. Ghisalberti (1978) reported that cats tolerated subcutaneous 
administration of 100 mglkg of an ether extract of propolis. Dobrowolski (1991) 
administered approximately 700 mglkg orally to groups of 10 mice (five males and five 
females) and monitored them 48 h post-dose. They reported that the propolis preparations 
were well tolerated and no death occurred during the 48 h observation period. While the 
food analysis center of Japan reported that the oral LDso of propolis from China and Brazil 
was 3600 mglkg in acute toxicity experiments (Chen & Van, 1999), Burdock (1998) found 
that none of his experimental animals died after administration of 200-5000 mglkglday. 
Despite the disparity in the reported toxicities, there is nevertheless, a rather low innate 
toxicity for propolis extracts. However, their use in humans should include a safety factor of 
1000 considering the lack of chronic toxicity studies. A safe dose in humans would be 1.4 
mglkg body weight/day or approximately 70 mglday (Karsten, 2001). Although reports of 
the toxicity of propolis are in disagreement, all the investigators consider propolis as a 
material on low toxicity, and a safe additional reagent in the food industry. 
1.2.2.2 Allergic reactions to propolis 
An allergic reaction to propolis may be caused by direct contact, but propolis taken 
orally would not cause an allergic reaction. Studies show that the allergic reaction of 
propolis is usually indirect, the main cause of allergic reactions for people are those with a 
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high sensitivity to the secretions of poplar (Burdock, 1998). 
Use of propolis in cosmetics, tooth pastes and self-treatment for various diseases led to 
a steady increase in the cases of propolis allergy which, formerly, was more common 
among beekeepers. The main allergens in propolis include a mixture of 3-methyl-2-butenyl 
caffeate (54%), 3-methyl-3-butenyl caffeate (28%), 2-methyl-2-butenyl caffeate (4%), 
phenyl ethyl caffeate (8%), and caffeic acid (1 %), benzyl caffeate (1 %). Apart from allergic 
reactions, no side effects of propolis treatment have been reported. Miyataka has reported 
that propolis also contains an unknown, water soluble non-flavonoid with anti-allergic 
action (Karsten, 200 I). 
1.3 Anti-tumor mechanisms of pro polis 
In this chapter, advances on the analysis of the functional components and anti-tumor 
mechanisms of propolis are investigated to further develop base-line data on the 
pharmacological usefulness of propolis. 
1.3.1 Functional components of propolis 
Propolis has a wide spectrum of pharmacological activities, which largely derive from 
the functional components: flavonoids and other volatiles such as flavonoids, flavonols, 
flavanones and flavanonol. More than 60 flavonoid components have been identified to 
date. The common components in propolis are shown in table 1.3. 
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Table 1.3 The common chemical components of pro polis frequently encountered 
flavonoids Cicheriin; 5-hydroxy-4',7 -dilunethoxyflavone; tectocluysin 
flavonols 
galangin; galangin-3-methylether; galangin-6-methylether; kaempferitrin; 
kaempferol; kaempferol-4,7-dimethylethe; kaempferol-3,4-dimethyether; 
quercetin; quercetin-3,3-dimethyether; fagopyrol; apigenin; mulberrin; 
rhammetin; isorhammetin 
flavanones 5-hydroxy-4', 7 -dimethoxyflavanone; 2,5-dihydroxy-7 -methoxyflavanone 
phenolic 
acid 
coumarin 
others 
benzoic aicd; hexbenzoic acid; vanillin; isovanillin; 
3,5-dideoxy-phenyhnethanol; cis-methylsulfone methanol; P-coumaric acid; 
caffeic acid; phenolic acid; isoferulic acid; 3,4-dimethylcinnamic acid; 
cinnamic acid; phenyl caffeic acid 
6,7-dihydroxycoumarine; 7-hydroxymethoxycoumarine 
sorboside, eugenol; phenylethyl methanol; divinyl ether; 
nutmeg ester acid 
1.3.2 Anti-tumor mechanisms of propolis 
1.3.2.1 Prevention and inhibition of the production of carcinogens and potential 
carcinogens 
As we know, nitrosamines and aflatoxins are highly carcinogenic (Tricker & 
Preussmann, 1991; Groopman & Kensler, 1993). The process of curing foods results in the 
production of nitrites, which yields nitrosamines, strong carcinogens, under the combined 
action of natural acids and bacteria in the stomach. However, substances like phenolic acid, 
Se, Vitamin C and l3-carotene can interrupt the synthesis of nitrosamine. Furthermore, the 
flavonoids of propolis can induce benzpyrene hydroxylase to reduce the toxicity of 
aflatoxin. Pepeljnjak (1982) found that propolis extractions had a significant inhibitory 
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effect on ochratoxin A. Quercetin methyl ether and fagopyrol are the inhibitors of 
benzpyrene, a carcinogen associated with lung cancer. Siskin isoflavone, kaempferol and 
quercetin can denature DNA to po-isomerase. 
Mahran (1996) studied the effects of propolis on liver damage caused by carbon 
tetrachloride (CTC), and found that water-soluble derivatives of propolis had a repair 
function: the main mechanism prevents lipid oxidation and modulates glutathione 
reductase. Basnet (1996) isolated two derivatives of quinate-2-cafferol diester: methyl 
3,4-di-o-caffeoyl quinate and 3,4-di-o-caffeoyl quinic acid by chromatographic analysis, 
and experimentally demonstrated that that these two components had better effects in 
recovering from liver damage than liquorice. Sharma and Pillai (1998) found that propolis 
could prevent liver necrosis caused by paracetamol by adding 50 mg/kg to decrease the 
incidence of liver carcinoma. 
1.3.2.2 Inhibition of cancer ceUs by propolis 
Some flavonoids in propolis can inhibit the growth of tumor cells. In this context, the 
inhibitory activities of acacetin, mulberrin, and catecholamine were greater than other 
compounds. Kaempferol has a marked ability to inhibit cell proliferation; while nobiletin 
inhibits the multiplication of human pinacocyte tumor cells at the dose of 2-8 Ilg/ml. 
Caffetannic acid phenyl-2-ester and terpenes can also inhibit the mUltiplication of tumor 
cells by inhibiting DNA synthesis. Quercetin can lead to the death of cancer cells. 
Flavonoids can induce undifferentiated sarcomata to change to mature cells. CAPE can kill 
or inhibit DNA growth and synthesis of amoebocytes. In addition, the combined 
application of CAPE and MPA had a stronger inhibitory effect on cell proliferation than 
either substance used alone (Matsuno et al., 1997). Mitamura et al. (1996) found during the 
course of experiments with mice that clerodane diterpenoids in methanol extractions of 
propolis could inhibit skin cancer induced by chemical materials by two mechanisms: one 
was to inhibit DNA synthesis at the beginning, the other was reduce DNA synthesis by a 
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remediation metabolism path, both of which inhibit the growth of tumor cells (Mitamura et 
al., 1996). Kimoto et al. (1998) found that Artepillin C was an effective anti-bacterial, 
cytotoxic to malignant neoplasm, and significantly inhibited the growth of tumor cells 
through the induction of cell apoptosis. Artepillin C had inhibitory effects on solid tumors 
and leucocythemia in monocyte cytotoxicity experiments. Moreover, in experiments with 
mice it has clearly been demonstrated that Artepillin C terminates mitosis and induces 
transplantation tumors to atrophy. The mechanism of Artepillin C inhibiting tumor cells is 
associated with the prevention of a proliferation of tumor blood vessels cutting off the 
nutrition of tumor cells (Kimoto et al., 1998). For growth and transfer, solid tumors rely on 
the formation of new blood vessels, which could deliver the necessary nutrients and 
oxygen supplied by new blood vessels; if the formation of new blood vessels were 
inhibited, the tumor cells would degenerate through lack of adequate nutrition. 
1.3.2.3 Anti-mutational effects of propolis 
Oxygen-derived free radicals (OFR) and lipid peroxidation (LPO) can lead to DNA 
damage and cross-linking thus initiating mutations in carcinoma. Superoxide dismutase 
(SOD) and flavonoids in propolis are the main effective components that scavenge free 
radicals and LPO in the body. Scheller and Wilczok (1990) studied the effects of ethanol 
extracts of propolis on free radicals by electron paramagnetic resonance and found that the 
flavonoids in propolis had strong inhibitory effects on the scavenging of free radicals such 
as 2,2-diphenyl-l-hydrazine. The component 3,4-dihydroxy-5-isopenene cinnamic acid in 
propolis was more effective in preventing oxidation of linoleic acid than 
butylhydroxytoluene. Kimoto and Kurimoto (1999) found that Artepillin C in propolis 
extracts could decrease renal damage caused by triacetic acid, nitrile iron, and prevent 
carcinomatous developments of the kidney and lung. Vachalkova (1995) found that 
quercetin, rhamneti and kaempferol etc. had significant inhibitory activity on mutants by 
polar spectrum analysis. Lin et al. (\999) studied the influence of ethanol extracts of 
propolis on glutathinone reductase and microsomal enzymes caused by chronic alcohol 
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toxicosis, and found that propolis, at the dose of 30mg/kg, could significantly inhibit the 
activity of cytochrome C reductase which directs the metabolism of cytochrome P-4S0, 
NADH II, so decreasing the production of glutathinone and hydroxy aniline to prevent 
lipid oxidation. 
1.3.2.4 Anti-bacterial and anti-viral activity of propolis 
Krochmal (1991) studied the anti-bacterial, anti-fungal, and anti-inflammatory effects 
of propolis and found that it had good inhibitory activity against bacteria and fungi located 
in the epidermis and mucosa. Serkedjieva (1992) found that prenyl ferulate strongly 
inhibited an influenza virus such as H3N z. Scheller et al. (1999) studied the combined 
effects of propolis and streptomycin, isoniazid, ethambutol hydrochloride and rifamycins 
to tubercle bacilli and found that propolis decreased the activity of tuberculostatics. Sato 
and Miyataka (1999) studied the effects of propolis on Helicobacter pylori which lead to 
gastric cancer and found that propolis could kill Helicobacter pylori and inhibit the activity 
of urease to accelerate the secretion of gastric fluids to reduce the emergence of stomach 
disease. Hegazi (2000) studied the components and anti-bacterial activity of propolis from 
Europe by GC and found that the main components of propolis were essentially the same, 
with trans-p-coumaric acid as the main component. The main chemical components of 
propolis from Germany were phenylethyl-trans-caffeate, benzyl ferulate and galangin. The 
main components of propolis from Austria were pinocembrin and coumaric acid, which 
effectively inhibited oidimycosis. The main components of propolis from France were 
mainly benzyl caffeate and pinocembrin, which have inhibitory activity against various 
bacteria, but the effect was no better than that of propolis from Germany and Austria. 
1.3.25 The immunity modulation activity of propoJis and changes in environmental factors 
Although propolis has no anti-genic activity, it can be used as an immunity adjuvant 
to improve the production of anti-bodies, so as to increase the gamma globulin content of 
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total serum protein. In addition, propolis can also enhance the phagocytosis ability of white 
blood cells and macrophagocytes and improve the immune ability for specificity and 
non-specificity in the body. Ivanovska et al. (1995 a, b) carried out a series of studies on 
the immune effects of propolis in vivo, and found that cinnamic acid and caffeic acid 
effectively inhibited erythrocytorrhexis, so improving the immune system. In addition, the 
immune modulation mechanism on infections caused by Gram-negative bacteria was 
mainly via enhancing the activity of macrophagocytes. Water-soluble derivatives of 
propolis were better at improving immunity than other solutions of propolis. The immunity 
enhancement ability of pro polis may well prevent leucocythemia and AIDS. 
1.3.3 Exploitation prospects of propolis in health foods 
With the developing ideas about life and health care, people now readily accept 
healthy foods with anti-carcinogenic properties. Propolis has been used since ancient times 
in China, and it is a natural product full of microelements, enzymes and flavonoids. In 
addition, it also can influence the synthesis of DNA and improve immunity. Because of its 
wide biological activity, propolis can be easily accepted by people. In addition, China is 
the largest of the beekeeping countries and propolis is very abundant so that the 
exploitation prospects of propolis are in an expanding phase. 
1.4 The effects and mechanisms of pro polis as an anti-diabetic preparation 
Diabetes mellitus has long been known to man and modern medicine finds that it is an 
endocrine disease caused by the absolute or comparative absence of insulin in the body 
resulting in elevated blood glucose levels. The main symptoms are excessive drinking, 
production of urea, and intake of food, decreasing body weight, dizziness and fatigue, all of 
which further lead to a wide spectrum of other diseases. After cardiovascular diseases and 
tumors, diabetes mellitus is the third cause of disease-induced human mortality. It is reported 
that there are more than 120 million diabetes mellitus patients in the world, and there are 
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more than 30 million patients in China (Jiang, 1992). According to the forecast of WHO, 
there will have been a four-fold increase in the incidence of this disease by 2010, and the 
total number of of diabetes mellitus patients may reach about 240 million (King & Roglic, 
1999). 
1.4.1 Categories and pathogenesis of diabetes mellitus 
(1) Type-l diabetes mellitus: also called insulin-dependent diabetes (IDD), occurs in 
about 10% diabetes mellitus patients, most being children but it also occurs in patients 
more than 80-90 years old. 
(2) Type-2 diabetes mellitus: also called non-insulin-dependent diabetes (NIDD), 
occurs in about 90% of diabetes mellitus patients, most of whom are more than 35 years 
old. There are evident family genetic tendencies to express the disease, and it has no 
association with the human leukocyte antigen (HLA), and there are neither insulin 
antibody cells nor insulin autoantibody in the serum. 
(3) Pregnancy diabetes mellitus: this type occurs during pregnancy, and the main 
patients are elder or fat puerpera. The incidence of this disease is low. 
Until now, the pathology and pathogenesis were not well known. Scientists only 
found some referenced pathogenesis such as autoimmune deficiency and genetic factors, 
virus infection, adiposity, ages and feeding customs. As far as we know, the pathogenesis 
of type-l and type-2 diabetes mellitus are quite different (Rabinovitch, 1994; Hgoty, 1995; 
Terauchi et at., 1997; UKPDS Group, 1998; Bloomgarder, 1999). 
1.4.2 Effects and mechanisms of propolis on diabetes mellitus 
1.4.2.1 Effect of propolis as an anti-viral preparation 
There are some flavonoids and terpenes, which can accelerate glucose to synthesize 
liver hepatin and modulate blood glucose (Wang & Jia, 1998). Propolis could activate cells 
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to accelerate tissue regeneration, and repair insulin cells and tissue. Liu and Xu (2000) 
reported that the efficiency of propolis used to cure diabetes was 94%, and found that 
propolis could modulate endocrine function, accelerate blood glucose metabolism, and 
stimulate the secretion of insulin so as to decrease the blood glucose level. 
3-0-methquercine could inhibit poliomyelitis, and quercine could decrease poliomyelitis. 
In addition, the effect of thistle extracts to inhibit pancreas inflammation has been 
established (Gao & Liu, 2000). 
1.4.2.2 Effect on immuno-modulation of propolis 
Propolis can strengthen immune systems and enhance immune activity. Propolis can 
not only improve the phagocytosis of macrophages to improve the quantity of antibodies, 
but also can improve the function of cell immunity and humoral immunity. In addition, it 
also can improve the whole immune system including thymus, spleen and other immune 
organs, which can maintain the homeostasis of immune function at an optimal level, and 
improve disease resistance and self-healing (Zhu & Lii, 1997; Orsi et al., 2000; Murad et 
aI., 2002). 
1.4.2.3 Anti-oxidative effects of propolis 
A relationship has recently been established between the increase of free radicals and 
the increase of blood glucose, and the change of free radicals, lipid peroxidation and 
low-density lipoproteins participate in the progress of diabetes mellitus. Oxygen radicals 
would damage cells and decrease cell activity (Chen, 1998). Propolis is a natural 
anti-oxidative reagent. Propolis exhibits good anti-oxidative ability in very low 
concentrations and improves the activity of SOD of body. As a natural anti-oxidative 
reagent, propolis can scavenge redundant free radicals and reduce the production of 
lipofuscin and liposomes and enhance cell energy to modulate tissue to delay aging (Huang 
et aI., 2000). 
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Soto (1998) found that thistle could scavenge free radicals, stabilize cell membranes 
to protect insulin cells, decrease the level of malonaldehyde and increase the level of 
glutathione, as well as inhibiting the increase of blood glucose caused by alloxan. 
1.4.2.4 Effects on cleaning blood of propolis 
Propolis can enhance heart constrictions to facilitate breathing, modulate blood 
pressure, and blood lipid. Studies and clinical experiments on propolis proved that propolis 
could intenerate and decrease brittleness of blood vasculature, so as to smooth the blood 
stream and modulate cycles to prevent hardening of the blood vasculature thus avoiding 
arteriosclerosis and modulating blood cycle (Shi, 1998). Because hyperlipidemia and high 
cholesterol are often associated with diabetes mellitus, the effect of propolis on cleaning 
blood would aid in the cure of diabetes mellitus. 
1.4.2.5 Effects of propolis on enzyme systems 
A. Pro polis can inhibit the activity of aldose reductase 
Aldose reductase (AR) serves as a coenzyme for the reduced form of 
nicotinamide-adenine dinucleotide phosphate (NADPH) and is the key restrictive enzyme 
in the process of sequestering alcohol. AR catalyse deoxidization reacts with hexose, 
which make glucose and lactose deoxidize to sorbol and galactol, and sorbol is oxidized to 
fructose under the effects of sorbol dehydrogenase, the second restrictive enzyme in the 
process of metabolizing alcohol, but it cannot oxidize galactol, so facilitating the 
metabolism of galactol causing galactosemia (Zuo & Yao, 1999). When the level of blood 
glucose is normal, AR is not activated, but in high concentrations of blood glucose, 
glucose is catalyzed to sorbol, but the activity of sorbol dehydrogenase does not increase 
with sorbol, and sorbol does not pass through cell membranes because of its polarity, 
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leading to an accumulation of sorbol (Song et al., 1991a). Numerous experiments showed 
that chronic syndromes of diabetes mellitus such as diabetic retinopathy, diabetic 
peripheral neuropathy and diabetic nephropathy were all associated with the accumulation 
of sorbol (Chen, 1998). 
Studies on natural sources of AR inhibitory action have made considerable progress 
and such compounds are mainly flavonoids, coumarin, and so on. Varma (1977) tested the 
inhibitory activity of AR in a series of studies with flavonoids and found that flavonoids, 
including quercetin and coumarin, were inhibitory to AR (Song & Han, 1994). Mao (1993) 
proved that flavonoids had inhibitory effects on AR, and the effect of quercetin was that 
the IC50 was 3.44xlO-7 mollL, nearly equal to that of Sorbinil which was the strongest 
inhibitory substance for AR. 
B. Effect of propolis to inhibit a-glucosidase 
Starch in food is digested by saliva and amylopsin to yield oligosaccharides, 
disaccharides, and trisaccharides. In the small intestine, all these kinds of saccharides are 
reduced to monosaccharides which are then absorbed. Normally, a-glucosidase exists in all 
the parts of the small intestine. The absorption of glucose is restrained in the upper areas of 
the small intestine after taking inhibitory a-glucosidase, and the absorption of glucose is 
centralized in the middle and lower areas of the small intestine, thus reducing the 
absorbing area and delaying absorption time, which is beneficial in decreasing postprandial 
blood sugar. Taking a-glucosidase as an inhibitory substance for a long time also could 
decrease fasting blood sugar, which probably is related with increasing insulin sensitivity. 
There have been many studies on a-glucosidase inhibitory action since the 1970s' 
with notable achievements in natural medicines. A traditional natural medicine of Brazil 
used in curing diabetes mellitus significantly inhibited the activity of a-glucosidase (Bai & 
Cai, 1999). Further studies showed that the main components of decreasing blood glucose 
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were flavonols such as myricetin, 4'-methylmyricetin-a-glucosidase, quercetin and two 
other new flavonols of citrin-I and citrin-II. All these components could significantly 
inhibit hyperglycemia caused by alloxan. Studies in vitro also found that these components 
also significantly inhibit the activity of a-glucosidase to delay the absorption of 
carbohydrate and thus decreasing hyperglycemia (Yu & Li, 2000). 
The main mechanisms of propolis on decreasing hyperglycemia were that the 
anti-oxidative activity of propolis, while not disrupting the stability of cell membranes, 
protects pancrease and modulating enzymes related to glucose metabolism affecting the 
absorption of glucose in the small intestine to delay hyperglycemia. In addition, propolis 
might also have a similar effect on insulin to modulate glucose metabolism and protect 
pancrease and inhibit the activity of AR and a-glucosidase to inhibit diabetes mellitus and 
syndromes. 
1.5 The functional factors of pro polis in the modulation of hyperlipidemia 
In recent years, studies have found that propolis has significant effects on modulating 
hyperlipidemia and has been termed "scavenger of blood", which is related to many of the 
functional factors of hyperlipidemic modulation by propolis. There are more than ten modulating 
hyperlipidemic factors in modem clinical use, and among them factors such as flavonoids, 
unsaturated fatty acids and terpenes are found in propolis (Fang, 1998 a, b; Stefano & Francesco, 
2002). 
1.5.1 Flavonoids 
Flavonoids have the ability to decrease blood lipid, scavenge free radicals and, 
enlarge coronary arterial blood vessels. There are more than 3000 kinds of flavonoids, the 
main components being flavones, flavonols, dihydroflavones, and so on. The contents of 
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flavonoids in different sources of propolis vary. The flavonoid content of propolis may 
exceed 12%, and is the principal basis of biological activity of propolis. More than 70 
flavonoids have been extracted from propolis in the world and they are mainly flavanones, 
flavonols, and dihydroflavones and so on (Bankova et al., 2000). 
Flavonols are the main components responsible for a decrease in blood lipid. In recent 
years, more than 20 kinds of flavonols have been identified in propolis (Peng, 1996). The 
principle flavonols in propolis are fagopyrol, quercetin, kaempferol, iso-rhammetin and so 
on. All of these components can increase the elasticity of capillary vessels to avert cerebral 
hemorrhage. Quercetin, which is the main component of many Chinese traditional 
medicines, is abundant and has wide biological properties, such as enlarging blood vessels, 
decreasing blood lipid, inhibiting the collecting of platelets and so on (Banskota et aI. , 
2000 a, b). Quercetin has the effect of inhibiting platelet collecting induced by arachidonic 
acid, and inhibits endotheliocytes from releasing endothelin to decrease the strain on blood 
vessels thus preventing the formation of thrombi. Fagopyrol and kaempferol are also 
abundant in propolis (Fang, I 998b). Zhao (2000) showed that the content of fagopyrol, 
kaempferol, and rhammetin in ethanol extracted propolis from the Beijing area were 
respectively O.l9g/100g, O.l7g/100g and 3.89g/100g. 
The other two large fractions of flavonoids in propolis are flavanones and 
dihydroflavonols. They can decrease blood lipid and strengthen capillary vessels and 
anti-inflammatory reactions. Compounds such as pop Ius and tectochrysin are the main 
components of propolis in temperate zones, and they have significant effects in decreasing 
blood lipid. Chrysin, caffeate, 4,6-dihydroxyl-hihydroflavone, and 3,5,7-trihydroxyl 
flavanol are also found widely in propolis and affect hyperlipidemia (Wu, 2000). 
In addition, the activity of superoxide dismutase (SOD) decrease, which causes an 
imbalance of prostacyclin and thrombus A2 and the collecting of platelets as well as 
releasing 5-hydroxytryptamine and increasing the activity of thrombin, which would cause 
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damage to the endothelium, hyperplasia of smooth muscle cells to form foam cells and 
finally to form arteriosclerosis (AS) (Feher, 1987). Scheler's (1990) studies showed that 
flavonoids in propolis are the effective components in scavenging free radicals, and also 
alkyloxyly negative ions and decrease the production of peroxide. 3,4-hydroxyl in the 
B-ring of flavonoids is the key structure to scavenge free radicals, others such as hydroxyls 
act synergistically (Yu, 1986). 
1.5.2 Polyunsaturated fatty acids (PUFA) 
Studies and clinical experiments show that PUF A has significant effects on decreasing 
triglycerides, total cholesterol, and increasing the level of high density lipid cholesterol, 
decreasing blood viscosity and platelet collecting to reduce thrombosis production (Xie, 
1998). PUFA is subdivided into n-3 and n-6 series, such as linolenic acid (18 : 3n-3) and 
linoleic acid (18 : 2n-6) and arachidonic acid (20 : 4n-6). The effects of linoleic acid, 
linolenic acid, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in PUFA on 
modulating hyperlipidemica are most significant (Hansen, 1994). 
The mechanisms ofPUFA decreasing total cholesterol (TC) and triglycerides (TG) are 
mainly to inhibit the synthesis of endogenous cholesterol and triglycerides. PUFA can 
significantly increase the level of high-density lipoprotein (HDL) by adding the activity of 
lecithin-cholesterol acyltransferase (LCAT) and LPL and inhibiting the activity of HEL, 
CAT and LPL. This would accelerate the production and maturation of HDL, and HEL 
would inhibit its decomposition (Liu, 1991). In addition, PUFA also has the ability to 
inhibit the collecting of platelets, which are related to n-3 PUFA, arachidonic acid and 
catalysis reactions caused by lipid oxidase, cyclooxygenase (COX), and prostate synthease 
(Wang, 1994). 
Propolis has a low amount of PUFA, the main components of which include linoleic 
acid, linolenic acid and arachidonic acid and so on. Mao (1998) studied 10 kinds offatty 
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acids in ethanol extracted propolis, and found that the content of PUFA in propolis was 
more than 57.9%, and mono-unsaturated fatty acids (MUFA) were 34.8%, PUFA, with two 
double bonds, was 23.4%, and saturated fatty acids was 37.63%, the proportion of 
saturated fatty acids (SFAS): MUFA: PUFA was 1: 0.93: 0.61. The ratio of unsaturated 
fatty acids (UFA) to SFAS more than 1 is the signal in natural food which has the 
biological properties to protect cardiovascular disease and decrease hyperlipemia (Sinclair, 
1990). 
1.5.3 Terpenes 
Propolis contains substantial quantities of terpenes, which can reduce the effects of 
hyperlipidemia. The terpenes in propolis mainly include triterpenes which decrease 
cholesterol in the serum of rats by inhibiting cholesterol absorption in the intestine 
(Enomoto, 1977), and diterpenic acids such as 8(17), 13E-Iabdadien-ls, 19-dioic acid 
IS-methyl ester, 19-oxo-8(17), 13E-Iabdadien-ls-oic acid, 13-dydroxy-8(17), 14-
labdadien-19-oic acid, and sesquiterpenes such as ledol, germacrene, spatulenol, 
isopatulenol and so on, which mainly act by inhibiting lipid synthetase such as acetyl 
coenzyme A carboxylase, citric acid lyase, acetyl coenzyme synthetase, and hydroxyl 
methylglutaryl coenzyme A reductase (Hall, 1980). 
1.5.4 Amino acids 
Some amino acids have the ability to decrease the level of blood lipid, the main 
mechanisms are by accelerating the excretion of cholesterol in the intestines, and 
combining with cholesterol to block the absorption of cholesterol, which affects patients 
with high cholesterol but has no effect on normal people. For example, thioproline can 
shorten the length of thrombi, decrease the wet weight and dry weight of thrombi, and 
decrease the conglutination of platelets, thus significantly inhibiting platelet collecting 
induced by adenosine diphosphate (ADP) in rabbits or rats. Thioproline is weakly 
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antagonistic to calcium, whereas thrombosis and platelet conglutination and depend on 
participation of calcium. Thus the mechanism of thioproline to inhibit AS was related with 
that of calcium antagonists (Hao et al., 1990). Studies showed that glycine ramification 
could decrease the level of triglycerides. There are more than 20 amino acids in propolis, 
which can to some degree affect the modulation of blood lipid (Guo & Zhou, 2000). 
1.5.5 Steroids 
The components of steroids in propolis are mainly lanosterol, cholesterol, fucosterol, 
stigmasterol and ~-dihydrofucosterol. The skeleton of steroids has free hydroxyls in 
positions Cs - C6 and C22 - C23, which are necessary to decrease cholesterol. Steroids 
mainly inhibit the absorbability of cholesterol in the intestine, the main mechanisms are 
that steroids and cholesterol would synthesis infusibility material to deduce the 
absorbability of cholesterol, the activity is related with alkyl in C24, /!,.22 of steroids. 
Secondly, steroids can inhibit the metabolism of cholesterol, for example ~-sitosterine 
inhibits the activity ofhydroxymethylglutaryl coenzyme A, which is the key enzyme in the 
synthesis of cholesterol (Wang, 1983). 
In summary, there are several lipid-modulating factors in propolis, but they do not exert 
unique effects alone but operate synergistically, so the mechanism of propolis modulating 
hyperlipidemiac is somewhat unique. In addition, the components in propolis are complex, 
and chemical components from different sources of propolis are significantly different 
(Bankova et al., 2000), so quality control must be taken when propolis is used to modulate 
hyperlipidemia. 
1.6 Research objectives 
In this dissertation the results of experiments performed to determine the effects (1) 
propolis on diabetes mellitus in rats, (2) compare the anti-inflammatory effects of ethanol 
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and water extracts of pro polis, (3) effects of pro polis in the treatment of hyperlipidemia, (4) 
the effectiveness of propolis in the treatment of induced tumors, and (5) ethanol and water 
extracts of propolis in general are reported. 
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CHAPTER 2 
2. EFFECTS OF PROPOLIS ON DIABETES MELLITUS IN RATS 
2.1 Summary 
The effects of ethanol (EEP) and water (WSD) extracts of propolis on diabetes 
mellitus in rats were analyzed. Both WSD and EEP decreased levels of fasting blood 
glucose levels (FBG), glycosylated haemoglobin (HBAlc), fructosamine (FRU), 
triglyceride (TG), total cholesterol (TC), creatinine (CREA), blood urea nitrogen (BUN), 
uric acid (UA), malodialdehyde (MDA), total protein (TP) and albumin (ALB), and 
decreased the ratio of kidney to body weight in rats with diabetes mellitus. The results 
indicate that both EEP and WSD improved metabolism of glucose, fat and protein and 
afforded renal protection for rats with diabetes mellitus. 
2.2 Introduction 
Recently, a few publications on the efficacy of propolis in the treatment of diabetes 
mellitus have appeared (Gao & Liu, 2000), but the literature reflects limitations including 
the absence of uniform and standard methods for the extraction of propolis. Likewise, the 
relative effects of propolis extracts obtained by different extraction methods on diabetes 
mellitus remain unknown. In this chapter, the effects of ethanol and water (EEP and WSD) 
extracts of propolis on diabetes mellitus induced in rats are assessed. 
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2.3 Materials and methods 
2.3.1 Drugs and reagents 
A bulk sample of propolis was obtained from honeybee colonies, Apis melli/era 
Iigustica, in North China in 2001 and the main plant origin was poplar (Populus sp.). A 30 
g sample of propolis was pulverized and extracted in water at 80oC for 12 hours (WSD). A 
similar sample was extracted in 80% ethanol (EEP). Alloxan was obtained from Sigma 
Company. Reagents for blood glucose, total cholesterol, triglycerides, creatinine, blood 
urea nitrogen, uric acid, total protein and albumin were obtained from Shanghai 
Fudan-Zhangjiang Bio-pharmaceutical Company, China. Reagents for malonaldehyde and 
glycosylated haematoglobin protein were obtained from Nanjing Jiancheng Biology 
Engineering Company, China. 
2.3.2 Laboratory animals 
Male rats (strain SD) 300 + 20 g were provided by the Shanghai Laboratory Animal 
Center of the Chinese Academy of Sciences (Certificate of animal quality: Zhong Ke Dong 
Guan No. 003), and used at The Research Center of the Laboratory of Animal Science, 
Zhejiang College of Traditional Chinese Medicine, Hangzhou, China. The rats were 
allowed a standard pellet diet and free access to water and maintained at 25°C under a 
12/12 hr light/dark cycle. The animals were maintained and the experiments performed 
according to the principles of the Helsinki accord. The experimental protocol was 
approved by the Animal Ethics Committee of Zhejiang University, Hangzhou. 
2.3.3 Induction and treatment of diabetes mellitus 
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Diabetes mellitus was induced in rats by intravenous injection of alloxan (40 mglkg) 
dissolved in physiological saline through the tail vena. Control rats were given intravenous 
injections of physiological saline. 7 days later, blood was taken from all rats at the tip of 
the tail and the serum centrifuged to measure blood glucose levels. 60 rats with a blood 
glucose concentration about 20 mmol/L were then randomly divided into 6 groups: a 
diabetes mellitus (model) control group, WSD1, WSD2, EEP1, EEP2 treated groups and 
an additional 10 rats as normal, healthy controls. 
2.3.4 Methods of drug administration 
WSD groups: the concentration of dry propolis material in the WSD solution was 
15mglml and the WSDI solution was prepared by diluting the stock solution 5 times and 
the WSD2 solution diluted 10 times. Rats in the WSDI and WSD2 groups were injected 
intragastrically with WSDI and WSD2 solutions (1 ml/ lOO g) respectively and treated 
twice (09:00 and 15:00) daily continuously for 4 weeks. 
EEP groups: the concentration of dry propolis material in the EEP solution was 100 
mglml and the EEPI solution was prepared by a 25-fold dilution of EEP and the EEP2 
solution diluted 50 times. Rats in the EEPI and EEP2 groups were injected intragastrically 
with EEPI and WSD2 (I mlllOO g) respectively and treated twice daily (09:00 and 13:00) 
continuously for 4 weeks. 
Positive control group: acarbose was diluted in physiological saline (I mglml). Rats in 
the positive control group were injected intragastrically with the acarbose solution (I 
mill 00 g) and treated twice daily (09:00 and 15:00) continuously for 4 weeks. 
Rats in the normal control group and diabetes mellitus model group were injected 
intragastrically with 0.9% physiological saline (1 mlll00 g) and treated twice daily (09:00 
and 15 :00) continuously for 4 weeks. 
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2.3.5 Methods of measuremeut 
Blood was takeu weekly from all rats at the cut tip of the tail, and the serum 
centrifuged at 3000 rpm/min to test blood glucose. At the end of the experiment, blood was 
taken from the eye for measurement of the other biochemical indexes. 
2.3.6 Data analyses 
Results are presented as means + standard deviations. The statistical analyses were 
performed by using ANOYA procedures and Tukey and Fisher's LSD multiple comparison 
tests with P < 0.05 considered as significant. 
2.4 Results 
2.4.1 Effect of propolis on blood glucose in diabetes mellitus 
The effects of propolis on blood glucose levels in rats with diabetes mellitus SD rats 
are shown in table 2.1. The experiment lasted 5 weeks. The first week involved the 
induction and treatment of diabetes mellitus and the subsequent 4 weeks involved drug 
administration. The results of table 2.1 show that blood glucose concentration in the 
diabetes mellitus model group increased significantly with time (F l ,48 = 45.86, P < 0.0001), 
whereas the increases in blood glucose concentration in the experimental groups were 
slower than that of diabetes mellitus model group (WSDl: F l ,48 = 15.61, P < 0.001; WSD2: 
F l ,48 = 20.64, P < 0.0001; EEPl: F l ,48 = 27.70, P < 0.0001; EEP2: F l ,48 = 32.58, P < 0.0001; 
Positive group: F l ,48 = 11.60, P < 0.01). The blood glucose levels of rats in each of the 
groups ofWSD1, WSD2, EEP1, EEP2 and the positive control group respectively were on 
average 15.3% (LSD: P < 0.05), 13.2%, 10.4%, 17.1% (LSD: P < 0.05) and 6.2% less than 
that of diabetes mellitus model group at the first week of drug administration. 
31 
By the second week of drug treatment, blood glucose levels in each group were not 
significantly different compared with that of diabetes mellitus model group. The blood 
glucose levels of rats in each of groups WSDl, WSD2, EEPl, EEP2, and the positive 
control group respectively were 8.8%, 4.9%, 20.2% (LSD: P < 0.05), 4.8% and 12.9% less 
than that of diabetes mellitus model group at the third week of drug treatment. During the 
last week, the blood glucose levels of the WSD 1, WSD2, EEP 1, EEP2, and positive control 
groups were respectively on average 16.0% (LSD: P < 0.05), 16.1% (LSD: P < 0.05), 
12.0%, 17.2% (LSD: P < 0.05), and 16.7% (LSD: P < 0.05) less than that of diabetes 
mellitus model group. It is apparent that after four weeks of propolis treatment that blood 
glucose levels significantly increased in rats with diabetes mellitus (F4.216 = 50.0, P < 
0.0001). 
Table 2.1 Changes in blood glucose (mmol/L) in uormal rats and those with diabetes 
mellitus over five weeks ( X ±sd) 
Group n 1 week 2 weeks 3 weeks 4 weeks 5 weeks 
Nanna! control 10 2.30±0.66** O.77±O.4I** 1.02±1.26** 0.78±0.57** 2.19±0.76** 
Model control 10 21.38±3.18 24.72±3.54 23.32±2.55 31.17±6.89 32.66±2.17 
WSDl 10 21.86±3.15 20.94±3.92* 2 1.98± 1.97 28.43±6.12 27.43±5.95* 
WSD2 10 20.90±2.44 21.47±4.58 22.79±2.54 29.63±7.11 27.41±3.93* 
EEPI 10 20.57±2.84 22.14±2.05 23.12±2.83 24.86±3.47* 28.74±5.87 
EEP2 10 19.45±3.52 20.49±4.81 * 23.90±4.03 29.68±3.43 27.04±4.12* 
Positive control 10 21.04±2.68 23.l9±4.23 23.30±2.88 27.15±7.01 27.20±6.02* 
LSD: *P<0.05, ANOVA: ** P < 0.0 I compared with diabetes mellitus model control group. 
32 
2.4.2 Effects of propolis on the levels of glycosylated haematoglobin (HbAlc), 
triglycerol (TG), total cholesterol (TC), total protein (TP), and albumin 
(ALB) in rats with diabetes mellitus 
The effects of propolis on the levels of HbAlc, TG, TC, TP, ALB in rats with 
diabetes mellitus are given in table 2.2. The results show that glycosylated haematoglobin 
protein in the EEP2 and WSD2 groups decreased by 13.3% (LSD: P < 0.05) and 12.0% 
(LSD: P < 0.05) respectively compared with that of diabetes mellitus model; the WSD 1, 
EEPl, and positive control groups showed no significant differences compared with the 
diabetes mellitus model group. TG in the WSD2, EEPI, EEP2 groups decreased 
respectively by 47.7% (LSD: P < 0.05),51.0% (LSD: P < 0.05),51.9% (Tukey: P < 0.05) 
compared with that of the diabetes mellitus model group. 
In the WSDI and positive control groups there was no significant difference 
compared with diabetes mellitus model group. TC in the EEPI and EEP2 groups decreased 
by 18.5% (LSD: P < 0.05) and 17.6% (LSD: P < 0.05) respectively compared with that of 
diabetes mellitus model group. The WSDl, WSD2 and positive control groups did not 
significantly differ from the diabetes mellitus model group. TP in the WSDl, WSD2, EEP1, 
EEP2, positive control groups increased 9.1%,5.5%,9.1%,11.3% and 18.0% (LSD: P < 
0.05) compared with that of diabetes mellitus model group. ALB in WSDl, WSD2, EEPl, 
EEP2, and positive control groups increased 9.1 %, 0.2%, 3.9%, 3.4%, 3.2% respectively 
compared with that of diabetes mellitus model group. 
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Table 2.2 Effects of propolis on the levels of HbAIc, TG, TC, TP, ALB in rats with 
diabetes mellitus (x ±sd) 
TG TC TP ALB 
Group n HbAlc 
(mmollL) (mmollL) (giL) (giL) 
Normal control 10 0.050±0.0 12** 0.64±0.17* 1.27±0.34 66.7±8.5** 30.1±3.5** 
Model control 10 0.075±0.005 3.97±2.14 1.48±O.25 49.4±9.1 23.2±3.6 
WSDI 10 0.069±0.011 3.40±1.90 l.54±0.37 53.9±5.4 25 .3±2.4 
WSD2 10 0.066±0.010* 2.07±0.65* 1.26±0.22 52.1±9.9 23.3±4.0 
EEPI 10 0.070±0.011 1.94±0.96* 1.21±0.20 53.9±8.9 24.1±4.0 
EEP2 10 0.065±O.0 11 * 1.91±0.75* 1.22±0.21 55.0±7.2 24.0±1.3 
Positive control 10 0.072±0.008 3.83±2.11 1.57±0.31 58.3±5.1 * 23.5±3.9 
ANOVA F6,63 = 6.93** F6,6J = 7.22** F6,63 = 3.25** F6,6J = 4.99*' F6,6J = 5.29** 
LSD: 'P < 0.05, ANOVA: '* P < 0.01 compared with diabetes mellitus model control group. 
2.4.3 Effects of propolis on the levels of fructosamine (FRU), creatinine (CREA), 
blood urea nitrogen (BUN), uric acid (UA), and malonaldehyde (MDA) in 
rats with diabetes mellitus 
The effects of propolis on the levels of FRU, CREA, BUN, UA, MDA in rats with 
diabetes mellitus are shown in table 2.3. The results show that FRU in WSDI, WSD2, 
EEPI, EEP2 and positive control groups were 6.78%, 10.50% (LSD: P < 0.05), 12.42% 
(LSD: P < 0.05), 9.78% (LSD: P < 0.05), 6.70% less than that of diabetes mellitus model 
group. CREA in EEP2 decreased 7.8% (LSD: P < 0.05) compared with that of diabetes 
mellitus model. The WSDI, WSD2, EEPI and positive control groups did not significantly 
differ from the diabetes mellitus model group. BUN in WSDI was 21.2% (LSD: P < 0.05) 
less than that of diabetes mellitus model group while there was no significant difference 
between the WSD2, EEPI, EEP2, positive control groups and the diabetes mellitus model 
group. UA in WSDI, WSD2, EEPI, EEP2 were 5.8%, 13.0% (LSD: P < 0.05), 15 ,5% 
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(LSD: P < 0.05), 7.1 % less than that of diabetes mellitus model group. MDA in the WSD1, 
WSD2, EEP1, EEP2 and positive control groups respectively were 12.8%, 19.9% (LSD: P 
< 0.05), 9.1 %,22.1 % (LSD: P < 0.05) and 12.2% less than that of diabetes mellitus model 
group. 
Table 2.3 Effects of propolis on the levels of FRU, CREA, BUN, UA, MDA in rats 
with diabetes mellitus (x ±sd) 
FRU CREA BUN UA MDA 
Group n 
(IlmollL) (IlmollL) (rnmollL) (IlmollL) (nmoIlL) 
Normal control 10 73.36±5.27** 60.43±S.93 S.64±O.39** lS9.42±19.92** 9.3±0.9** 
Model control 10 104.79±13.72 67.16±S.61 19.87±6.36 238.06±50.76 18.1±5.2 
WSDI 10 96.67±8.41 6S.S7±2.77 lS.67±2.20* 224.7S±39 .73 lS.8±2.3 
WSD2 10 93.78±lS.38 67.42±S.46 17.39±S.14 207 .92±9 .97* 14.S±1.6* 
EEPI 10 9 !.76±1O.72* 66.67±7.07 19.33±4.29 20 1.67±32.21 * 16.4±S.5 
EEP2 10 94.S4±6.64 * 60.43±4.74* 18.11±2.17 221.60±26.24 14.1±3.1* 
Positive control 10 97.46±7.741 66.2S±7.16 17.09±3.61 224.70±25.73 IS.9±4.4 
ANOYA Fo.o3 = 8.84** Fo,o3 = 2.59* Fo,63 = 15.23** Fo,o3 = 6.S9** Fo,o3 = S.74** 
LSD: *p < O.OS, ANOYA: ** P < 0.01 compared with diabetes mellitus model control group. 
2.4.4 Effects of pro polis on the level of kidney weight/body weight in rats with 
diabetes mellitus 
The effects of propolis on the levels of kidney weightlbody weight in rats with 
diabetes mellitus are shown in table 2.4. The results show that kidney weight/body 
weights in the WSD1, WSD2, EEP1, EEP2 and positive control groups were lower, but 
not significantly so, than that of diabetes mellitus model group. 
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Table 2.4 Effects of pro polis on the levels of kidney weight/body weight in rats 
with diabetes mellitus 
Group 
Body weight Kidney weight Kidney weight/body weight 
n 
(g) (g) xlOO 
Nonnal control 10 33S.0±18.4** 1.2S±0.08 3.73±0.21** 
Model control 10 202.3±28.4 l.30±0.16 6.47±0.52 
WSDI 10 228.8±22.3 l.39±O.18 6.11±0.76 
WSD2 10 241.3±43.2* 1.47±0.21* 6.23±1.21 
EEPI 10 221.7±18.8 l.3S±0.14 6.12±0.62 
EEP2 10 220.S±36.0 1.33±0.19 6. 14±0. 11 
Positive control 10 232.1±33.4* 1.43±0.13 6.21±O.49 
LSD: *p < O.OS , ANOYA: ** P < 0.01 compared with diabetes mellitus model control group. 
2.5 Discussion 
2.5.1 Effects of propolis on blood glucose 
During their IS-year study, The United Kingdom Prospective Diabetes Study 
(UKPDS) group demonstrated that type-2 diabetes mellitus was an acute and progressive 
disease. They found that the levels of glycosylated haematoglobin protein and fasting 
blood glucose levels persistently increased, which demonstrated that p cells of the pancreas 
decayed with time. Similarly, the UKPDS study also demonstrated that in patients with 
type-2 diabetes mellitus, it was very important to improve blood glucose levels, which 
could decrease the danger of diabetes mellitus syndrome (UKPDS Group, 1998). Moreover, 
propolis enhances cell activity, accelerating tissue regeneration and ultimately the repair of 
damage to the pancreatic cell system (Burdock, 1998), further lessening the effects of 
diabetes mellitus. 
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Considering the results of analyses of fructosamine, glycosylated haematoglobin 
protein and fasting blood glucose, it is evident that the concentration of fructosamine and 
glycosylated haematoglobin protein among the different propolis-treated groups was 
significantly lower than that of diabetes mellitus model, indicating that propolis effectively 
controls blood glucose levels. In addition, the varying concentrations of fasting glucose 
levels observed weekly demonstrate that propolis is associated with a decrease in rising 
blood glucose levels, and the effect was enhanced with time. Fructosamine levels derive as 
a by-product of the reaction between glucose and albumin, which occurs in serum with 
keto-amine. The concentrations of fructosamine in serum were relatively steady and were 
not affected by diet. Fructosamine levels very likely reflect the changes in blood glucose 
over several weeks just as occurred in the case of glycosylated haematoglobin protein 
(Grey et al., 1995). Against this, levels of fasting blood glucose reflected instantaneous 
blood glucose concentration. 
2.5.2 Effects of propolis on blood lipid 
Diabetes mellitus is often associated with blood lipid abnormalities, mainly the levels 
of TC which are associated with increases in high blood pressure, atherosclerotic and 
coronary heart disease. A relationship between blood lipid abnormalities and 
atherosclerotic conditions has been previously predicted (Hu et al., 200 I). 
Propolis could well increase the contractibility of heart, deepen breath and modulate 
blood pressure, purify blood, as well as modulate blood lipid. Much experimental data 
supports the interpretation that propolis modulates high blood lipid, high total cholesterol, 
high blood viscosity and also functions as a prophylactic against atherosclerosis as well as 
enhancing blood circulation in the heart and blood vessels in the brain. Because patients 
with diabetes mellitus often exhibit high levels of blood lipid and total cholesterol, the 
activity of blood vessel scavengers would be conducive to reducing the severity of diabetes 
mellitus (Havsteen, 2002). 
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By testing TC and TG in this experiment, we found that the levels of diabetes mellitus 
in rats after treatment with propolis were lower compared to those of the diabetes mellitus 
model. Moreover, EEP had a greater effect than did WSD. So it is inferred that propolis 
modulates the metabolism of lipid thus reducing the syndrome associated with blood lipid 
abnormalities. 
2.5.3 Effect of propolis on renal function 
Another acute syndrome of diabetes mellitus is diabetes mellitus nephropathy, the 
obvious symptoms of which are increases of creatinine, blood urea nitrogen and uric acid 
concentrations in the serum, and increased kidney weight/body weight (UKPDS Group, 
1998). From the results of the experiment, it was found that the diabetes mellitus SD rats 
treated with propolis, the serum levels of creatinine, blood urea nitrogen, uric acid and 
kidney weight/body weight were lower than that of diabetes mellitus SD rats. Based on 
these results, it appears that propolis could protect the kidney in diabetes mellitus. 
2.5.4 Effects of propolis on protein metabolism 
Diabetes mellitus causes abnormalities of protein metabolism in addition to increases 
in blood glucose and blood lipid levels. The major symptom is the greater consumption of 
total protein and albumin (UKPDS Group, 1998). From the results of this experiment it is 
evident that propolis decreased the consumption of total protein and albumin leading to the 
inference that propolis modulates the metabolism of protein. 
2.5.5 Effects of propolis on lipid peroxidation 
That there is a relationship between the increase of free radicals and an increase in 
blood glucose, as well as changes of free radicals and lipid peroxidation under low density, 
lipoprotein conditions driving the progress of diabetes mellitus is well established. Oxygen 
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radicals would otherwise lead to cell damage, while MDA, as a kind of lipid peroxidation 
mechanism, would reflect the degree of oxidation in the body (Chen, 1998; Hilmi & Serdar, 
1999; Muruganandan et al., 2002). Whereas propolis is a natural anti-oxidant, at low 
concentrations, it leads to increases in the activity of SOD thus reducing the output of lipid 
peroxidation and protecting the body. The results of the present experiments show that the 
level of MDA decreased after treatment with propolis, which is evidence that propolis 
decreases the products of lipid peroxidation. 
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CHAPTER 3 
3. EFFECTS OF PROPOLIS ON BLOOD GLUCOSE, BLOOD 
LIPID AND FREE RADICALS IN RATS WITH DIABETES 
MELLITUS 
3.1 Summary 
The effects of ethanol (EEP) and water (WSD) extracts of propolis collected from 
North China on blood glucose, blood lipid and free radicals in rats with diabetes mellitus 
were studied. The results show that EEP and WSD led to decreased levels of blood glucose 
(FBG), fructosamine (FRU), malonaldehyde (MDA), nitric oxide (NO), nitric oxide 
synthetase (NOS), total cholesterol (TC), triglyceride (TG), low-density lipoprotein 
cholesterol (LDL-C), very-low density lipoprotein cholesterol (VLDL-C) in the serum of 
fasting rats; and to increased serum levels of high-density lipoprotein cholesterol (HDL-C) 
and superoxide dismutase (SOD). This suggests that propolis can control blood glucose 
and modulate the metabolism of glucose and blood lipid, leading to decreased outputs of 
lipid peroxidation and scavenge free radicals in rats with diabetes mellitus. 
3.2 Introduction 
Recent articles on propolis credit it with curing diabetes mellitus (Stefano and 
Francesco, 2002), but detailed studies are few and no uniform criteria for the extraction and 
preparation of propolis solutions exist nor do standard methods for the preparation of 
propolis in the treatment of diabetes mellitus in rats. The effects of propolis on blood 
glucose, blood lipid and free radicals in rats with diabetes mellitus were studied and are 
reported here. 
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3.3 Materials and methods 
3.3.1 Drugs and reagents 
Propolis was obtained from colonies of honeybees, Apis mellifera L., in North China in 
2001 and the main plant origin was poplar (Populus sp.). Water soluble derivatives (WSD) 
of pulverized propolis were obtained by extraction of a 30 g sample at 80°C for 12 hours. 
Similar samples of propolis were also extracted in 80% ethanol. Alloxan was obtained 
from the Sigma Chemical Company. Blood glucose reagents were obtained from the 
Shanghai Bio-product Research Institute of the Ministry of Health, P. R. China. 
Fructosamine reagent was obtained from Shanghai Fu-dan- zhangjiang Bio-pharmaceutical 
Company Ltd. Shanghai, China. Reagents for total cholesterol, triglycerides, low-density 
lipo-protein cholesterol, high-density lipo-protein cholesterol were obtained from Cicheng 
Biochemistry Reagent Company, Ningbo, China. Reagents for superoxide dismutase, 
malonaldehyde, nitric oxide and nitric synthetase were obtained from Jiancheng Biology 
Engineering Research Institute, Nanjing, China. 
3.3.2 Laboratory animals 
Male rats (strain SD) of about 350 ± 30 g were provided by the Shanghai Laboratory 
Animal Center of the Chinese Academy of Sciences (Certificate of animal quality: Zhong 
Ke Dong Guan No. 003), and used at The Research Center of the Laboratory of Animal 
Science, Zhejiang College of Traditional Chinese Medicine, Hangzhou, China. The rats 
were allowed a standard pellet diet and free access to water and maintained at 25°C under a 
12/12 hr light /dark cycle. The animals were maintained in keeping with the Helsinki 
accord and the experimental protocol was approved by the Animal Ethics Committee of 
Zhejiang University. 
3.3.3 Induction and treatment of diabetes mellitus 
Diabetes mellitus was induced in rats by the intravenous injection of alloxan (40 
mg/kg) dissolved in physiological saline through the tail vena. Normal control rats were 
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given only physiological saline intravenously. Seven days later, blood was taken from the 
cut tip of the tail and the serum centrifuged to test for blood glucose. 72 rats with a blood 
glucose concentration of about 20 mmol/L were randomly divided into 6 groups including 
a diabetes mellitus (model) control group and WSD I, WSD2, EEP I, EEP2 groups and a 
positive control group. An additional 12 rats were used as the normal control group. 
3.3.4 Method of drug administration 
WSD group: the concentration of dry material of WSD was about 15 mg/ml, and the 
WSDI solution was prepared by a three-fold dilution of WSD; the WSD2 solution was 
prepared by a six-fold dilution of WSD. Rats in the WSDI and WSD2 groups were each 
given intragastrically the WSD I and WSD2 solutions at a rate of I mlllOO g respectively. 
EEP group: the concentration of dry material of EEP was 100 mg/ml, and the EEPI 
solution was prepared by a 20-fold dilution of EEP; the EEP2 solution was prepared by a 
40-fold dilution of EEP. Rats in EEPI and EEP2 groups were each given intragastrically 
the EEPI and WSD2 solutions at the rate of I mill 00 g respectively. 
Positive control group: acarbose was diluted in physiological saline to a concentration 
of I mg/m!. Rats in the positive control group were given acarbose solution intragastrically 
at a rate of I mlllOO g. 
The normal control and the model groups were given 0.9% physiological saline (I 
mIll 00 g) intragastrically and treated twice. 
All rats were injected intragastrically twice daily (09:00 and 15 :00) continuously for 7 
weeks during the course of the eight week long experiment. 
3.3.5 Methods of measurement 
Blood was collected from the cut tip of the tail of all rats each week and the serum 
centrifuged at 3000 rpm/min to test blood glucose. At the end of the experiment, blood was 
collected from the eyes of the rats to test other biochemical indexes. The test methods were 
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done according to the reagent protocols prepared by the manufacturing firms. 
3.3.6 Data analyses 
Results are presented as means ± standard deviations. Statistical analyses were 
performed using regression and ANOV A procedures and Tukey multiple pairwise 
comparison tests with a probability level ofP < 0.05 being considered as significant. 
3.4 Results 
3.4.1 The effects of propolis on blood glucose in rats with diabetes mellitus 
The experiment lasted 8 weeks: the first week involved the induction of diabetes 
mellitus and the remaining 7 weeks the period of drug administration. The effects of 
propolis solutions on blood glucose in rats with diabetes mellitus are given in table 3.l. 
The results show that blood glucose concentration in the diabetes mellitus model group 
increased with time (F1,94 = 29.77, P < 0.0001), while the small changes in the rats with 
diabetes mellitus treated with propolis were not significant (WSD I: F 1,94 = 2.08, P = 
0.1524; WSD2: F1,94 = 0.05, P = 0.8285; EEPI: F1,94= 0.84, P = 0.3619; EEP2: F1,94 = 2.33, 
P = 0.1299; Positive group: F1,94 = 0.96, P = 0.3296). Blood glucose levels in rats with 
diabetes mellitus of the different treatment groups showed no significant differences at the 
end of the first week of drug administration (P > 0.05). 
The blood glucose levels of rats in WSDI, WSD2, EEPI, EEP2 and positive control 
groups decreased 22.2% (P < 0.05), 17.9%, 15.1%, 4.3% and 16.7% respectively 
compared with that of diabetes mellitus model at the second week of drug administration. 
The blood glucose levels in the WSD I, WSD2, EEP I, EEP2 and positive control groups 
decreased 22,2% (P < 0.01), 28.0% (P < 0.01), 20.8% (P < 0.01), 2.6% and 14.0% (P < 
0.0 I) respectively compared with that of diabetes mellitus model group by the end of the 
third week of drug administration. The blood glucose levels in the WSD I, WSD2, EEP I, 
EEP2, and positive control groups decreased 18.2% (P < 0.05), 12.7%, 6.8%, 10.6% and 
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14.8% (P < 0.05) respectively compared with that of diabetes mellitus model group by the 
end of the fourth week of drug administration. 
The blood glucose levels in the WSD 1, WSD2, EEP 1, EEP2 and positive control 
groups decreased 25.7% (P < 0.01), 13.6%, 18.4% (P < 0.05), 19.0% (P < 0.05) and 
24.7% (P < 0.01) respectively compared with that of diabetes mellitus model group by the 
end of the fifth week of drug administration. The blood glucose levels in the WSD 1, 
WSD2, EEP1, EEP2 and positive control groups decreased 34.8% (P < 0.01), 26.4% (P < 
0.01),22.6% (P < 0.01), 11.4% and 18.4% (P < 0.01) respectively compared with that of 
diabetes mellitus model group by the sixth week of drug administration. The blood glucose 
levels in the WSD1, WSD2, EEP1, EEP2, and positive control groups decreased 29.5% (P 
< 0.01),25.9% (P < 0.01), 20.4% (P < 0.01), 18.2% (P < 0.05) and 22.9% (P < 0.01) 
respectively compared with that of diabetes mellitus model group by the seventh week of 
drug administration (table 3.1). 
3.4.2 The effects of propolis on blood lipid in rats with diabetes mellitus 
The effects of propolis on blood lipid in rats with diabetes mellitus are given in table 
3.2. The results show that TC in the WSD1, WSD2, EEPI, EEP2 and positive control 
groups decreased 18.4% (P < 0.01), 20.1% (P < 0.01),15.8% (P < 0.05),7.7% and 19.2 (P 
< 0.01) compared with that of diabetes mellitus model group. The increases of HDL-C in 
the WSD1, WSD2, EEP1, EEP2 and positive control groups (6.2%, 11.1%, 3.7%, 13.6% 
and 16.0%) compared with that of diabetes mellitus model are not significant (P > 0.05). 
LDL-C in the WSD1, WSD2, EEP1, EEP2 and positive control groups decreased 42.7% (P 
< 0.01), 46.3% (P < 0.01), 58.5% (P < 0.01), 52.4% (P < 0.01) and 53.7% (P < 0.01) 
respectively compared with that of diabetes mellitus model group. VLDL-C in the WSD1, 
WSD2, EEP1, EEP2 and positive control groups decreased 34.9% (P < 0.05),36.8% (P < 
0.01),25.0% (P > 0.05), 28.9% (P > 0.05) and 44.1% (P < 0.01) respectively compared 
with that of diabetes mellitus model group. TG in the WSD1, WSD2, EEP1, EEP2 and 
positive control groups decreased 10.7%,23.7%,27.5%,38.2% (P < 0.01) and 30.5% (P < 
0.05) respectively compared with that of diabetes mellitus model group. 
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Table 3.1 Changes in blood glucose in rats with induced diabetes mellitus and normal rats for eight weeks (x ± sd) 
Group n I week 2 weeks 3 weeks 4 weeks 5 weeks 6 weeks 7 weeks 8 weeks 
Normall 12 3.80±0.90** 4.32±0.56** 4A6±0.S6** 3.8S±0.50** 3A3±OAI** 4.51±0.62** 4.91±0.38** S.IS±0.80** 
contra 
Model 
control 12 21.91 ±2.00 22.69±4.72 22AS±S.87 22.54± 1.77 23.49±2.S0 2S.36±3A8 26.99±1.72 27.57±3.60 
WSDI 12 21.94±2.01 19.64±3.63 17A6±2.97* 17.S4±2.61** 19.22±4.88 18.84±3A3** 17.60±SAI** 19.44±S.31** 
WSD2 12 21.93±2.20 20.l2±2AI 18.43±2.46 16.22± I.SS** 20.50±0.9S* 21.92±3.81 19.87±4.SI** 20.43±6.28** 
EEPI 12 21.90± 1.20 19.72±4.93 19.06±3.19 17.84± 1.8S** 21.90±2.52 20.70±S.58* 20.91 ±6.90** 21.9S±S.IS** 
EEP2 12 22.06± 1.82 19.10±3.29 21.47± 1.4S 21.96± 1.23 21.01 ±S.4S 20.54±S.47* 23.92±6.40 22.5S±4.03* 
~~~~~ 12 21.9S± 1.8S 19.D4±3.57 18.70±4.24 19.39±2.61 * 20.02±3.32* 19.09±2.07** 22.04±3.24** 21.26±3.2S** 
* P < O.OS, ** P < 0.01 compared with the diabetes mellitus model control group. 
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Table 3.2 Effects of propolis on the level of total cholesterol (TC), high density 
lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), very 
low density lipoprotein cholesterol (VLDL-C), triglycerol (TG) in rats with induced 
diabetes mellitus (x ± sd) 
Group TC (mmollL) HDL-C LDL-C VLDL-C TG (mmoIlL) n (mmollL) (mmoIlL) (mmollL) 
Normal control 12 2.01 ±0.19' 0.91 ± 0.07 0.49 ± 0.22' 0.49 ± 0.30" 1.24 ± 0.32 
Model control 12 2.34 ± 0.44 0.81±0.09 0.82±0.39 1.52±0.24 1.31 ±0.35 
WSD1 12 1.91 ± 0.23" 0.86 ± 0.14 0.47±0.29" 0.99 ± 0.33" 1.17 ± 0.28 
WSD2 12 1.87±0.23" 0.90 ± 0.13 0.44±0.12" 0.96 ± 0.35" 1.00±0.30 
EEP1 12 1.97 ± 0.28' 0.84±0.23 0.34±0.16" 1.14 ± 0.25 0.95 ± 0.37 
EEP2 12 2.16 ± 0.20 0.92 ± 0.18 0.39 ± 0.09" 1.08±0.44 0.81 ± 0.34" 
Positive control 12 1.89 ± 0.25" 0.94 ± 0.17 0.38±0.13" 0.85 ± 0.58" 0.91 ± 0.26' 
ANOVA F6 77 = 4.82" F 6•77 = 1.18 F 6 77= 6.19" F 6,77 = 8.40 
.. 
F 6,77 = 4.07"' 
* P < 0.05, ** P < 0.01 compared with diabetes mellitus model control group. 
3.4.3 The effects of propolis on the levels of fructosamine, superoxide dismutase, 
malonaldehyde, nitric oxide and nitric oxide synthetase in rats with induced diabetes 
mellitus 
The effects of propolis on the levels of fructosamine (FRU), superoxide dismutase 
(SOD), malonaldehyde (MDA), nitric oxide (NO) and nitric oxide synthetase (NOS) in rats 
with induced diabetes mellitus are given in table 3.3. 
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Table 3.3 Effects of propolis on the levels of FRU, SOD, MDA, NO, NOS in rats 
with induced diabetes mellitus (x ± sd) 
Group n FRU (ll moVL) SOD (NU/ml) MDA(nmoVL) NO(llmoVL) NOS (U/ml) 
Nonna! control 12 224.83 ± 13046" 152.70± 14.05" 5.65± 1.85" 5A3±0.89" 9.36±2.23" 
Model control 12 288.25 ± 6.97 116.08 ± 8.89 9.14± 1.80 20.44±4.65 13.98±2.97 
WSDI 12 222.58± 16041" 143.18± 13.85" 4.87± 1.38" 16.63±2.22 9.92±3.12" 
WSD2 12 232.92 ± 22.69" 143.67±5.87" 6.31 ± 1.60" 16.65±3.90 12.30±4.1O 
EEPI 12 215.25±25.06" 136.33 ± 10.95" 6.02±1.51" 18.09±9.l9 10.98± 1.32 
EEP2 12 257.00 ± 22.20" 126.24± 14.57 5.67±2.66" 16.64±5.03 10041 ± 1.22' 
Positive control 12 239.50±23.5i' 138.l2± 19.59" 5043 ± 1.90" 15.1O±6.89 11.71 ± 1.76 
ANOVA F6•77 = 19.85" F6•77 = 10.15" F6•77 = 6.75" F6•77 = 9.58" F6•77 = 4048" 
• P < 0.05, •• P < 0.01 compared with diabetes mellitus model control group. 
The results of table 3.3 show that FRU in the WSDI, WSD2, EEPI, EEP2 and 
positive control groups significantly decreased 22.8% (P < 0.01), 19.2% (P < 0.01), 25.3% 
(P < 0.01), 10.8% (P < 0.01) and 16.9% (P < 0.01) respectively compared with that of 
diabetes mellitus model group and this result was consistent with that of fasting blood 
glucose levels. 
SOD in the WSDI, WSD2, EEPI and positive control groups significantly increased 
23.3% (P < 0.01), 23.8% (P < 0.01), 17.4% (P < 0.01), and 18.9% (P < 0.01) respectively 
compared with that of diabetes mellitus model group. MDA in each experimental group, 
WSDI, WSD2, EEPI, EEP2 and positive control significantly decreased 46.7% (P < 0.01), 
31.0% (P < 0.01), 34.1% (P < 0.01), 38.0% (P < 0.01) and 40.6% (P < 0.01) compared 
with that of diabetes mellitus model group. 
The decreases of NO in the WSDI, WSD2, EEPI, EEP2 and positive control groups 
(18.6%, 18.5%, 11.5%, 18.6% and 26.1% respectively) compared with that of diabetes 
mellitus model group are not significant (P> 0.05). NOS in each of the groups, WSDI, 
WSD2, EEPI, EEP2 and positive controls decreased 29.0% (P < 0.01), 12.0% (P> 0.05), 
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21.5% (P> 0.05), 25.5% (P < 0.05) and 16.2% (P> 0.05) respectively compared with that 
of diabetes mellitus model group. 
3.5 Discussion 
3.5.1 The effects of propolis on blood glucose 
The United Kingdom Prospective Diabetes Study (UKPDS) recognized that type-2 
diabetes mellitus is an acute, progressive disease and during their IS-year study found that 
the level of glycosylated haematoglobin protein and fasting blood glucose level 
persistently increased. This demonstrated that the ~ cell system of the pancreas becomes 
impaired with time. This study also confirmed that in the patients with type-2 diabetes 
mellitus, it was very important to improve blood glucose levels, decreasing the danger of 
the diabetes mellitus syndrome (UKPDS Group, 1998). It has now also been demonstrated 
that while propolis enhances cell activity and accelerates the regeneration of tissue and 
repair among damaged pancreatic cell (Burdock, 1998), so that it is clearly a therapeutic 
adjunct for the cure of diabetes mellitus. 
Fructosamine is a by-product of the reaction between glucose and albumin, which 
co-occur with keto-amines in serum. The concentration of fructosamine in serum was 
relatively steady and could not be affected by diet. Fructosamine could reflect blood 
glucose changes for 2-3 weeks in a manner similar to glycosylated haematoglobin protein 
(Grey et al., 1995) whereas fasting blood glucose reflects instantaneous blood glucose 
concentration. 
From the results of fructosamine and fasting blood glucose, it is evident that the 
concentrations of fructosamine in different propolis-treated groups were lower than that of 
diabetes mellitus model group, which demonstrates that propolis can efficaciously control 
blood glucose for some time. In addition, given the weekly concentrations of glucose in 
fasting animals, it is probable that propolis could decrease levels of blood glucose and that 
the effect is amplified over time. 
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3.5.2 The effects of propolis on blood lipid in rats with induced diabetes mellitus 
Diabetes mellitus is often associated with blood lipid abnormalities, mainly increased 
levels of TC, TG, LDL-C and decreased levels of HDL-C, which lead to high blood 
pressure, atherosclerosis and coronary heart disease. At present a relationship between 
blood lipid abnormalities and atherosclerosis remains hypothetical. However, it seems 
likely that propolis could increase the contractibility of heart, deepen breath and modulate 
blood pressure, purify blood, as well as modulate blood lipid (Havsteen, 2002; Lin et ai., 
1999). Numerous studies have shown that propolis could modulate high blood lipid, high 
total cholesterol, high blood viscosity and reduce atherosclerosis as well as to improve 
blood circulation (Stefano & Francesco, 2002; Burdock, 1998; Lin et ai., 1999; Fang et al., 
2000; Karsten, 2001). Because patients with diabetes mellitus often have high blood lipid, 
high total cholesterol, the activity of blood vessel scavengers would contribute to the cure 
of diabetes mellitus. 
By testing LDL-C, VLDL-C, TC, TG, HDL-C in this experiment, it was found that 
after propolis treatments of rats with induced diabetes mellitus, the levels of LDL-C, 
VLDL-C, TC, TG were lower compared with that of diabetes mellitus model, but the level 
of HDL-C was higher than that of diabetes mellitus model group. So, it is reasonable to 
conclude that propolis could modulate lipid metabolism and reduce the syndrome caused 
by blood lipid abnormalities. 
3.5.3 The effects of propolis on free radicals in rats with induced diabetes mellitus 
Several studies have documented the relationship between the increase of free radicals 
and the increase of blood glucose, as well as changes of free radicals, lipid peroxidation 
and low-density lipoprotein in the progress of diabetes mellitus. Oxygen radicals would 
harm cells and MDA, as a kind of lipid peroxidation, would reflect the degree of oxidation 
in the body. SOD is a scavenger of free radicals, which has important effects in the 
control of oxidation reactions in the body. The concentration of SOD in type-2 diabetes 
mellitus was significantly higher than that of normal (Akgul et ai., 1997). The cause was 
probably decreased activity of SOD because higher blood glucose could combine with 
SOD. In low concentrations propolis is a natural anti-oxidative, and increases the activity 
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of SOD thus reducing the output of lipid peroxidation (Marcucci, 1995; Isla et ai. , 2001 ; 
Song et ai., 2002; Krol & Czuba, 1990). From these experiments, it appears that the levels 
of SOD increased and that of MDA decreased after treatment with propolis. This suggests 
that propolis has effective anti-oxidative properties and could well scavenge excess free 
radicals. 
3.5.4 The effects of propolis on NO and NOS in rats with induced diabetes mellitus 
NO is an endothelial-enlarging factor produced by NOS, catalysing L-arginine. NO is 
also associated with many physiological and pathological changes in the body. NO 
enlarges blood vessels, reduces blood pressure and the multiplication of nonstriated-muscle 
cells in blood vessels as well as the agglutination of haematoblasts; nonetheless, excessive 
NO is pathogenic. The changes characteristic of the micro-cycle in type-2 diabetes mellitus 
includes damage to the endothelial cells and incrassation of the blood vessel matrix. This 
results in the reduction of blood vessel roughness, diameter and obstructions (Nomara et 
ai., 2000). 
Moreover, these pathological changes are relative to increased levels of NO. From the 
results, we conclude that the levels of NO and NOS in the diabetes mellitus group was 
higher than that of normal rats. However, following treatment with propolis, the levels of 
NO and NOS in diabetes mellitus decreased compared with that of diabetes mellitus model. 
This suggests that propolis decreases the level of NO by decreasing the output of NOS thus 
protecting the endothelial cells of blood vessels and reducing neuronal toxicity. Propolis 
exerts its pharmacological effects by decreasing the action of NO and PGE2 and reducing 
the activation effect of protein kinase to the diabetes mellitus or tumor model (Burdock, 
1998). 
3.5.5 The active components ofEEP and WSD need further research 
Although the main pharmacological constituents of the crude extracts of propolis 
were flavonoids (fagoyprol, quercetin, kaempferol, isoharnmetin, etc.), there may be other 
water-soluble substances in WSD because the anti-inflammatory mechanisms were 
different between the WSD and EEP (Hu et ai. , 2003). Because the extracts of propolis 
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were crude and not purified it is not possible to precisely attribute specific effects to 
specific constituents. Further research on the full complement of active components of 
EEP and WSD are clearly required. 
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CHAPTER 4 
4. EFFECTS OF POLLEN AND PROPOLIS ON DIABETES 
MELLITUS IN SD RATS 
4.1 Summary 
Diabetes mellitus SD rats were given pollen, water and etbanol extracts of propolis 
intragastrically twice a day for four weeks and were tested for indexes of serum and 
kidney weightJbody weight. After four weeks treatment, pollen had the ability to protect 
the kidney from the complications of diabetes mellitus. Pollen and propolis treatments 
decreased the levels of fructosamine, triglyceride, cholesterol, creatinine, malonaldehyde, 
blood urea nitrogen, and the consumption of total protein and albumin. It can be concluded 
that pollen and propolis have a positive effect on diabetes mellitus in SD rats and may 
enhance the metabolism of glucose, fat and protein, and decrease the danger of diabetes 
mellitus affixation disease. 
4.2 Introduction 
Diabetes mellitus is a common incretion disease, caused by the absolute or relative 
absence of insulin, and results in deregulated metabolism. Diabetes mellitus remains an 
acute disease that continues to endanger human health (UKPDS Group, 1998). Articles on 
the effects of pro polis and bee pollen curing diabetes mellitus (Song et aI., 1991b; Jiang & 
Kong, 1996; Wang & Jia, 1998; Gao & Liu, 2000) have recently been published, but 
detailed studies are few. Moreover, there are no uniform criteria for the extraction of 
propolis, and the analysis of different extraction methods of propolis on diabetes mellitus 
remains lacking. In tbis experiment, I studied the effects of bee pollen and propolis on the 
metabolism of blood glucose, blood lipid and protein from a series of biochemical indexes 
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including blood glucose, blood lipid, kidney weightlbody weight to provide experimental 
data to test the efficacy of bee pollen and propolis in curing diabetes mellitus. 
4.3 Materials and methods 
4.3.1 Materials 
Male rats (strain SD) about 300 ± 20 g birth weight were provided by the Shanghai 
Laboratory Animal Center of the Chinese Academy of Sciences (Certificate of animal 
quality: Zhong Ke Dong Guan No. 003), and used at The Research Center of Laboratory 
of Animal Science, Zhejiang College of Traditional Chinese Medicine, Hangzhou, China. 
The animals were maintained and the experiments performed according to the principles 
of the Helsinki accord. The experimental protocol was approved by the Animal Ethics 
Committee of Zhejiang University, Hangzhou, China. 
Propolis and bee pollen were purchased from Lingzhi Apiary, Hangzhou, China. The 
propolis was produced in North China in 200 I and the main plant of origin was poplar 
(Populus sp.). Alloxan was purchased from the Sigma chemical Company. The reagents for 
blood glucose, fructosamine, total cholesterol, triglycerides, creatinine, total protein and 
albumin were supplied by Fudan-Zhangjiang Bio-pharmaceutical Company Ltd. Shanghai, 
China. The reagent for malonaldehyde was provided by Jiancheng Biology Engineering 
Research Institute, Nanjing, China. 
4.3.2 Induction and treatment of diabetes mellitus in SD rats 
Diabetes mellitus was induced in rats by the intravenous injection of alloxan (40 
mglkg) dissolved in physiological saline. Control rats were injected with physiological 
saline alone. 7 days later, blood samples from the cut tip of the tails of all SD rats were 
taken and the serum centrifuged to test blood glucose. Rats with a blood glucose 
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concentration of about 20 mmol/L were selected and then randomly divided into 4 groups 
of 10 diabetes mellitus rats, each: (I) diabetes mellitus control rats, (2) those given bee 
pollen, (3) those given WSD (water-soluble derivatives of propolis), (4) those given EEP 
(ethanol extract of pro polis) and (5) a group of 10 healthy SD rats as normal controls. 
4.3.3 Method of drug administration 
Bee pollen: the concentration of bee pollen solution was about 0.375 g/ml, and 
administered intragastrically at a rate of I mlllOO g body weight. 
WSD (water-soluble derivative of propolis): WSD was prepared according to the 
following method: 30 g of raw propolis was pulverized in a mill, extracted in water at 
80°C for 12 hours, sonicated for 30 minutes at 25 khz, cooled and filtered at room 
temperature, and the dry material was concentrated to about 150 mg/ml and then diluted 5 
times for the group of WSD and administered intragastrically at a rate of I mIll 00 g body 
weight. 
EEP (ethanol extract of propolis): EEP was extracted by 80% ethanol and the dry 
material content was about 750 mg/m!. It was then diluted 25 times for the group of EEP 
and administered intragastrically at a rate of I mIll 00 g body weight. 
Positive control group: acarbose was diluted in physiological saline to a concentration 
of I mg/ml and administered intragastrically. 
SD rats in the normal control group and the diabetes mellitus model group were given 
0.9% physiological saline intragastrically at I mlllOO g body weight. 
All SD rats were treated intragastrically twice a day for about four weeks of the five 
week-long experiment. 
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4.3.4 Methods of measurement 
Blood was taken from the cut tip of the tails of all SD rats each week after they had 
fasted 12 hours. The serum samples were centrifuged at 3000 rpm/min for 10 min to test 
blood glucose. At the end of the experiment, blood samples were taken from the eyeball 
and the serum centrifuged to conduct the other biochemistry indexes. 
4.3.5 Statistical analyses 
Data were reported as means + standard deviations. Comparisons between groups 
were made using ANOV A and repeated measures ANOV A procedures. Tukey and Fisher 
LSD multiple pairwise comparisons tests were used to test for differences between groups 
and the model control group. 
4.4 Results 
4.4.1 Effects of propolis and bee pollen on blood glucose in diabetes mellitus SD rats 
The effects of propolis on blood glucose in diabetes mellitus SD rats are shown in 
table 4.1. The blood glucose level of SD rats in each group of bee pollen, WSD, EEP 
decreased by 13.39%, 13.15%, 17.10% (LSD: P < 0.05) respectively compared with that 
of diabetes mellitus model at end of the first week of drug administration. The blood 
glucose level in the group of bee pollen and WSD rats decreased 1.29% and 2.30% 
respectively compared with that of diabetes mellitus model at the end of the second week 
of drug administration. The blood glucose level in each of the groups of bee pollen, WSD, 
and EEP decreased 6.90%, 4.94%, 4.78% respectively compared with that of diabetes 
mellitus model at the end of the third week of drug administration. The blood glucose 
level in each group of bee pollen, WSD, EEP decreased 16.04% (LSD: P < 0.05), 16.07% 
(LSD: P < 0.05), 17.21% (LSD: P < 0.01) respectively compared with that of diabetes 
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mellitus model on completion of the experiment at the end of the fourth week of drug 
administration. From the results, we deduced that bee pollen and propolis could control 
increases in blood glucose in diabetes mellitus to some degree. 
Table 4.1 Changes in blood glucose of diabetes mellitus and normal SD rats for five weeks (x ± sd) 
Group n I week 2 weeks 3 weeks 4 weeks 5 weeks 
Nonnal 10 2.30±0.66** 0.79±0.41*· 1.02±1.26*· 0.78±0.S7** 2. 19±O.76·· 
Model 10 21.38±3.18 24.72±3.S4 23 .32±2.SS 31.17±6.89 32.66±2.17 
Bee pollen 10 21.14±3.20 21.41±3.34 23 .02±2.l4 29.02±4.44 27.42±4.97* 
WSD 10 20.90±2.44 21.47±4.S8 22.79±2.53 29 .63±7.11 27.41±3.93* 
EEP 10 19.4S±3.52 20.49±4.81* 23 .90±4.03 29.68±3.43 27.04±4.12** 
*P< 0.05, ** P < 0.01 compared with diabetes mellitus model control group. 
4.4.2 Effects of bee pollen and propolis on the levels of fructosamine, triglyceride, 
total cholesterol, creatinine, total protein, albumin and malonaldebyde in 
diabetes mellitus SD rats. 
The effects of bee pollen and propolis on the levels of fructosamine (FRU), 
triglyceride (TO), total cholesterol (TC), creatinine (CREA), total protein (TP), albumin 
(ALB) and malonaldehyde (MDA) in diabetes mellitus SD rats are shown in table 4.2. 
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Table 4.2 Effects of bee pollen and propolis on the level of FRU, TG, TC, CREA, 
TP, ALB and MDA in diabetes mellitus SD rats (x ±sd) 
Group FRU TG TC CREA TP ALB MDA n (mmol!L) (mmol!L) (I:'!!!0I!L ) (giLl (giL) (nmoVL) 
Nonnal 10 73.36±5.27** 0.64±0.17** 1.27±0.34 60.43±5.93* 66.7±8.5** 30.1±3.5** 9.3±O.9** 
Model 10 104.79±13.72 3.97±2.14 1.48±0.25 67.16±5.61 49.4±9.1 23.2±3.6 18.1±5.2 
Pollen 10 97.37± 15.06 2.22±0.73** l.36±0.36 66.13± 12.56 53.0±5.7 23.l±1.2 l4.7±2.5 
WSD 10 93.79±15.38 2.07±0.65** 1.26±0.22 67.42±5.46 52.1±9.9 23.3±4.0 l4.5±1.6 
EEP 10 94.54±6.64 1.91±0.75** 1.22±0.20 60.43±4.74* 5S.0±7.2 24.0±1.3 l4.1±3.1* 
*p < 0.05, ** P < 0.01 compared with diabetes mellitus model control group model. 
The FRU level of SD rats in each group of bee pollen, WSD, EEP decreased 17.1 %, 
10.5%, 9.8% respectively compared with that of diabetes mellitus model at end of four 
weeks of drug administration. The TG level of SD rats in each group of bee pollen, WSD, 
EEP decreased 44.2% (P < 0.01), 47.8% (P < 0.01), 51.9% (P < 0.01) respectively 
compared with that of diabetes mellitus model at end of four weeks of drug administration. 
The TC level of SD rats in each group of bee pollen, WSD, EEP decreased 7.8%, 15.1 %, 
17.6% (LSD: P < 0.05) respectively compared with that of diabetes mellitus model at end 
of four weeks of drug administration. The CREA level of SD rats in EEP group decreased 
10.0% (LSD: P < 0.05) compared with that of diabetes mellitus model at end of four 
weeks of drug administration. The TP level of SD rats in each of the groups of bee pollen, 
WSD, EEP increased 7.29%,5.52%,11.34% respectively compared with that of diabetes 
mellitus model at end of four weeks of drug administration. The MDA level of SD rats in 
each group of bee pollen, WSD, EEP decreased 18.5%, 19.9%, 22.1% (P < 0.05) 
respectively compared with that of diabetes mellitus model at end of four weeks of drug 
administration. 
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4.4.3 The effects of bee pollen and propolis on body weight, kidney weight and kidney 
weightlbody weight. 
Table 4.3 Effect of bee pollen and propolis on body weight, kidney weight and 
kidney weight / body weight (x ±sd) 
Group 
Body weight Kidney weight Kidney weighVbody weight 
n 
(g) (g) X 100 
Nonnal control 10 335.0±IS.4** 1.25±0.OS 3.73±0.21*· 
Model control 10 202.3±2S.4 1.30±0.16 6.47±0.52 
Bee pollen 10 227.6±22.1 1.37±O.17 6.00±0.SO 
WSD 10 241.3±43.2** 1.47±0.21 6.23±1.21 
EEP 10 220.5±36.0 1.33±0.19 6.14±0.11 
** P < 0.01 compared with diabetes mellitus model control group model. 
The effects of bee pollen and propolis on body weight, kidney weight and kidney 
weightlbody weight are shown in table 4.3. From the result of kidney weightlbody weight, 
we could see that the effect in the groups of bee pollen and EEP was better than others 
although not significant. 
4.5 Discussion 
4.5.1 Effects of bee pollen and propolis on blood glucose 
As is well known, the level of fasting blood glucose concentration shows 
instantaneous changes of blood concentration. From the results of five weeks of treatment, 
it was found that the level of blood glucose decreased significantly by the end of the first 
week and the fourth week after drug administration compared with that of model group. It 
is necessary to further investigate the effects of bee pollen and propolis on blood glucose 
in diabetes mellitus rats over a more extended time period. 
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Fructosamine was a consequence of the reaction between glucose and albumin, which 
occurs in serum with keto-amines. The concentration of fructosamine in serum was 
relatively steady and was not affected by diet. Fructosamine could reflect the blood 
glucose changes for 2-3 weeks just like glycosylated haematoglobin protein (Li et aI. , 
200 I b). It could reflect blood glucose changes better than instantaneous changes of blood 
concentration, so that the results on fructosamine further support an interpretation that bee 
pollen and propolis may control the level of blood glucose to some degree. 
4.5.2 Effects of bee pollen and propolis on the metabolism of blood lipid 
Diabetes mellitus often co-occurs with blood lipid abnormalities, mainly resulting in 
higher levels of TC and TG than normal, and which could lead to high blood pressure, 
atherosclerotic and coronary heart disease. At present, the relationship between blood lipid 
abnormalities and atherosclerotic conditions has been confirmed. 
Propolis could increase the contractibility of the heart, deepen respiration, modulate 
blood pressure, purify blood, as well as modulate blood lipid. Numerous reports have 
shown that propolis could modulate high blood lipid, high total cholesterol, high blood 
viscosity and protect against atherosclerotic conditions and protect the blood vessels of the 
heart and brain to improve blood circulation. Because patients with diabetes mellitus often 
have high blood lipid and high total cholesterol, the activity of blood vessel scavengers 
would contribute to the cure of diabetes mellitus. 
From the statistical analysis of the results it was found that the levels of the 
triglycerides in the groups bee pollen and propolis treated animals were lower than that of 
the model control group. Furthermore, the difference in the groups of WSD and EEP were 
significant compared with that of model control. I deduce that the effect of propolis to 
decrease the level of triglyceride was better than that of bee pollen. 
From the statistical analysis of the results for total cholesterol, it was found that the 
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level in the group of bee pollen and propolis was lower than that of model control group. 
Furthermore, the difference in the group of EEP was significant compared with that of 
model control. It is inferred that bee pollen and propolis could control increases in blood 
lipid and the effectiveness of pro polis was better than that of bee pollen. 
4.5.3 Effects of bee pollen and propolis on diabetes mellitus nephropathy 
Another acute syndrome of diabetes mellitus is nephropathy, the main symptom of 
which is damage to the kidney. From the results of kidney weightlbody weight analysis, it 
was found that the ratio in the group of bee pollen was smallest, the effect in the group of 
propolis was no better than that of bee pollen, but the effect in the group ofEEP was better 
than that of WSD. From the results for creatinine, it was found that the difference in the 
EEP group was significant compared with that of model control group. Bee pollen 
produced more effective protection for the kidney than did propolis. 
4.5.4 Effects of bee pollen and propolis on fat metabolism 
Diabetes mellitus often causes disturbances of protein metabolism. From the 
statistical analysis of the results for total protein and albumin, it was found that the 
wastage of total protein and albumin in the groups of bee pollen and propolis was lower 
than that of model control group, which showed that bee pollen and propolis could 
modulate the disturbances of protein metabolism in diabetes mellitus. 
4.5.5 Effects of bee pollen and propolis on free radical in diabetes mellitns 
The relationship between the increase of free radicals and the increase of blood 
glucose, and the change of free radicals, lipid peroxidation and low-density lipoprotein are 
associated with progressive diabetes mellitus. Oxygen radicals would harm cells and DA, 
as a result of lipid peroxidation and would reflect the oxidation degree of body. 
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From the experiment, it can be seen that the level of MDA decreased after treatment 
with bee pollen and propolis, which indicates that bee pollen and propolis have effective 
anti-oxidative properties and could scavenge much of the free radical pool in the body. 
Furthermore, the effect of propolis was better than that of bee pollen. 
Absence of insulin in diabetes mellitus is related to the function of P cells. 
Malnutrition inducing the absence of vitamins and some mineral elements such as vitamin 
B6, Cr, Zn, Fe, Mg, Ca, P also could lead to damaging p cells. Vitamin B6 is abundant in 
pollen and some micro-mineral elements in pollen to protect p cells and aid in the 
secretion of insulin. 
Besides these, propolis is a complex material, and the chemical components of 
different sources are different, as is the biological activity of different extraction methods. 
From this experiment, it is evident that the biological activity of WSD and EEP was not 
the same, but they were useful in the control of diabetes mellitus. It is necessary to study 
the mechanism of propolis and bee pollen on curing diabetes mellitus more extensively. 
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CHAPTERS 
5. ANTI-INFLAMMATORY EFFECTS OF ETHANOL AND WATER 
EXTRACTS OF PRO POLIS 
5.1 Summary 
Propolis solutions extracted by ethanol (EEP) and water (WSD) were assessed for 
their anti-inflammatory effects using Freund's complete adjuvant (FCA) induced arthritis 
in rats. Both EEP and WSD showed inhibitory effects on swelling induced by FCA and 
decreased the degree of local inflammatory responses. EEP and WSD significantly 
inhibited the increase of interleukin-6 (IL-6) in inflamed tissues, but had no significant 
effect on levels of interleukin-2 (IL-2) and interferon-y (IFN-y). The results are consistent 
with the interpretation that EEP and WSD may exert these effects by inhibiting the 
activation and differentiation of mononuclear macrophages. 
5.2 Introduction 
Propolis has a very low water solubility and studies on such derivatives are few 
indeed. Its anti-complementary activity in vitro and complementary activity in vivo have 
been documented (Ivanovska et al., 1995a). Previous results indicated that the action of 
WSD depends on the route of WSD administration and not on relative differences in the 
effects of WSD and EEP. In this experiment, the effects of propolis solutions extracted by 
ethanol (EEP) and water (WSD) on Freund's complete adjuvant (FCA) induced arthritis in 
rats were studied to further assess the pharmacological properties of propolis. 
Multiple-arthritis is an important character of the arthritic rat model induced by FCA and 
exhibits important similarities to human rheumatoid arthritis. The model is also sensitive to 
anti-inflammatory and immune-inhibiting medicines (Ivanovska et al., 1995a; Hu et al., 
2003). 
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5.3 Materials and methods 
5.3.1 Laboratory animals 
Male Wistar rats of about 200 ± 20 g were provided by the Shanghai Laboratory 
Animal Center of the Chinese Academy of Sciences (Certificate of animal quality: Zhong 
Ke Dong Guan No. 003), and used at The Research Center of Laboratory Animal Science, 
Zhejiang College of Traditional Chinese Medicine, Hangzhou, China. Standard 
international animal ethical procedures were followed with respect to housing at five 
animals per cage and feeding the animals. 
5.3.2 Drugs and reagents 
Propolis was obtained in North China in 2001 and the main plant origin was poplar 
(Populus sp.). The samples were stored at -20°C prior to analysis and before 
experimentation samples were assayed for flavonoid content to obtain a uniform batch of 
experimental propolis. 
5.3.2.1 Determination of total contents of flavonoids in propolis 
Instrument 
UV-Vis Spectrophotometer 
Reagents 
Preparation of standard rutin solution 
Weigh out 200 mg rutin dried to constant weight in a negative pressure drier with 
120°C, put it into a 100-ml volumetric flask, add 70 ml methanol (AR) to the same 
volumetric flask. Heat up this volumetric flask slightly to dissolve the mixtures through 
water bath, shake the solution up after cooling. Absorb 10 ml of this solution to another 
100-ml volumetric flask; add distilled water into the second volumetric flask to 100mi and 
shake up the new solution. The new solution is the standard rutin solution with a 
concentration of 0.2 g rutin per ml. 
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Preparation of 5% NaNOz 
Weigh 5 g NaN02, dissolve it with distilled water and then add distilled water to 100 
m!. 
Preparation of 10% AI (NOzh 
Weigh 109 Al (N02)3, dissolve it with distilled water and then add distilled water to 
100 m!. 
Preparation of NaOH 
Weigh 4.3 g NaOH, dissolved it with distilled water and add to 100 m!. 
Determination methods 
Preparation of standard curve 
Absorb standard rutin solution respectively 1.0 ml, 2.0 ml, 3.0 ml, 4.0 ml, 5.0 ml, 6.0 
ml, put them respectively into 25-ml volumetric flasks, all are added water to 6.0ml, then 
add I ml 5% NaN02 to every volumetric flask. Shake these solutions equably and stable 
for 6 minutes, then add 10% Al (NOZ)3 solution 1 ml to all volumetric flasks. Six minutes 
later, add 10 ml NaOH to every volumetric flask and then add distilled water to all 
volumetric flasks to 25 m!. Shake these solutions equably and stable for 5 minutes, 
determine their absorbance at the wavelength of 550 nm and draw the standard curve. 
Determination oftotal contents of flavonoids in samples 
Weigh 5 g propolis and put it into Soxhlet apparatus, add 120 ml ether to the apparatus 
and heat up for recycling until the extraction solution become colourless. Cool the 
apparatus and take away the ether solution, then add 90 ml methanol into the apparatus. 
Heat up until the extraction solution becomes colourless. Transfer methanol solution to a 
100-ml volumetric flask, clean the former volumetric flask with a little methanol and 
transfer the cleaning methanol into the same 100-ml volumetric flask. Add methanol to this 
volumetric flask to 100 ml and shake and stable the solution. Absorb 3 ml this kind of 
solution and put it into a 25-ml volumetric flask. According the methods of the preparation 
of standard curve (refer to step 2.1), to determine the absorbance of propolis solution, 
conduct the following experiment since the step of adding distilled water to the 25-ml 
volumetric flask to 6 m!. 
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Calculations 
A 
x=--------
10.0 3.00 1000 mx-- x-- x 
100 100 
where X = the total contents of flavonoids (calculated through the contents of rutin), mglkg, 
A = the recovery contents of rutin in sample solution, and m = the weight of propolis, g. 
5.3.2.2 Preparation of WSD and EEP 
The WSD was prepared according to the following method: 30 g of raw propolis was 
pulverized in a mill, extracted in water at 80°C for 12 hours, sonicated for 30 minutes at 25 
khz, cooled and filtered at room temperature. EEP was obtained as follows: 30 g propolis 
powder was extracted in 100 ml 80% ethanol, sonicated for 30 minutes at 25 khz, and 
filtered. WSD and EEP were prepared to obtain a solution of I gil of propolis extract. 
Pharmaceuticals included prednisone acetate (Xianju Pharmacy Ltd. Company), Freund's 
complete adjuvant (Sigma Company, Lot: 68H8504); ELISA reagents for endogenous rat 
interleukin-2 (IL-2) (RND Company, Lot: R2000), the endogenous rat interleukin-6 (IL-6) 
(Bender Company, Lot: BMS625) and the endogenous rat interferon-y (IFN-y) (Hyzult 
Company, Lot: HkOIO) were obtained from JINGMEI Biotech Company. 
5.3.3 Protocols 
The experimental protocol was designed in terms of the Helsinki convention and 
approved by the Animal Ethics Committee of Zhejiang University. The general 
methodology followed was that of Tang et al. (2000). 50 male Wistar rats were randomly 
divided into 5 groups, and treated once daily intragastrically with (I) EEP, (2) WSD, (3) 
sterile saline (normal control group), (4) sterile saline (model control group), and (5) 
prednisone acetate (positive control group) respectively. Both right and left hind paw 
cubages of all rats were measured manometrically before treatment. On day I of the 
experiments the animals were treated with prednisone acetate and the propolis solution. 3 
days later, all the rats were treated with FCA (0.1 ml) by intradermal injection on the pad 
of the right hind paw (except for the group 3). On the 1st through the 5th, and on the 7th, 
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11th, 13th 16th, 19th day after treatment, the cubages of both right (site of primary 
infection) and left (site of secondary infection) hind paws were measured and assessed for 
any anti-inflammatory effects which were measured as the degree of swelling. On the 19th 
day, all the rats were weighed and then killed. The right hind paw, thymus and the adrenal 
glands were excised and weighed separately. The right hind paws were placed in 5 ml 
sterile saline at 4°C over night. The samples were then centrifuged at 3000 rpm, and the 
supernatant used to measure the levels of prostaglandin-E2 (PGE2), IL-2, IL-6 and IFN-y. 
Quantitative measurements of rat IL-2, IL-6 and IFN-y were determined with an enzyme 
linked Immunosorbent assay method (Ossege et ai., 1998; Gould et ai., 1998) and the 
levels of PGE2 were measured by absorption spectrometry (Jiang & Geng, 1998; Naderali 
& Poyser, 1997). Both the thymus and adrenal gland indices were measured as the weight 
of the individual organ divided by total animal body weight and expressed as mg 
organ/IOO g total body weight. 
5.3.4 Statistical analyses 
Data are reported as means ± standard deviations. Levene's test and Kolmogorov 
Smirnov test were used to test for homogeneity of the variances and normality of the 
response variables respectively. Comparisons between groups were made using ANOYA 
and repeated measures ANOYA procedures. Thkey's multiple pairwise comparisons tests 
were used to test for differences between groups and the model control group. 
5.4 Results 
Effects of WSD and EEP on body weight, thymus index, and adrenal gland index in 
FCA-induced arthritic rats are given in table 5.1. There was no significant difference in the 
mean initial weight of the rats between groups (F3,28 = 0.93, P = 0.4389), whilst there was 
a significant difference in mean weight on the 19th day between the groups (F3,28 = 4.2, P = 
0.0139). The results showed that both WSD and EEP could prevent body weight loss 
(Tukey: WSD: P = 0.0232, EEP: P = 0.1851), but had no effect on the thymus index or 
adrenal gland index. Weight, thymus index and adrenal index passed Levene's test of 
homogeneity (P > 0.05) and Kolmogorov Smirnov test of normality (P > 0.20). 
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Table 5.1 Effects of WSD and EEP on body weight, thymus index and adrenal gland 
index in FCA-induced arthritic rats (x + sd) 
Weight of 
On the 19th day after injecting FCA 
Dose Group (mV100g) n normal rats Thymus index Adrenal index (g) Weight (g) (mg/IOOg) (mgIlOOg) 
Model control 8 205.5±5.3 266.5±19.7 l56.8±25.0 l7.8±2.4 
Prednisone acetate 10mg/kg 8 200.4±6.8 269.5±20.3 l40.3±20.9 l2.9±2.5" 
WSD 8 204.8±5.6 294.0±11.7' l59.5±17.3 l6.7±2.l 
EEP 8 205.0±9.4 285.l± 18.8 l63.9± 12.9 l6.0±1.l 
*p < 0.05, **p < 0.01 compared with model control group. 
The results of WSD and EEP on paw swelling of the primary (right paw) and 
secondary (left paw) sites in FCA-induced arthritic rats are given in tables 5.2 and 5.3. The 
results of a repeated measures ANOVA showed a significant difference in mean 
FCA-induced paw swelling of the primary infection between the groups (F3,20 = 7.42, P = 
0.0016), days (F 10,200 = 69.08, P < 0.0001) and interactions of groups x days (F30,200 = 1.89, 
P = 0.0053). EEP and WSD inhibited swelling in the primary affection but the decrease in 
swelling was not significant for all the different days (table 5.2). The decrease, however, 
was significant on day 7 for EEP and WSD and day 13 for EEP when compared to the 
model group. Swelling passed Levene's test of homogeneity for each of the 20 time 
periods (P> 0.01) and Kolmogorov Smimov test of normality (P > 0.10). 
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Table 5.2 Effects of WSD and EEP on swelling of the right hind paw in FCA-
induced arthritic rats (x + sd) (the primary affection) 
Group Model control Prednisone acetate WSD EEP 
Dose (mJJlOOg) - lOmglkg I 1 
n 6 6 6 6 
Cubage before 
inflammation (ml) 1.01 ±0.05 0.98±0.08 1.02±0.07 1.02 ± 0.07 
Id 1.43±0.1O 1.37±0.08 1.33±O.1O 1.37±0.04 
2d 1.89±0. IS 1.68±0.IS 1.71±0.07 1.72±0.18 
3d 1.84±0.17 1.68±0.09 1.80±0.18 1.76±0.19 
Cubage of Sd l.70±0.13 l.57±0.16 1.78±0. IS 1.64±0.14 
right hind 
7d 1.82±0.23 1.44±0.06' 1.52±0.IS' 1.47±0.08' 
paw after 
1.46±0.lO' 9d l.7S±0.22 I.S8±0.13 1.62±0.12 
inflammation 
(ml) lld I.S7±0.ll I.S4±0.16 1.37±0.OS 1.41±0. IS 
13d l.70±0.08 1.43±0.OS' 1.61±0.12 I.S2±0.09· 
16d I.S2±0.08 1.43±0.23 1.49±0.ll I.S3±O.1O 
19d l.74±O.21 I.S3±O.16 l.53±0.21 1.6S±0.13 
*p < 0.05 compared with model control group. 
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Table 5.3 Effects of WSD and EEP on swelling of left hind paw (x + sd) (the 
secondary affection) 
Group Model control Prednisone acetate WSD EEP 
Dose (mII100g) - 10 mglkg 1 1 
n 6 6 6 6 
Cubage before 
inflammation (mI) 1.00±0.04 0.98±0.08 1.03±0.04 1.01±0.12 
Id 1.04±O.10 0.97±0.06 1.04±0.08 0.98±0.07 
2d 1.08±O.13 0.94±0.08 0.98±0.13 1.02±0.09 
3d 1.04±O.18 1.13±0.06 0.98±0.17 1.00±0.13 
Cubage 
before Sd l.O8±O.09 1.l0±0.lO l.O7±O.20 l.Ol±O.lO 
inflam- 7d 1.2S±O.18 1.07±O.1O 1.03±O.17 O.98±O.lS 
malion of 9d 1.20±O.16 l.lS±0.06 1.14±O.17 1.22±O.O7 
left hind lld 1.13±O.12 l.21±O.13 l.07±0.lS l.O9±O.O7 
paw (mI) 
13d 1.19±O.14 1.10±0.14 1.16±0.O8 1.22±O.14 
16d l.02±O.OS O.94±O.O9 l.O3±0.12 l.O8±O.14 
19d l.30±0.09 l.1S±O.12 1.23±0.04 1.22±O.13 
The results of a repeated measures ANOVA showed no significant difference in 
FCA-induced paw swelling of the secondary infection between the groups (F3,20 = 1.11, P 
= 0.3693). There were significant differences between days (F IO,200 = 12.75, P < 0.0001) 
and interactions of groups x days (F3o,200 = 1.71, P = 0.0168) EEP and WSD had some 
inhibitory effect on swelling but the results when compared to the model control group 
were not significant. 
The effects of WSD and EEP on the level of PGE2, IL-2, IL-6 and IFN-y in the 
extravasate of the right paw of FCA-induced arthritic rats are given in table 5.4. The 
transformation Loge(IL-6) was used in the ANOVA because IL-6 failed Levene 's test of 
homogeneity of the variances. The results showed significant differences in the mean 
levels of PGE2 between the groups (F4,25 = 15.4, P < 0.0001), of IL-6 (F4,25 = 8.68, P = 
69 
0.0002) and of IFN-y (F4"s = 5.87, P = 0.0018) (table 5.4). EEP had a significant inhibitory 
effect on the level of PGE, in FCA-induced arthritic rats (Tukey: P < 0.05). WSD and EEP 
had significant inhibitory effects on the level of IL-6 (Tukey: P < 0.0 I), but had no 
significant effects on the levels of IL-2 and IFN-y. PGE" IL-2, IL-6 and IFN-y passed 
Kolmogorov Smirnov test of normality (P > 0.20). PGE" IL-2, Log,(IL-6) and IFN-y 
passed Levene's test of homogeneity (P > 0.05). 
Table 5.4 Effects of WSD and EEP on the levels of PGE2, IL-2, IL-6 and IFN-"( in 
the extravasate of FCA-induced arthritis rats (x +sd) (n = 6 for each group) 
GrouI' Dose(mVIOOg) PGE, IL-2 (Eg) IL-6 (Eg) IFN-y lEg) 
Normal control 0.011±O.006" 19.7S±S.27 106.67±16.33 733.33±8S.71' 
Model control 0.047±O.011 12.3S±S.14 138.67±37.80 623.33±73.12 
Prednisone acetate IOmg/kg O.030±0.010' 17.17±4.67 66.00±23.66** S86.67±4S .90 
WSD 0.034±0.00S 14.S8±S.89 78.33±11.69*' 69S.00±96.69 
EEP 0.026±0.007" IS.27±4.06 88.33±19.41' S6S.00±4S.06 
'P < O.OS , "P < 0.01 compared with model control group. 
5.5 Discussion 
The characteristics of inflammation can be divided into acute, chronic, irritability and 
immunity related inflammation. The arthritic rat model induced by FCA is associated with 
the immunity inflammation reaction in this experiment. Cytokines play an important role 
in immune and inflammatory responses in vivo, being one group of low molecular weight 
proteins secreted by immune cells (lymphocyte and mononuclear-macrophage) and to 
fibroblasts and endothelial cells. The cytokines were divided into two groups: (I) 
Iymphokines (such as IL-2, IL-4, IL- IO and IFN-y etc.) secreted by T-cells with an immune 
function and (2) monokines (such as IL-I, IL-6, IL-8 and TNF-o. etc.) secreted by 
mononuclear-macrophages with moderate inflammatory activity. The results of the present 
experiment show that EEP and WSD had significant inhibitory effects on the levels of IL-6 
in FCA-induced arthritis rats, but not on the levels ofIFN-y and IL-2. This suggests that, in 
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the course of the anti-inflammatory effects ofWSD and EEP, the humoral immune system 
(not cell system) plays an important role. This suggests that inhibiting the activation and 
differentiation of mononuclear macrophages is one of the possible mechanisms for the 
anti-inflammatory and immune effects ofWSD and EEP. 
Any factor that induces tissue damage could be described as the pathogenesis of an 
inflammation. There are two kinds of induced inflammation factors : the inflammation 
stimulation factor, which mainly includes physical (e.g. , bruises, burns, frostbite, radial 
damage etc.) and chemical factors (acid, alkali, digestive liquid, allergens, mineral oil etc.), 
and biochemical factors (microorganisms, parasites, endotoxins, transplant heterogeneity 
and animal toxins). Other inflammatory media include histamine, bradykinin, 
prostaglandin, platelet activation factor, neutrophils hydrolase, inflammation 
pre-stimulation factors (TNF -a, 1L-I, lL-6, cell chemotaxis factor etc.), adherence cell 
(select element, conformity element, adherence cell between cells, blood vessel cell 
adherence cell etc.), cruor system stimulation factor, acute reaction protein (C reaction 
protein, LPS combined protein, serum starched protein A etc.) (Akarasereenont et al., 
1995). EEP and WSD could inhibit the increase of PGE2, which was perhaps the 
mechanism underlying the anti-inflammatory properties of propolis. 
The main characteristic of rheumatoid arthritis (RA) is the ongoing damage in 
arthrosis of cartilage and bone, and at the same time with a disturbance of immune function. 
In the context of RA, there exist neutrophils, activation macrophages, lymphocytes and 
other elements associated with the abduction, activation and releasing of cytokine, which is 
perhaps one of the mechanisms of RA. In the case of rheumatoid arthritis, the 
concentration of cytokine derived from T cells was generally low, whereas that of 
mononuclear macrophages was significantly higher (Xu, 1996). WSD and EEP can inhibit 
the increase of inflammatory medium and decrease the activation and inducing effects of 
cytokines, which indicates that both extracts exhibit the same anti-inflammatory effects. 
WSD is processed in a simple manner, at low cost and of lower allergenic effects and 
olfactory irritability. Likewise, it differs from the glucocorticosteroids, which have the side 
effects of weight loss and partial inhibition of the immune system. 
Further study and analysis of the absorption, metabolism, distribution and excretion 
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and the effective components of WSD should be perfonned, especially to isolate and fully 
characterize the active principles of propolis (Tan, 2001). Likewise, different solvents may 
change the confonnation ofthe ingredients and hence influence their effects. 
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CHAPTER 6 
6. EFFECTS OF ETHANOL AND WATER EXTRACTS OF 
PROPOLIS ON ACUTE INFLAMMATORY ANIMAL MODELS 
6.1 Summary 
The anti-inflammatory effects of ethanol (EEP) and water (WSD) extracts in ICR mice and 
Wistar rats were analyzed. The results showed that both WSD and EEP exhibited significant 
anti-inflammatory effects in animal models with respect to thoracic capillary vessel leakage in 
mice, Carrageenan-induced oedema, Carrageenan-induced pleurisy and acute lung damage in 
rats. The mechanisms for the anti-inflammatory effects probably involve decreasing PGEz and 
NO levels. 
6.2 Introduction 
Propolis is generally insoluble in water, so that pharmacological studies on 
water-soluble derivatives of propolis are few indeed. Thus, the effects of propolis solutions 
extracted by ethanol (EEP) and water (WSD) on acute inflammatory conditions were studied to 
further assess its solubility properties in relation to the biological activity of this beekeeping 
by-product. 
6.3 Materials and methods 
6.3.1 Laboratory animals 
Experiments were performed using male ICR mice of about 18-22 g and male Wistar 
rats about 180-220 g provided by the Shanghai Laboratory Animal Center of the Chinese 
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Academy of Sciences (Certificate of animal quality: Zhong Ke Dong Guan No. 003) at The 
Research Center of the Laboratory of Animal Science, Zhejiang College of Traditional 
Chinese Medicine, Hangzhou, China. The animals were maintained and the experiments 
performed according to the principles of the Helsinki accord. The experimental protocol 
was approved by the Animal Ethics Committee of Zhejiang University, Hangzhou, China. 
6.3.2 Drugs and reagents 
Propolis was obtained in North China in 2001 and the main plant origin was poplar 
(Populus sp.). Water-soluble derivatives (WSD) of propolis were obtained after it was 
comminuted in water at 80°C for 12 hours. Ethanol extracted propolis (EEP) was extracted 
in 80% ethanol. The concentrations ofWSD and EEP were I g pure propolis per L solution. 
Prednisone acetate and dexamethasone acetate were obtained from Xianju Pharmacy 
Ltd.Zhejiang, China; carrageenan, lipopolysaccharide (LPS) and Evans Blue were obtained 
from Sigma Company. Total protein reagent was obtained from Cicheng Biochemistry 
Reagent Company, Ningbo, China. Other reagents, such as malodialdehyde (MDA), 
superoxide dismutase (SOD) and glutathione-peroxidase (GSH-PX), nitric oxide (NO), and 
lysozyme, were produced by the Institute of Jiancheng Biology Engineering, Nanjing, 
China. Instruments used were standard laboratory equipment: YP600 electronic 
microbalance and FAlO04 electron analysis scale (Shanghai Second Balance Instrument 
Plant, Shanghai, China), Micro half-automatic biochemistry instrument (VITALAB 
Company, Holland), TCL-16G frozen centrifugation and 80-2B centrifugation (Shanghai 
ANTING Science Instrument Plant, Shanghai, China), 723 Spectrophotometer (Shanghai 
Second Analytical Instrument Plant, Shanghai, China). 
6.3.3 Thorax capillary vessel leakage in mice 
The methodology used was that of Lu (1999). 40 male ICR mice were randomly 
divided into 4 groups, and given intragastrically (I) EEP, (2) WSD, (3) sterile saline 
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(nonnal control group), or (4) prednisone acetate (positive control group) respectively and 
treated once daily continuously for 5 days. One hour after the last dose was given, each 
mouse was given intravenously 2% Evans Blue (0.1 mlliO g) through the tail vena, and 
given intraperitoneally 0.6% acetic acid (0.2 ml/each) at the same time. Twenty minutes 
later the mice were killed, and each thorax was washed with 5 ml distilled water. The 
washing liquid was centrifuged to obtain a supernatant for the measurement of optical 
density (OD) and read spectrophotometric ally at 590 nm so that the OD value could serve as 
a test for any capillary vessel leakage. 
6.3.4 Carrageenan-induced paw oedema in rats 
The methodology used was that of Wei (1999). Thirty-two male Wistar rats were 
randomly divided into 4 groups, and given intragastrically (l) EEP, (2) WSD, (3) sterile 
saline (nonnal control group), or (4) dexamethasone acetate (positive control group) 
respectively and treated once daily continuously for 5 days. The right hind paw cubage of 
all rats was measured before treatment. Thirty minutes later, each rat was treated 
(intradennal injection) with I % Carrageenan (0.1 ml) on the pad of the right hind paw, and 
given intraperitoneally sterile saline (4 mlllOO g avoirdupois). Inflammation, measured as 
paw cubage, was measured hourly for six hours to assess possible anti-inflammatory effects 
on oedema. 
6.3.5 Carrageenan-induced pleurisy in rats 
The methodology used was that of Geng (2002). 60 male Wistar rats were randomly 
divided into 5 groups, and given intragastrically (I) EEP, (2) WSD, (3) sterile saline 
(model control group), (4) sterile saline (nonnal control group), or (5) prednisone acetate 
(positive control group) respectively and treated once daily continuously for 7 days. Thirty 
minutes after the initial treatments, all the rats (except those in nonnal control group) were 
injected with 1% Carrageenan (0.2 mIlIOO g) in the right thorax after light anaesthesia with 
ether, while rats in the nonnal control group were treated with sterile saline. Inflammation 
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was induced within 4 hours. Eight hours later, all the rats were killed by decollation and the 
extravasate in the thorax collected by aspiration. Each thorax was then washed with 2 ml 
sterile saline, after which the extravasate and washing solution were mixed. One hundred 
micolitres of the solution was used to count WBC, the rest was centrifuged and stored at 
-20°C. An aliquot of 0.5 ml of sup em at ant was used to measure protein levels; while 0.15 ml 
solution and I ml 0.5N KOH-methanol was used to measure optical density (OD) at 278 nm 
with a TU-I 00 I ultra-spectrophotometer after incubation in water at 50°C for 20 minutes, 
and the OD value measured to calculate the content of prostaglandin-Ez (PGE2). Another 
solution sample of 200 ~l was used to measure nitric oxide (NO) levels. 
6.3.6 Acute lung damage in rats 
The methodology used follows that of De Jongh (1997). 60 male Wistar rats were 
randomly divided into 5 groups, and given intragastrically (I) EEP, (2) WSD, (3) sterile 
saline (normal control group), (4) sterile saline (model group), or (5) dexamethasone acetate 
(positive control group) respectively and treated once daily continuously for 7 days. All the 
rats were given oleic acid (0.2 ml/kg) intravenously through the tail vena. Four hours later, 
all the rats were given lipopolysaccharide (LPS) (2 mglkg) intravenously through another 
tail vena, and 2 hours later, all the rats were killed to count WBS, and the left lung weighed 
to calculate the lung index. 
6.3.7 Statistical analyses 
Data are reported as means ± standard deviations. Levene's test and the Kolmogorov 
Smimov test were used to test for homogeneity of the variances and normality of the 
response variables, respectively. Comparisons between groups were made using ANOYA 
and repeated measures ANOYA procedures. Tukey's multiple pairwise comparisons tests 
were used to test for differences between groups and the model control group. 
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6.4 Results 
6.4.1 The effect of propolis on celiac capillary leakage in mice 
A significant effect of propolis on celiac capillary leakage in mice was found between 
the groups (F3,26 = 3.1, P = 0.0442). The results show that WSD has a significant inhibitory 
effect on acetic acic-induced celiac capillary leakage (Tukey: P = 0.0616). The effect of 
WSD was similar to that of prednisone acetate, but the effects of EEP and WSD compared 
with positive drug treatment were not significant (table 6.1). Celiac capillary leakage passed 
Levene's test of homogeneity (F = 2.6, P = 0.0723) and Kolmogorov Smimov test of 
normality (d = 0.09, P > 0.20). 
Table 6.1 Effects of propolis on celiac capillary leakage induced by acetic acid in mice (x + sd) 
Group Dose (ml/10g) n OD 
Nonnal control 0.2 8 0.621 ±0.088 
Prednisone acetate IOmglkg 7 0.518 ±0.060 
WSD 0.2 7 0.510 ± 0.1l4· 
EEP 0.2 8 0.533 ± 0.Q48 
'P < 0.05 compared with model control group. 
6.4.2 The effects of Carrageenan-induced paw oedema in rats 
The results of a repeated measures ANOVA showed a significant effect of propolis on 
carrageenan-induced paw oedema between the groups (F3,28 = 41.8, P < 0.0001), times 
(F6,168 = 211.5, P < 0.0001) and interactions of groups x time (F18,168 = 14.4, P < 0.0001). 
The results show that after the second hour, EEP and WSD all had significant inhibitory 
effects on carrageenan-induced paw oedema (table 6.2). Oedema passed Levene's test of 
homogeneity for each of the 7 time periods (P > 0.05) and Kolmogorov Smimov test of 
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l 
normality (d = 0.16, P > 0.20). 
Table 6.2 Effects of propolis on carrageenan-induced hind paw oedema in rats (x + sd) 
Group Model control Dexamethasone WSD 
acetate 
n S S S 
Normal paw 0.S6±0.17 1.1l±0.14 L11 ±0.1O cuba~e (mn 
1 h 0.19±0.IS 0.23±0.17 0.12±0.OS 
2h 0.S9±O.14 0.2S±O.17' 0.26±O.14' 
oedema 3h 0.6S±0.12 0.19±0.14" 0.34±0.IS· 
degree 
4h 0.77±0.12 0.29±O.13" 0.24±0.12" ( mI ) 
Sh 0.61±0.IS 0.07±0.OS" 0.26±0.02' 
6h 0.S4±0.12 O.OS±O.OS" O.IS±O.12" 
'P < O.OS, "P < 0.01 compared with model control group. 
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Figure 6.1 Effects of WSD and EEP on paw edema in rats 
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6.4.3 The effects of Carrageenan-induced pleurisy in rats 
The results showed significant effects of propolis on pleurisy extravasate between the 
groups (F4,34= 37.4, P < 0.0001), on WBC counts (F4,34= 15.1, P < 0.0001), on lymphocyte 
(F4,34 = 25.2, P < 0.0001), and neutrophils (F4,34 = 25.2, P < 0.0001) (table 6.3), and significant 
effects of pro polis on protein level (F4,25= 27.1, P < 0.0001), NO (F4,25 = 24.5, P < 0.0001) and 
PGE2 (F4,25 = 21.2, P < 0.0001) in carrageenan-induced pleurisy (table 6.3). The results show 
that the WBC count in the model control is significantly higher than that of normal control 
(Tukey: P < O.oJ), and the ratio of lymphocytes in WBC was significantly lower (Tukey: P < 
0.01). The ratio ofneutrophils is significantly higher (Tukey: P < 0.01) than that of the normal 
control group, typical in acute infianunation, thus indicating that the model was successful. The 
EEP and WSD had inhibitory effects on the increase of pleurisy extravasate, especially in the 
group of WSD compared with that of model group (Tukey: P < 0.01), the difference was 
significant. EEP and WSD inhibited the increase of WBC count and neutrophils, which 
indicated that they could probably alleviate inflanunatory reactions but the results were not 
significant at the 5% level. EEP and WSD of pro polis significantly decrease the level ofPGE2 
and protein in pleurisy extravasate (Tukey: P < 0.0 I). EEP also significantly decreased the level 
of NO (Tukey: P < 0.01) (table 6.4). WBC, lymphocyte and neutrophils passed Levene's test of 
homogeneity (P > 0,05); pleurisy extravasate failed due to the zero variance in the normal 
group. All four response variables passed Kolmogorov Smimov test of normality (P > 0.20). 
Protein, NO and PGE2 passed Levene's test of homogeneity (P > 0.05) and Kolmogorov 
Smimov test of normality (P > 0.10). 
Table 6.3 Effects of propolis on pleurisy extravasate and leucocyte counts in rats (x + sd) 
Group Dose Extravas-ate 
WBC Lymphocyte N eutrophils 
(ml/IOOg) n (ml) (X 109 • L·1) (%) (%) 
Nonnal control 8 0.10±0.00" 7.03±3.66·' 47.38±4.57" 52.63±4.57" 
Model control 7 1.99±0.35 29.83±7.77 15.l4±4.81 84.86±4.81 
Prednisone acetate 7.5mg/kg 9 1.62±0.34 25.64±5.3l 27.67±8.77" 72.33 ± 8.77" 
WSD I 6 1.08 ± 0.34" 22.07±8.58 25.00±5.62 75.00±5.62 
EEP 9 1.54±0.44 28.01 ±7.42 23.67±7.25 76.33±7.25 
.p < 0.05, "P < 0.01 compared with model control group. 
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Table 6.4 Effects of propolis on the levels of total protein, NO and PGE2 in the pleurisy 
extravasate of rats (x + sd) 
Group Dose (mil 1 00 g) n Protein (gIL) NO (umoVL) PGE, (OD) 
Normal control 6 3.S3±0.93" 6.12±2.36" 0.004 ± 0.002" 
Model control 6 22.73±3.89 32.33±6.68 0.194±0.021 
Positive control 7.5mglkg 6 9.58±3.37" 14.88 ± 4.9S" 0.076±0.02S" 
WSD 6 I3.64±2.97" 2S.1S±3.83 0.091 ±0.067" 
EEP 6 16.60±4.6S' 20.2S±S.67" 0.OS3±0.03S" 
'P < 0.05, "P < 0.01 compared with model control group. 
6.4.4 The effects of propolis on acute lung damage in rats 
The results of propolis on WBC count and lung index in the lung damage model are 
given in table 6.5. Lung index, neutrophils and lymphocyte response variables failed 
Levene's test of homogeneity ofthe variances (P < 0.01) but passed Kolmogorov Smirnov 
test of normality (P > 0.20). Kruskal-Wallis nonparametric ANOVA procedures were used 
since transformation of the variables failed to stabilize the variances between the groups. 
The results from table 6.5 showed that the WBC count, neutrophils and lung index in lung 
damage model group were significantly higher than that of normal control, and the ratio of 
lymphocyte was lower, which indicate that the model was successful (Lung index: ~.lO = 
13.7, P = 0.0084; WBC: F4,25 = 24.9, P< 0.0001; Neutrophils and lymphocyte: ~,25 = 17.6, 
P = 0.0014). EEP and WSD inhibited acute lung damage-induced lung oedema but the 
results were not significant at the 5% level. EEP had good ability to inhibit the increase of 
neutrophils (Mann Whitney: P = 0.024) and the decrease oflymphocyte (Mann Whitney: P 
= 0.024). 
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Table 6.5 Effects of propolis on the leucocyte count and lung index of acute lung injury 
in rats (x +sd) 
Group Dose Lung index WBC N eutrophils Lymphocyte (mIIlOOg) n (X 109 • L' l) (%) (%) 
Normal control 6 0.84±0.06" 5.47± 1.43" 17.17±8.18" 82.83 ± 8.18" 
Model control 6 1.43 ± 0.12 11.03±0.92 58.50± 6.83 41.50 ± 6.83 
DexamedJasone acetate 7.5 mglkg 6 1.31 ±0.22 5.27± 1.16" 46.17 ± 22.83 53.83 ±22.83 
WSD 6 1.20±0.31 6.IO±0.63" 36.67± 13.19 63.33 ± 13.19 
EEP 1 6 1.14±0.27 10.93±2.43 22.33 ± 10.23' 77.67± 10.23' 
'P < 0.05, "P < 0.01 compared with model control group. 
6.5 Discussion 
In order to study the effects of EEP and WSD on acute inflammatory performance, 
laboratory animal models were assessed as follows: Carrageenan-induced paw oedema in rats, 
acetic acid-induced capillary vessel leakage in the mouse abdomen, carrageenan-induced 
pleurisy and oleic acid plus LPS-induced acute lung damage in rats. The results showed that 
EEP and WSD both had high inhibitory activity on leakage, oedema, conglomeration and 
increase of WBC. These results strongly suggest that EEP and WSD have anti-inflammatory 
properties and alleviated the extent of the inflammatory reaction. 
NO could accelerate an inflammatory reaction by enlarging blood vessels to cause 
oedema. This could increase the expression of inflammatory reactions and accelerate the 
development of blood poisoning by activating prostaglandin synthesis as occurs in the 
progress of rheumatism (Schmidt & Walter, 1994; Akarasereenont et al., 1995). In the 
experiment, EEP and WSD were demonstrated to inhibit the increase of PGE2, and had a 
significant inhibitory effect on NO in carrageenan-induced pleurisy exudation. They also 
decreased the reciprocity between NO and PGE2 and decreased the activation ("domino 
effect") of various enzymes, which in tum could decrease the degree of an inflammatory 
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reaction (Kujumgiev et al., 1999; Song et al., 2002). 
Although the mechanism of WSD and EEP on anti-inflammatory performance appeared 
similar, there were also some differences. In the Carrageenan-induced pleurisy and oleic acid plus 
LPS-induced acute lung damage studies, WSD not only inhibited the increase ofWBC count, but 
also inhibited the increase of neutrophils (but not significantly at 5%). This would explain how 
WSD could inhibit the increase of WBC and alleviate inflammatory reactions during an acute 
inflammatory period. From the results it is possible that propolis components other than 
flavonoids exert anti-inflammatory effects. Although EEP did not significantly inhibit WBC, it 
may possibly alleviate the inflammatory degree synergistically by inhibiting NO. 
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CHAPTER 7 
7. THE EFFECTS AND MECHANISM OF PROPOLIS ON 
ACUTE LUNG INJURY 
7.1 Summary 
The mechanism by which propolis protects rats against acute lung injury induced by 
oleic acid and lipopolysaccharide (LPS) was studied. 40 male Wistar rats were divided into 5 
groups: normal group, model control group, positive group (dexamethasone), groups treated 
by propolis solutions extracted by ethanol and water. Rats were first injected with oleic acid 
through the tail vein, and then given another injection of LPS 4 hours later. The effects of 
propolis on acute lung injury was evaluated by counting leukocytes and lung index, changes 
in the pathological samples examined by microscopy and testing the expression activity of 
NF-KBp65 immuno-histochemically and in situ hybridization. The propolis solutions can 
counteract lung edema, decrease inflammation and inhibit the expression and activation of 
NF-KBp65 . The anti-inflammatory mechanism of propolis is to restrain the activation of 
NF-KB p65. 
7.2 Introduction 
Propolis has wide biological properties such as anti-inflammatory and immuno-
modulatory effects, scavenges free radicals, improves blood rheology, protects blood vascular 
endothelial cells, etc. (Banskota et ai., 2000a, b; Moon et ai., 2001; Li et ai., 2001a; Qi et ai., 
200 I; Santos et ai. , 2002). There are few reports about the effects of propolis on leukocyte 
adherence and interference with inflammatory rolling, sticking and expression. In this chapter 
the effects of propolis on inflammation and its possible mechanisms of action are investigated. 
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7.3 Materials and methods 
7.3.1 Materials 
Male Wistar rats of 220 ± 20 g birth weight were provided by the Shanghai Laboratory 
Animal Center of the Chinese Academy of Sciences (Certificate of animal quality: Zhong Ke 
Dong Guan No. 003), and used at The Research Center of Laboratory Animal Science, 
Zhejiang College of Traditional Chinese Medicine, Hangzhou, China. LPS (Lot: 70k4108, 
0111: B4) and DEPC were purchased from Sigma Company. Dexamethasone (010235) and 
oleic acid (OA) was purchased from Xianju Pharmacy Ltd.; Antibody of rCAM-I, CD54, 
BA0541 and Kappa B (BA0610) were purchased from Wuhan Boshide Biology Engineer 
Company, Wuhan, China. Reagent of NF Kappa B p65 used in situ hybridization and SABC 
used in immuno-histochemistry were purchased from Wuhan Boshide Biology Engineer 
Company, Wuhan, China. The reagent of DAB and poly-I-Iysine were purchased from Wuhan 
Boshide Biology Engineer Company, Wuhan, China. Propolis was purchased from Hangzhou 
Lingzhi Apiary of China. Propolis was produced in the North China in 2001 and the main 
plant origin was poplar (Populus sp.). 
7.3.2 Methods (Zhang et al., 2000) 
40 male Wistar rats were randomly divided into 5 groups: a normal control group, a 
model control group, medicine positive control group, and the groups treated with EEP 
(ethanol extract propolis) and WSD (water soluble derivative of propolis). Rats in the normal 
control group, EEP and WSD groups were administrated intragastrically respectively with 
physiological saline, EEP and WSD at the dose of 300 mglkg body weight for 7 days. Rats in 
the medicine positive control group were given dexamethasone i.p. at a dose of 0.75 mglkg 
body weight for 7 days prior to beginning the experiment. On the eighth day, all rats were 
treated with oleic acid at a dose of 0.2 ml/kg body weight through the tail vein. 4 hours later 
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all rats were given LPS at a dose of 2 mglkg body weight i.v. Two hours later all the rats were 
killed, their leukocytes counted, and the left lung taken to calculate lung index, the right lung 
was preserved with 4% polyformaldehyde, then sectioned and stained with a hematoxylin and 
eosin (HE) stain for pathological examination with a normal microscope. In addition, 
NF-KBp65 expression activity was tested immuno-histochemically. The detailed procedure 
was: de-wax the slice of tissue for hydration then treat with 3% H20 2 for 10 min at room 
temperature and avoiding light in order to destroy the activity of endogenetic enzyme. Then 
the tissue was washed with distilled water three times to rehabilitate the antigen. Then the 
histological section was placed in 0.01 molL-1 citrate buffer (PH 6.0), heated in a microwave 
oven for 5 min, discontinued for 20 min, then re-heated for 5 min and then allowed to cool. 
The tissue sections were then washed with O.1M PBS 3 times for 5 min each. Then normal 
goat serum blocking liquid (1 : 10) was added and the tissue incubated for 20 min at room 
temperature. Then rat p65 monoclonal antibody was added and the tissue incubated for 20 
min at 37°C and then held over night at 4°C. The next day, the sections were re-washed with 
0.1 mol·L-1 PBS three times for 2 min and then biotinylated antibody was added for I h at 
room temperature. Sections were then washed with 0.1 mol'L-1 PBS 3 times for 2 min, and 
placed in streptavidin diluent marked with horseradish enzyme and incubated for 20 min at 
37"C. They were then washed with 0.1 mol'L-1 PBS 4 times for 5 min, and colour-enhanced 
with DAB, then washed with tap water, re-dyed with HE, then dehydrated and sealed with 
moderate balata. Five histological sections chosen randomly were examined by microscopy 
and photographs obtained for computer image analysis. 
7.3.3 Statistical analyses 
Data were reported as means ± standard deviations. Comparisons between groups were 
made using ANOVA. Tukey's and Fisher LSD multiple pairwise comparisons tests were used 
to test for differences between groups and the model control group. 
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7.4 Results 
7.4.1 Effects of propolis on the leucocyte count and lung index of rats with acute lung injury 
The total leucocyte count and lung index in the animal model group chalIenged twice 
with oleic acid and LPS were significantly higher than that of normal rats. The change in 
leucocytes showed that the ratio of lymphocytes decreased and the ratio of neutrophils 
increased significantly, which indicated the animal model group was successful in our 
experiment. The propolis solutions extracted by ethanol and WSD had a significant effect on 
edema caused by acute lung injury (Fisher LSD: P < 0.05). EEP and WSD both prevented an 
increase of neutrophils, and the difference was significant compared with that of model 
control (Thkey: P < 0.05). The detailed results are shown in table 7.1. 
Table 7.1 Effects of pro polis solutions on the leucocyte count and lung index of acute 
lung injury in rats (n = 8, x ±sd) 
Group Dose Lung index Total WBC Neutrophils Lymphocyte mg-kg·' x I09-L.' % change % change 
Nonnal control 0.84±0.05" 5,48± L42" 17.13±8.13" 82.88±8.13" 
Model control L43±O.12 1 L03±O.94 58.50±6.26 4L50±6,48 
Dexamethasone 7.5 L31±O.22 5.26±l.l6" 46.13±22.88 53.88±22.33 
WSD 300 1.20±0.3i" 6.10±0.68'· 36.63±13.28' 63 .25± 13 .13' 
EEP 300 1.18±0.28' 1O.93±2.29 22.38±10.31" 77.63± 10.31" 
, P < 0.05, •• P < 0.01 compared with that of model control. 
7.4.2 Effects of propolis on pathological changes in the morphology of rats with acute 
lung injury 
From the results of the microscopical observations, the lung colour of rats in the normal 
control group was red, the lung floccular structure was clear, there was no exudation in the 
alveolus coelom, no inflammation or incrassation of the alveolus walI, and no inflammatory 
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exudation in bronchial wall. The lung colour in the model control rat tissues was purplish, and 
there was significant congestive oedema under the alveolar membrane. Oedema was 
widespread under the alveolar membrane, there was exudation of inflammatory cells 
indicative of widespread macrophages, and the exudation in alveolus was filled with red 
serum and inflammatory cells. Inflammatory cells could also be seen in the group of WSD 
and EEP rats as well as the incrassation of the alveolus wall, but the degree was significantly 
less than that of model control. This can be seen in figures 7.1-7.3. 
7.4.3 The effects of propolis on the expression and activation of NF-tdJ p65 of rats with 
acute lung injury. 
The result of immuno-histochemical analyses showed that the cytoplasm in normal lung 
was brown, with few macrophages in the nuclei. The color of the cytoplasm and nucleus in 
the lung of the model control rats was brown. Most brown particles had entered the nucleus, 
which showed that NF-lCB p65 had been activated, because p65 is mainly expressed in 
macrophages, fibroblasts and the bronchial epithelium. Both EEP and WSD significantly 
inhibited the activation of p65 protein (the brown particles were less than that of model 
control), the total number of positive cells was significantly less than that of the model control 
in five histological sections that were analyzed (P < 0.01), as can be seen in figures 7.4-7.6 
and table 7.2. 
Table 7.2 The activation of NF-KB p65 in lungs of rats determined by immuno-
histochemistry (n = 8, x ±sd) 
Group Dose I mg·kg·1 
Nonnal control 
Model control 
Dexamethasone 7.5 
WSD 300 
EEP 300 
**p < 0.01 compared with model control group. 
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Total positive cells in 5 sections 
192.81±24.26" 
635 .81 ±21.l6 
399.00±34. l6·· 
346.81±44.12" 
323.19±45.86" 
7.5 Discussion 
The experiment showed that both WSD and EEP could inhibit the increase of neutrophils, 
which suggests that both materials could inhibit inflammatory cells from spreading to an 
inflamed region and so reduce the degree of inflammation. 
NF-KB is a transcription modulation factor in upstream enhancement elements of the k 
chain in immunoglobulins that occur in many kinds of cells and tissues and has wide 
biological properties. When NF-KB is increased, it could accelerate the transcription of 
cytokine, adhesion factor, chemotactic factor (Natarajan et aI., 1996; Baeuerle & Baichwal, 
1997) and modulate the gene expression of cytokine in an inflammatory medium. Besides 
these, it also takes part in immune and inflammatory reactions. NF-KB is intimately associated 
with inflammatory disease, so that its activation would be enhanced in the disease of asthatics, 
acute decompensation, and rheumatic arthritis. LPS can lead to activation of monocyte NF-KB 
and when activated can increase the secretion of TNF-u and IL-l. On the other hand, both 
cytokines reverse NF -KB and lead to a graded reaction of inflammation inducing further 
injury to the tissues. NF-KB is a dimer comprised of two subunits of p50 and p65; p65 is the 
expression product of c-rel-one of the carcinoma genes, whereas Rei protein contains a 
transcription activation region (Wei, 2001). 
The experiment showed that propolis solutions extracted by ethanol and water could both 
inhibit the expression and activation ofNF-KBp65 to reduce the synthesis of p65 protein, and 
effectively control graded responses of inflammation to reduce further damage in an animal 
with acute lung injury. The mechanism probably was that caffeic acid phenethyl ester (CAPE) 
in propolis inhibits the activation and expression of NOS, and further inhibits the combination 
ofNF-kB and NO and transcription ofmRNA (Song et aI., 2002). 
88 
Figure 7.1 HE-stained section of the alveolus in the model group (40 X 3.3) 
Figure 7.2 HE-stained section ofthe alveolus in the EEP group (40 X 3.3) 
Figure 7.3 HE-stained section of the alveolus in the WSD group (40 X 3.3) 
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Figure 7.4 Immuno-histochemically stained section of alveolus in model group (l 00 X 3.3) 
Figure 7.5 Immuno-histochemically stained section of alveolus in EEP group (l 00 X 3.3) 
Figure 7.6 Immuno-histochemically stained section of alveolus in WSD group (l00X3.3) 
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CHAPTERS 
S. EFFECTS OF PRO POLIS ON BLOOD LIPID AND LIVER 
LIPID IN HYPERLIPIDEMIC SD RATS 
S.l Summary 
The effects of water and ethanol extracts of propolis on blood lipid and liver lipid of 
hyperlipidemic SD rats were studied. The results showed that both preparations of propolis 
had an inhibitory effect on the level of triglyceride (TO), total cholesterol (TC), low 
density lipo cholesterol (LDL-C), glutamic-pyruvic transaminase (OPT) and glutamic-
oxalacetic transaminase (OOT) in serum, and TC, TO and malonaldehyde (MDA) in liver; 
but the two extracts were without effects on high density lipo cholesterol (HDL-C), MDA, 
superoxide dismutase (SOD) and nitric oxide (NO) in serum. Ethanol extracts of propolis 
also reduced body weight, liver weight and liver index of hyperlipidemic SD rats, but the 
water-extracted propolis could not reduce those indexes. The results showed that the two 
extracts contribute to the improvement of lipid metabolism in hyperlipidemic SD rats and 
provide them with the required anti-oxidative activity. 
S.2 Introduction 
Propolis has wide biological properties such as anti-inflammatory, anti-viral, 
immuno-modulating, softening blood vessels, clearing blood, modulating microcirculation, 
anti-oxidation and anti-tumor among others (Marcucci, 1995; Isla et ai., 2001; Hu et ai. , 
2003 ; Hu & Xuan, 2003). In fact, hyperlipidemia is a disease of the hyperlipoprotein kind, 
in which the concentration of low-density lipoproteins (LDL) and very low-density 
lipoproteins (VLDL) in blood serum is too high. Hyperlipidemia and hyperlipoprotein are 
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the major factors associated with the induction of arteriosclerosis. In recent years, there 
have been some reports on the effect of propolis as a cure for hyperlipidemic disease (Fang, 
1998b; Stefano & Francesco, 2002), but the normative experiments are absent. In this 
chapter, studies on the effects of propolis on hyperlipidemia, liver lipid and anti-oxidation 
are reported. 
8.3 Materials and methods 
8.3.1 Materials 
8.3.1.1 Animals 
Male rats (strain SD) of about 220 ± 20 g were provided by The Shanghai Laboratory 
Animal Center of The Chinese Academy of Sciences (Certificate of animal quality: Zhong Ke 
Dong Guan No. 003), and used at The Research Center of Laboratory Animal Science, 
Zhejiang College of Traditional Chinese Medicine, Hangzhou, China. The animals were 
maintained and the experiments performed according to the principles of the Helsinki accord. 
The experimental protocol was approved by the Animal Ethics Committee of Zhejiang 
University, Hangzhou, China. 
8.3.1.2 Drugs and reagents 
Propolis was supplied by Hangzhou Lingzhi Apiary of China. Propolis was produced in 
North China in 2002 and the main plant origin is poplar (Populus sp.); WSD (water soluble 
derivatives of propolis) was extracted using a natural surface active agent and ultra sonicated at 
80·C for 12 h. EEP (ethanol extracted propolis) was extracted in 80% ethanol. 
Xuezhikang capsules (a regulator for blood lipid extracted from a Chinese medicine 
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"red koji") were supplied by Weixin Biology Science and Technique Company Ltd. , 
Beijing, China. Reagents for total cholesterol (TC), triglycerides (TG), high density 
Iipo-cholesterol (HDL-C), and low density Iipo-cholesterol (LDL-C) were purchased from 
Cicheng biochemistry Company Ltd., Ningbo, China. Reagents for malonaldehyde (MDA), 
nitric oxide (NO) and superoxide dismutase (SOD) were provided by Iiancheng Biology 
Engineering Research Institute, Nanjing, China. Others reagents were all A.R., made in 
China. 
8.3.2 Methods 
8.3.2.1 Replication of hyperlipidemia in SD rats 
Blood was taken from the cut tip ofthe tails of SD rats having fasted 12 hours and the 
serum centrifuged at 3000 rfmin for 10 min to test for TC and TG. According to the level 
of TC, all SD rats were randomly divided into seven groups of ten rats each, and at the 
same time, all rats were fed with hyper-lipid feed (0.5% bile, 1% cholesterol, 10% pig fat, 
10% yolk, 78.5% common feed). Two weeks later, blood was taken from all SD rats to test 
TC and TG to determine if all SD rats had become hyperlipidemic. According to the level 
of TC all SD rats were randomly divided into 10 groups: the normal control group, model 
control, positive control (Xuezhikang), WSD 1 (low dose of WSD), WSD2 (high dose of 
WSD), EEPI (low dose ofWSD), EEP2 (high dose ofWSD) groups and then, all SD rats 
were treated with different drugs for 28 days according to groups. 
8.3.2.2 Treatment methods for hyperlipidemic SD rats 
The group ofWSD: rats in WSDI group were given propolis intragastrically at a rate 
of 50 mglkg body weight, and the dry material of propolis was 2.5 mg/mL; rats in the 
WSD2 group were given propolis intragastrically at a rate of 100 mg/kg body weight, and 
the dry material of propolis was 5 mg/mL. 
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The group of EEP: rats in the EEPI group were given propolis intragastrically at a 
rate of 50 mg/kg body weight, and the dry material of propolis was 2.5 mglmL; rats in 
EEP2 group were given propolis intragastrically at a rate of 100 mg/kg body weight, and 
the dry material of propolis was 5 mglmL. 
The group of positive control: rats in Xuezhikang group were given the drug 
intragastrically at a rate of 600 mg/kg body weight, and Xuezhikang was diluted to 30 
mglmL. 
Rats in the normal and model control groups were given physiological saline 
intragastrically 0.9% at a rate of 2 mlllOO g body weight. 
All rats were treated intragastrically twice a day at 9:00 am and 3:00 pm. 
8.3.2.3 Methods of measurement 
Blood was taken from the cut tip of the tails of all SD rats after fasting 12 hours every 
other two weeks and the serum was centrifuged at 3000 r/min for 10 min to test TC and TG. 
At the end of the experiment, blood was taken from all SD rats from the eyeball and the 
serum centrifuged to test other biochemical indexes including TC, TO, HDL-C, LDL-C, 
GOT, GPT, SOD, MDA, NO. The livers were ground in 10% physiological saline to test 
TC, TO, MDA. The test methods were done according to the specifications for each 
reagent. 
8.3.3 Statistical analyses 
Data were reported as means + standard deviations. Comparisons between groups 
were made using ANOVA and repeated measures ANOVA procedures. Tukey and Fisher 
LSD multiple pairwise comparisons tests were used to test for differences between groups 
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and the model control group. 
8.4 Results 
8.4.1 Effects of propolis on blood lipid and arteriosclerosis (AS) in hyperlipidemic SD rats 
Changes of TC and TG in serum in hyperlipidemic SD rats for six weeks are given in 
table 8.1. The results of a repeated measures ANOVA showed a significant effect of 
propolis on TC and TG in serum between the groups (TC: F6,63 = 27.0, P < 0.0001; TG: 
F6,63 = 12.5, P < 0.0001), times (TC: F 3,189 = 211.3, P < 0,0001 ; TG: F3,189 = 124.4, P < 
0.0001) and interactions of groups x time (TC: F18,189 = 9.9, P < 0.0001; TG: F18,1 89 = 5.9, 
P < 0.0001). The results show that the level of TC and TG of rats fed hyperlipid feed were 
higher than that of the normal control group two weeks later (P < 0.05). The levels of TC 
and TG in the control groups WSDI, WSD2, EEPI and EEP2 were significantly lower 
compared with that of model control after six weeks (LSD: P < 0.01). 
The effects of propolis and Xuezhikang on HDL-C, LDL-C and AS of hyperlipidemic 
SD rats are given in table 8.2. The results show that HDL-C in each group was 
significantly decreased (P < 0.05) and LDL-C was significantly increased (P < 0.05) for 
Xuezhikang, WSD 1 and WSD2 groups compared with that of normal control, which 
demonstrates that the model of hyperlipidemic rats was a success. After six weeks of 
treatroent, the difference in HDL-C in each group was not significant, but did inhibit the 
increase of LDL-C (P < 0.05), especially in the group of Xuezhikang, EEPI and EEP2; 
LDL-C respectively decreased from 33.1%, 49,8% and 44.7% compared with that of 
model group; moreover, each group, except the model control group, decreased AS (P < 
0.01) 
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Table 8.1 Blood TC and TG (mmoUL) changes of hyperlipidemic rats for six weeks (x + sd) 
Group n zero week 2
nd week 4th week 6th week 
TC TG TC TG TC TG TC TG 
Normal control 10 2.09±O.31 1.l0±0.27 1.96±O.21·' 1.84±O.33" I.Sl±O.23" 1.17±O.28' 2.63±O.57" 1.53±O.2S" 
Model control 10 2.16±O.24 1.01±O.29 3.5S±O.42' 2.54±O.60 4.24±O.76' 1.67±O.49 6.07±1.07' 3. I 9±1.l 6' 
Xuezhikang 10 2.14±O.12 l.lS±0.16 3.62±0.38' 2.89±0.82' 3.33±0.74'" 0.9S±O.19" 4.22±I.S7"" 1.53±O.3S" 
WSDI 10 2.12±O.30 1.29±O.39 3.42±O.31' 2.87±O.39' 3.7 I±O.54' 1.34±O.38 4.8I±O.4I '" 2.S I±O.70'" 
WSD2 10 2.08±O.26 1.16±O.36 3.4S±O.49" 2.70±0.86' 3.3S±O.70" 1.36±0.34 4.17±O.62'" 1.7I±O.74" 
EEPI 10 2.19±O.24 1.09±O.20 3.S2±O.3S' 2.62±0.57 3.24±O.53'" l.lS±O.29' 3.99±O.61'" 1.19±O.50" 
EEP2 10 2.00±0.17 1.07±O.28 3.SI±O.43' 2.6S±O.40' 3.34±O.3S'" 1.13±O.24' 3.92±0.77'" 1.33±0.39" 
Compared with model, • P < O.OS, •• P < 0.01; compared with normal group, ' P < O.OS . 
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Table 8.2 Effects of propolis on HDL-C, LDL-C and AS in hyperlipidemic rats (x +sd) 
Group n HDL-C(mmoIlL) LDL-C(mmoIlL) AS 
Normal control LO 2.20±0.45** 1.09±O.23** 0.63±0.20** 
Model control 10 1.24±0.26d 2.93±0.64d 4.06±1.30d 
Xuezhikang LO 1.25±0.26d 1.96±0.77**d 2.37±0.80*·d 
WSDI LO 1.46±O.34d 2.40±0.21d 2.13±0.39**· 
WSD2 LO l.53±0.47d 2.03±0.37**· 2.03±0.56*·d 
EEPI LO l.39±0.70· 1.47±0.52** 2.44±0.93 *.d 
EEP2 10 l.36±0.35d 1.62±O.63·· 2.41±0.84,·d 
Compared with model,' P < 0.05," P < 0.01; compared with nonnal group, d P < 0.05. 
8.4.2 Effects of propolis on body and liver weight, liver index, TC and TG in liver, 
GPT and GOT in serum of hyperlipidemic SD rats 
The effects of propolis on body weight, liver weight, liver index, TC and TG in liver, 
GPT and GOT in serum of hyperlipidemic SD rats are given in table 8.3. The results show 
that the effect of Xuezhikang on TC and TG in liver was not significant compared with 
that of model control, but decreased GOT (P < 0.05) and GPT (P < 0.01) in serum; WSDI 
significantly decreased TC, and the effect on TG was not significant although the trend was to 
decline. WSD2, EEPI and EEP2 significantly decreased the level of TG and TC compared 
with that of the model control group, and at the same time, they also decreased the level of 
GOT and GPT. The group of Xuezhikang and EEP significantly decreased liver index (P < 
0.05), but the effect ofWSD was not significant (P > 0.05). 
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Table 8.3 Effects of propolis on body weight, liver weight, liver index, TC and TG in 
liver, GPT and GOT in serum of hyperlipidemic rats (x + sd) 
TC TG GPT GOT Body weight Liver weight L· . d 
Group n (mrnollL) (mrnollL) (UIL) (UIL) (g) (g) lver m ex 
Normal control 10 0.33±O.08" 1.08±O.l4 29.7±3.9" 44.2±1O.l" 358.401;28.4" 7.7S±O.89·· 2.16±O.29" 
Model control 10 2.04±O.4O" 2.90±0.59" 69.2±11.9" 71.4±11.S" 437.9ilS.4" l6.42±1.2l" 3.7S±O.43" 
Xuezhikang 10 1.82±O.64" 2.6l±O.62" 36.9±9.4" S7.7±16.4· 41O.W7.3 ." ."'6. ."'6-l1.31±O.98 2.7S±O.33 
WSDl 10 1.63±O.44·" 2.5l±O.SS" 56.4±10.9''' 43.0±5.l" 434.2±3S.7" l5.46±1.4S" 3.S6±O.4S" 
WSD2 10 1.4O±O.2z" " 2.28±0.43'·" 46.3±8.9"" 41.1±14.2" 4l8.8il2.5" ." lS.29±1.32 3.6S±O.39" 
EEPI 10 1.6O±O.40 '" 2.39±O.S3·" 3S.3±5.9" 3S.6±6.0" 41O.2±16.6·" 13.9S±O.96"" 3.40±0.3(" 
EEP2 10 1.67±O.36·" 2.40±0.38·" 34.0±6.S" 38.6±8.7" 406.6±29f" l2.34±1.l2"· 3.03±O.34"· 
Compared with model, • P < O.OS, .* P < 0.01; compared with normal group, " P < O.OS. 
8.4.3 Effects of propolis on MDA, SOD, NO in serum and MDA in livers of 
hyperlipidemic SD rats 
The effects of propolis on MDA, SOD, NO in serum and MDA in livers of 
hyperlipidemic SD rats are given in table 8.4. The results show that all groups except WSDI 
and Xuezhikang groups significantly decreased the level of MDA (P < 0.05) in liver; al1 
groups decreased the level of MDA in serum but the decreases were not significant. The 
differences in all groups were not significant for SOD compared with that of the model 
group; Xuezhikang very significantly increased the level of NO (P < 0.0 I), whereas the 
differences in the propolis groups were not significant. 
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Table 8.4 Effects of propolis on MDA, SOD, NO in serum and MDA in livers of 
hyperlipidemic rats (x + sd) 
MDAin liver MDAin serum SOD NO 
Group n (nmollmg prot) (nmollmL) (Nu/mL) (UmollL) 
Normal control 10 179.9±13.7 " 8.26±0.88" 13l.4±6.6· 7.80±2.0·· 
Model control LO 232.5± L3.2· Ll.52± l.23 · ll9.6±9.2· L5 .5±4.L · 
Xuezhikang LO 225.3±L7.6· L2.58± l.48· LL6.5±8.4· 21.3±3.0 •• 
WSDL 10 223.1 ±1 8.7· I !.70±l.47· ll6.6±12.2· 16.3±4.7· 
WSD2 LO 21O.8±18.6·· 1l.45±2.04· 123.4±4.3 18.L±3 .4· 
EEPI 10 213.6±22.3·· 10.54±1.45· 12l.8±8.1 16.2±5.5· 
EEP2 10 214.9±15.8·· 1l.28± l. 06· L2l.5±7.5 16.7±3.2· 
Compared with model, * P < 0.05, ** P < 0.0 L; compared with normal group, • P < 0.05. 
8.5 Discussion 
Previous studies showed that increased levels of TC, TO, LDL-C and decreased 
levels of HDL-C are the major factors in the induction of arteriosclerosis and 
cardiovascular disease (Zhang & You, 1998). From the results of the present experiments, 
we found that Xuezhikang, WSD, EEP all inhibited an increase ofTC, TO, LDL-C caused 
by hyperlipid feed, and very significantly decreased the level of AS which showed that 
they were effectively hyperlilpidemic rats. It is noteworthy that the effect of Xuezhikang 
and EEP was greater than others; and the level of HDL in hyperlipidemic rats decreased, 
while Xuezhikang, WSD, and EEP had no significant effect on HDL-C. That propolis 
might modulate hyperlipidemia is apparently related to the composition of propolis (Fang, 
1998b; Stefano & Francesco, 2002), especially the flavonoids, which can exceed 12% of 
propolis. Flavonoids could modulate hyperlipidemia probably by two different 
mechanisms: control of HMG CoA deoxidase in the synthesis of cholesterol, or, 
flavonoids also could inhibit the activity of phosphodiesterase thus delaying the 
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decomposition of cAMP to inhibit the activity of HMG CoA deoxidase. Such mechanisms 
could well protect liver and decrease the synthesis of peroxidation (Havsteen, 2002). 
Blood lipid disturbance is an important factor for liver fat and damage, when the 
gastroduodenum takes fat in excess of normal needs, superfluous NEFA, the precursor of 
TO, is released. If the synthesis of TG is in excess of that of VLDL, this would lead to the 
sequestration ofTG to form liver fat. And, VLDL would transfer TG finally to LDL. From 
the results of this experiment, hyperlipidemic rats' body weights are greater than that of 
normal rats, the level of GOT and GPT in serum is increased, and the livers became 
enlarged and jaundiced. Xuezhikang and EEP significantly decreased the sequestration of 
fat, the enlargement of the liver and liver index, whereas the effect in WSD was not 
significant. Xuezhikang, WSD and EEP all decreased the levels of ALT, AST in blood so 
inhibiting the increase of MDA to protect liver. 
Studies showed that there is a relationship between arteriosclerosis and liver damage 
and lipidoxidation, and that the levels of TC and TG in blood has a positive relationship 
with lipidoxidation, so that LDL would form OX-LDL under peroxidation, which is the 
major factor causing the accumulation of lipid and foam producing cells (Chisolm & Marc, 
1994). The present experiments showed that the level of MDA in the serum of rats fed 
hyperlipid feed resulted in enhanced peroxidation. Xuezhikang, WSD, EEP all decreased 
the levels of MDA in liver, whereas MDA in serum tended to decline. None of the groups 
exhibited any significant effects on SOD. Besides these, compared with that of normal 
control, the level of NO increased in hyperlipidemic rats, which was not in accordance 
with other reports (Wu & Sun, 2003). Previous studies showed that there are at least two 
components which have anti-oxidative effect, one is the compound with the structure of 
C6-C)-C6, in which the main mechanism was to chelate metal ions to inhibit the formation 
of hydroxyl free radicals, which are also important constituents of propolis, the other is 
caffeic acid phenethyl ester (CAPE), which can form xanthine oxidase to reduce the 
production of free radicals (Russo et aI., 2002). 
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From these experiments, it was found that propolis extracted in water or ethanol 
could both decrease hyperlipidemia and protect the liver against oxidation, but the effect 
of EEP was better than WSD. Besides, propolis has no significant toxic effects (Karsten, 
2001), and is an effective, low toxicity material that can protect liver and modulate blood 
lipid. It provides a broad background for further exploration. 
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CHAPTER 9 
9. DETERMINATION OF THE ANTI-TUMOR AND ANTI-
INFLAMMATORY EFFECTS OF DIFFERENT PROPOLIS 
EXTRACTS 
9.1 Summary 
The flavonoids of different propolis extracts and their phannacological effects were 
assayed for their biological activity on SI80 entity-tumor mice, chronic tampon granuloma 
mice, acute pleurisy rats and acute arthritic rats. The 80% ethanol extracts of propolis had 
the highest flavonoid content (51.36 mg/ml); the flavone content in water extracts of 
propolis obtained with a natural surface-active agent, under ultrasonic perturbation at 80°C 
for 12 h, was 6.7 times as that of propolis extracted with water at room temperature. 
Compared to the ethanol extracts, the water extracts of propolis have the same or a greater 
anti-tumor or anti-inflammation effect at the same dosage as did the ethanol extracts. Water 
extracts of propolis show considerable phannacological potential especially because of its 
low side effects and ease of preparation. 
9.2 Introduction 
Recently, there have been several reports on the anti-tumor effects of propolis 
(Johnson et a!., 1996; Sato & Miyataka, 1999; Banskota et al., 2002), but published data on 
the relationship between extraction methods and effects are wanting. In this chapter, the 
flavonoid content of propolis extracted by different methods is discussed as well as the 
effects ofWSD (water-soluble derivatives of pro polis) and EEP (ethanol extracts of pro polis) 
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on Sl80 entity-tumor mice, chronic tampon granuloma mice, acute pleurisy rats and acute 
arthritic rats were also studied in order to further assess the pharmacological effect of 
propolis. 
9.3 Materials 
9.3.1 ~aterials 
Propolis was purchased from Hangzhou Lingzhi Apiary of China. The propolis was 
produced in North China in 2001 and the main plant of origin was poplar (Populus sp.). 
Carrageenan (Lot: 117HOI51) was purchased from Sigma Company, prednisone acetate 
(010772) and dexamethasone (010235) were purchased from Xianju Pharmacy Company, 
Zhejiang, China; the reagent of cholesterol was purchased from Cicheng Biochemistry 
Company, Ningbo, China. 
9.3.2 Animals 
Male Wistar rats of about 200 ± 20 g and ICR mice of about 20 ± 2 g were provided 
by the Shanghai Laboratory Animal Center of the Chinese Academy of Sciences 
(Certificate of animal quality: Zhong Ke Dong Guan No. 003), and used at The Research 
Center of Laboratory for Animal Science, Zhejiang College of Traditional Chinese 
Medicine, Hangzhou, China. The animals were maintained in keeping with the Helsinki 
accord and the experimental protocol was approved by the Animal Ethics Committee of 
Zhejiang University, China. 
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9.4 Methods 
9.4.1 The preparation of propolis solutions and measurement of flavonoid content 
EEP: The crude propolis samples were extracted in ethanol as the solvent at 40%, 50%, 
60%,70%,75%, 80%,90% and 95% and then filtered; WSD-l: propolis was extracted 
with water at room temperature. WSD-2: propolis was extracted with a special method with 
water using a natural surface-active agent and ultrasonicated at 80°C for 12 h. The methods 
for measuring the flavonoid content of propolis obtained by different methods were 
compared against a fagopyrol standard curve (See section 5.3 .2.1.). Each sample was 
measured three times and averaged (cf. table 9.1). 
9.4.2 The effect of propolis on 5180 entity-tumor, chronic tampon granuloma in mice 
40 mice were inoculated with SI80 entity-tumor cells below the axilla under asepsis 
(Li, 1991). The mice were randomly divided into 4 groups of 10 mice each (5 male and 5 
female). Groups included the model control, a group given propolis extracted with 95% 
ethanol, a group given propolis extracted with 80% ethanol and the WSD-2 group. Each 
mouse was given intragastrically 600 mglkg propolis (measured as crude propolis) once a 
day, and the mice in the control group were given distilled water intragastrically. The 
experiment ran for 10 days and on the 11 th day, all mice were killed, the tumor cell tissue 
removed and weighed to determine the effective anti-tumor rate. 
48 male ICR mice were implanted with a disinfectant tampon 10 ± 1 mg to induce 
granuloma (Chen, 1993). The surgical wounds of the mice were treated 4 times with two 
drops of penicillin as an anti-infectant. The mice were then divided into four groups: the 
model control group, positive control (prednisone acetate), WSD-2 and EEP groups with 
80% ethanol. Mice in the propolis groups were given intragastically EEP or WSD at a 
dosage of 600 mglkg and treated once daily continuously for 7 days. On the gth day, all 
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mice were killed and the tampon with granuloma removed for weighing, then dried at 60°C 
for 14 hours and then the granuloma weighed. 
9.4.3 The effect of pro polis on Carrageenan-induced paw oedema in rats (Xu et al., 1991) 
32 male Wistar rats were randomly divided into 4 groups, and given intragastrically (1) 
EEP (propolis extracted with 80% ethanol), (2) WSD-2, (3) sterile saline (normal control 
group), or (4) dexamethasone acetate (positive control group) respectively and treated once 
daily continuously for 5 days. The right hind paw cubage of all rats was measured before 
treatment. 30 minutes later, each rat was treated (intradermic injection) with 1 % 
Carrageenan (0.1 ml) on the pad ofthe right hind paw, and given sterile saline (4 mil l 00 g) 
intraperitoneally. Inflammation, measured as paw cubage, was measured hourly for six 
hours to assess possible anti-inflammatory effects on oedema. 
9.4.4 The effect of pro polis on Carrageenan-induced pleurisy in rats (Xu et al., 1991) 
60 male Wistar rats were randomly divided into 5 groups, and given intragastrically (1) 
EEP (propolis extracted with 80% ethanol), (2) WSD-2, (3) sterile saline (model control 
group), (4) sterile saline (normal control group), or (5) prednisone acetate (positive control 
group) respectively and treated once daily continuously for 7 days. 30 minutes after the 
initial treatments, all the rats (except those in normal control group) were injected with 1 % 
Carrageenan (0.2 mill 00 g) in the right thorax after light anaesthesia with ether, while rats 
in the normal control group were treated with sterile saline. Inflammation was induced 
within 4 hours . Eight hours later, all the rats were killed by decollation and the extravasate 
in the thorax collected by aspiration. Each thorax was then washed with 2 ml sterile saline, 
after which the residual extravasate and washing solution were mixed. 1 00 ~I of the 
solution was used to count WBC, the rest was centrifuged and stored at -20°C. An aliquot 
of 0.5 ml of supernatant was used to measure protein levels; while 0.15 ml solution and 1 
ml 0.5 N KOH-methanol was used to measure optical density (OD) at 278 nm with a 
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TU-IOOI ultra- spectrophotometer after incubation in water at 50°C for 20 minutes, and the 
OD value measured to calculate the content of prostaglandin-E2 (PGE2). Another solution 
sample of 200 III was used to measure nitric oxide (NO) levels (Tan, 200 I). 
9.4.5 Statistical analyses 
Data were reported as means ± standard deviations. Comparisons between groups 
were made using ANOYA and repeated measures ANOYA procedures. Tukey and Fisher 
LSD multiple pairwise comparisons tests were used to test for differences between groups 
and the model control group. 
9.5 Results 
9.5.1 The flavonoid content of propolis extracts 
The content of flavonoids in propolis extracted with 80% ethanol was 51.36 mg/ml, 
which was the highest yield. For propolis extracted with 70% and 90% ethanol, the content 
was 27.10 mg/ml and 26.07 mg/ml respectively; the lowest yield was that extracted with 
40% ethanol. The flavonoid content in WSD-l was only 1.91 mg/ml, whereas the content 
in WSD-2 was 12.76 mg/m. The detailed results are given in table 9.1. 
Table 9.1 The flavonoid content of propolis extracts 
Extraction 
Concentration of ethanol WSD 
methods 40% 50% 60% 70% 80% 90% 95% 
EEP EEP EEP EEP EEP 
WSD-I WSD-2 
EEP EEP 
Flavonoid 
4.73 9.23 21.52 27.10 51.36 26.07 22.64 1.91 12.76 
content mean 
Std. Dev. 0.03 0.04 0.03 0.05 0.06 0.04 0.03 0.01 0.04 
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9.5.2 Effects of propolis extracts on S180 tumor growth in mice 
The tumor weight of mice in the group, which were administered propolis, was 
significantly lower than that of model control (P < 0.01). The inhibition of the tumor rate 
was 55.75%-80.78%, and the group administered WSD-2 had the highest inhibition rate, 
next was the group treated with 80% EEP. 
In the experiment of chronic tampon granuloma, mice in groups 80% and 95% EEP 
and WSD-2 all exhibited an inhibitory effect compared with that of the model control, the 
difference was significant (P < 0.01). The effect in the group of WSD-2 corresponded to 
that of the prednisone acetate group. The detailed results are given in tables 9.2 and 9.3. 
Table 9.2 Effect of propolis extracts on S180 tumor growth in mice 
Groups Dose (mglkg) 
Model control 
95%EEP 600 
80%EEP 600 
WSD-2 600 
Compared with that of model control, "P < 0.01 
n 
Average tumor 
weight (g) 
10 1.26±0.03 
10 0.56±0.06" 
10 0041 ±0.Ql" 
10 0.24±0.01 " 
Inhibitory 
tumor rate (%) 
55.75 
67.36 
80.78 
Table 9.3 Effects of propolis extracts on the weight of granuloma in mice 
Group Dose (mglkg) n Weight of granuloma (mg) 
Model control 600 12 34.74±1.30 
Prednisone acetate 10 12 2 l.l 7± 1.03" 
WSD 600 12 21.23±1.06"" 
80% EEP 600 12 24.80±2.IS"" 
Compared with that of model control, '*P < 0.01 
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9.5.3 Effects of propolis on Carrageenan-induced paw oedema in rats 
Mice in the groups of WSD and EEP exhibited a significant inhibition effect on right 
hind paw edema caused by carrageenan two hours after administration. The degree of right 
hind paw edema in the mice of each group was significant, and the degree of edema was 
highest in the model control and WSD groups four hours later, whereas in the 
dexamethasone and EEP groups required three hours to reach their highest values. The 
results are given in table 9.4. 
9.5.4 Effects of propolis on Carrageenan-induced pleurisy in rats 
The total white blood cells in the model group was significantly higher than that of 
normal group, and the ratio of lymphocyte decreased, whereas neutrophils increased in the 
white blood cell fraction, which demonstrated that the pleural model was successful. EEP 
and WSD had significant antagonistic effects on more pleural exudation (EEP: P < 0.05; 
WSD: P < 0.01). EEP had no significant effect on total white blood cells, but it had a 
trend to significantly inhibit the increase of neutrophils (LSD: P < 0.05). EEP and WSD 
also had a significant effect on reducing the output of NO and PGE2 in the pleural 
exudation, and could significantly reduce the output of protein. The results are given in 
tables 9.5 and 9.6. 
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Table 9.4 Effects of propolis solutions on edema of the right hind paw induced by Carrageenan 
Group 
Model control 
Dexamethasone 
WSD 
EEP 
n 
S 
S 
S 
S 
Paw cubage of normal 
mice 
(mJ) 
0.S6±O.17 
1. 11±O. 14"" 
1. 11±O. 10"" 
1.26±O.13" 
The degree of edema (mJ) 
Ih 2h 3h 4h Sh 6h 
0.19±O.IS 0.59±O.14 0.68±O.12 0.77±O.12 0.6I±O.IS 0.S4±O.12 
0.23±O.17 0.28±O.17"" 0.19±O.14"" 0.29±O.13"" 0.07±O.OS"" 0.08±O.OS"" 
O.I2±D.OS 0.26±O.14"" 0.34±O.1S"" 0.24±O.12"" 0.26±O.02"" O.IS±O.12"" 
0.16±O.09 0.23±O.I1"" 0.30±0.09"" 0.13±O.12"" 0.19±O.1O"" 0.16±O.09"" 
Compared with that of model control, "P < 0.01 
109 
Table 9.S Effects of propolis on pleurisy extravasate and leucocyte counts in rats 
Dose Exudation Total WBC 
Group n (X 109 • L") Neutrophilsl % (mg/kg) (ml) 
Normal control 8 O.IO±O.OO·' 7.03±3.66" 52.63±4.57" 
Model control 7 1.99±0.35 29.83±7.77 84.86±4.81 
Prednisone acetate 7.5 9 1.62±O.34* 25.64±5.31 72.33±8.77" 
WSD 300 6 1.08±0.34" 22.07±8.58* 75.00±5.62* 
EEP 300 9 1.54±0.44* 28.01 ±7.42 76.33±7.25* 
Compared with that of model control, LSD: *p < 0.05, **p < 0.01 
Table 9.6 Effects of propolis on the levels of total protein, NO and PGE2 in the 
pleurisy extravasate of rats 
Group Dose Protein (gIL) NO (umollL) PGE2 (OD) (mg/kg) n 
Normal control 6 3.53±0.93" 6.12±2.36" 0.004±0.002" 
Model control 6 22.73±3.89 32.33±6.68 0.194±0.021 
Positive control 7.5 6 9.58±3.37" 14.88±4.95" 0.076±O.025" 
WSD 300 6 13.64±2.97" 25 .15±3.83* 0.091±0.067" 
EEP 300 6 16.60±4.65* 20.25±5.67" 0.053±0.035" 
Compared with that of model control, LSD: *p < 0.05, **p < 0.01 
9,6 Discussion 
9.6.1 The anti-tumor effects and the flavonoid contents of propolis 
There are many studies on the anti-tumor effects of propolis (MatsUDo et al., 1997; 
Scheller et al., 1989; Kimoto et ai., 1998,2000; Kawabe et al., 2000). In this experiment, 
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propolis was proved to have good anti-tumor effects according to S180 entity-body tumor 
mice and the edema model. The inhibitory effect on tumor rate in the group of WSD was 
some SO.7S%, which was far greater than that of propolis extracted in 95% ethanol. This 
result was consistent with that of other findings (Mitamura et at., 1996; Gao et al., 2000). 
The flavonoid content in propolis extracted by different methods was significantly 
different. The highest value was that of propolis extracted with SO% ethanol. The 
flavonoid content in propolis extracted by a special method with water (use natural surface 
active agent, under ultrasonic, SO°C, 12 h) was 6.7 times than that of extracted by common 
water at room temperature. 
9.6.2 The interaction of the inflammatory medium 
WSD and EEP had marked anti-inflammatory effects on acute arthritis and acute 
pleurisy, as well as inhibitory effects on exudation, edema, collecting white blood cells 
and reducing inflammatory reactions. NO could accelerate inflammatory reactions by 
stretching blood vessels to form edema and increasing the exudation of inflammatory 
materials to accelerate the progress of blood poisoning, and activating prostaglandins in 
the process of rheumatism (Sun & Xu, 2002). This experiment showed that WSD and EEP 
could inhibit the increase of PGE2, and inhibit the output of NO in exudation in pleurisy 
caused by Carrageenan, decrease the interaction of NO and prostaglandins to decrease 
activation of a range of enzyme to decrease the degree of inflammation, which probably 
was one of the main mechanisms in the anti-inflammatory reactions. 
9.6.3 Future ofWSD propolis products 
For many years there was no material progress on the methods of propolis extraction 
by water simply because propolis was long thought to be insoluble in water. The main 
types of propolis used in recent years are tinctures, troches and capsules. The main 
extraction solvent is ethanol, but because of this inevitable alcoholic content, development 
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in the use of propolis has been limited. This experiment showed that propolis extracted by 
a special method with water had the same or better anti-inflammation and anti-tumor 
effects than that of EEP. Moreover, there may be other water-soluble, anti-inflammatory 
and anti-tumor components besides flavonoids in propolis. Propolis extracted by water has 
the cultural advantage that solvent is non-alcoholic. 
112 
CHAPTER 10 
10. COMPARISONS OF THE ANTI-TUMOR EFFECTS AMONG 
PROPOLIS, BEE POLLEN AND ROYAL JELLY 
10.1 Summary 
The SI80 entity-tumor mice were given intragastrically aqueous extracts of propolis, 
aqueous extracts of bee pollen and royal jelly and treated once daily continuously for 15 
days. The tumors were removed and weighed. The results showed that the anti-tumor 
effectiveness of aqueous extracts of propolis, pollen and royal jelly were 79.9%, 69.0% 
and 75.8%, when compared to the control group. 
10.2 Introduction 
Cancer, cardiovascular syndromes and diabetes mellitus are particularly dangerous 
diseases that threaten human health. Modem medicine suggests that about 35% of the 
incidence of cancer is related to nutritional patterns (Eddy, 1986). Some studies indicate 
that cancer can be prevented, and the manipulation of diet may well constitute a 
preventative measure (Howe et al., 1992; Miller et al., 1994). Today, increasingly more 
people have become aware of the relationship between nutrition and cancer. Although 
methods for the treatment of cancer primarily depend on chemotherapy and the analysis of 
genetic predisposition, manipulation of nutrition holds its importance. Bee products such 
as propolis, bee-collected pollen and royal jelly are considered good healthy foods, and 
have been widely used in folk medicine for many years, particularly in Asia. The principal 
constituents of propolis of contemporary interest are the more than 38 flavonoids. There 
are also relatively large concentrations of amylose in bee-collected pollen and superoxide 
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dismutase (SOD), glucose oxidase (GOD), 10-hydroxy-a-dece-noic acid (IO-HDA) in 
royal jelly (Wang, 1982; Huang, 1993; Hu & Xuan, 2003). There are several reports that 
these components have a degree of anti-tumor efficacy (Bankova et al., 1983; Siaga, 1983; 
Tamura, 1987; Lfarin, 1993; Huang et al., 2000). Here the results of experimental studies 
on the effects of extracts of propolis, bee-collected pollen and royal jelly for anti-tumor 
efficacy are reported. 
10.3 Materials and methods 
10.3.1 Materials 
Mice (strain ICR, 16 males and 16 females) about 18-22 g birth weight were provided 
by the Shanghai Laboratory Animal Center of the Chinese Academy of Sciences 
(Certificate of animal quality: Zhong Ke Dong Guan No. 003), and used at The Research 
Center of Laboratory Animal Science, Zhejiang College of Traditional Chinese Medicine, 
Hangzhou, China. 
Propolis, bee-collected pollen and royal jelly were purchased from Hangzhou Lingzhi 
Apiary of China. Propolis was produced in the North China in 2001 and the main plant of 
origin was poplar (Populus sp.). Other materials included SI 80 entity-tumor, physiological 
saline and distilled water. 
10.3.2 Methods 
10.3.2.1 Preparation of experimental materials 
WSP (water soluble derivative of pro polis): the concentration of pure propolis was 10 
gIL. Pollen extraction: 20 g bee-collected pollen were placed in 400 ml of distilled water 
for about 4 h and then filtered and refrigerated. Royal jelly diluent: the concentration of 
royal jelly was about 25 mg/ml, and was refrigerated. The animals were maintained and 
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the experiments performed according to the principles of the Helsinki accord. The 
experimental protocol was approved by the Animal Ethics Committee of Zhejiang 
University, Hangzhou, China. 
10.3.2.2 Anti-tumor experiments 
36 mice were randomly divided into 4 groups of 8 each, four males and four females. 
Sl80 entity-tumor mice were maintained for ten days. They were then killed and the ascites 
solution was collected and diluted 4 times to inoculate each mouse with 0.2 m1J20 g body 
weight under epidermal armpit of the forelimb. All operations were performed under 
aseptic conditions. Each group was treated respectively with propolis, bee-collected pollen 
and royal jelly intragastrically, and the control group treated with distilled water with 0.5 
ml120 g·d. The experiment lasted for 15 days and on the sixteenth day, all mice were 
dissected to recover tumor tissue which was then weighed. 
10.4 Results 
The results are shown in tables 10.1 and 10.2. The average tumor weights of the 
propolis, bee-collected pollen and royal jelly groups were significantly lower than that of 
the control group, and the difference was significant (P < 0.01). Comparing the incidence 
of anti-tumor efficacy against the control group, the anti-tumor rates for propolis, 
bee-collected pollen and royal jelly groups were 79.9%, 69.0% and 75.8%, respectively. 
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Table 10.1 The tumor weights of each treatment group 
Treatment Average tumor 
Tumor weight (g) 
group weight (g) 
Propolis 0.28 0.28 0.28 0.24 0.21 0.21 0.30 0.29 0.26±0.03·· 
Bee pollen 0.36 0.43 0.46 0.33 0.45 0.31 0.42 0.49 0.41 ±0.07·· 
Royal jelly 0.39 0.38 0.28 0.28 0.34 0.29 0.35 0.25 0.32±0.05·· 
Control 1.35 1.34 1.28 1.33 1.29 1.24 1.33 1.33 1.3 1±0.04 
Compared with that of control group, "P < 0.01 
Table 10.2 The anti-tumor rate of each treatment group 
Group Propolis Bee pollen Royal jelly Control 
Anti-tumor rate (%) 79.9 69.0 75.8 
Anti-tumor rate (%) = (the average tumor weight of control - average tumor weight of experimental 
groups) / the average tumor weight of control 
10.5 Discussion 
10.5.1 The anti-tumor effects of propolis, bee pollen and royal jelly 
In this experiment, we found that propolis, bee-collected pollen and royal jelly 
exhibited anti-tumor effective rates of 79.9%, 69.0% and 75.8% respectively. These results 
confirm those of Wang et al. (1986) who reported that the anti-tumor effective rates were 
about 70%. The anti-tumor rates of propolis, bee pollen and royal jelly were all higher than 
the standard index, which is based on a universal standard that a substance has anti-tumor 
properties if its anti-tumor effective rate is over 30% (Xu et aI., 1991). 
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In the experiment, the increase in body weight in the group of propolis treated animals 
was significantly lower than that of the group treated with bee-collected pollen and royal 
jelly. In addition, the tumor multiplication rate in the propolis treated group was also lower 
than that of other groups. The body weight increases in the bee pollen and royal jelly 
groups was rapid. While the inhibition effect was initially weak, the effect increased with 
time. The probable cause was that the immune system strengthened for a few days after 
administration of bee pollen and royal jelly intragastrically (Wang et al., 1986; Qiu et al., 
1993; Li et al., 2000). On the other hand, there could well be several different mechanisms 
for the effects of the propolis extracts, which contain numerous flavonoids such as 
mulberrin, quercetin, kaempferol, galangin, etc. Kimoto et al. (1998) reported that 
3,5-diprenyl-4 hydroxylcinnamic acid had anti-bacterial effects expressed as a cytotoxicity 
to malignancy, possibly resulting in apoptosis. In addition, propolis could also modulate 
the reactivity of the immune system (Mitamura et al., 1996; Mahran, 1996; Kimoto et al., 
1998; Sharma & Pillai, 1998; Fang, 1998a; Hu & Li, 2002). However, the mechanisms of 
the extracts of these bee products in exerting anti-tumor effects need further study. 
10.5.2 The combined effects of propolis, bee pollen and royal jelly 
It is well known that pollen is a mini-type nutrition pool, and includes amino acids, 
enzymes, vitamins and trace elements. The anti-tumor effects of propo1is have been widely 
studied (Scheller et al., 1989; Mitamura et al., 1996; Kimoto et aI., 1998,2000; Sato & 
Miyataka, 1999). In addition, it may be that there are some unknown, but active nutritional 
components in royal jelly. So the combined effects of pollen, propolis and royal jelly may 
well prove more effective and possibly synergistic than any of these bee products used 
alone; but this certainly requires further study. 
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Appendix 1 
Original Experimental Data 
Table 2.1: Changes in blood glucose in normal rats and those with diabetes mellitus 
over five weeks 
(1) Normal control group 
1 week 2 weeks 3 weeks 4 weeks 5 weeks 
3.29 1.41 3.57 0.36 3.29 
1.61 0.31 0.43 0.53 1.91 
2.98 1.01 0.14 0.36 1.95 
2.04 0.65 0.02 2.22 2.23 
2.97 0.88 0.57 1.10 2.23 
2.46 1.26 1.63 0.45 0.83 
1.26 0.20 0.13 0.54 2.78 
2.45 1.09 2.89 0.51 1.17 
2.13 0.62 0.15 1.04 2.78 
1.78 0.43 0.65 0.68 2.70 
2.297±0.655 0.786±0.409 1.018 ±1.264 0.779 ±0.568 2.187±0.760 
(2) Model control group 
I week 2 weeks 3 weeks 4 weeks 5 weeks 
19.55 29.66 19.39 30.95 30.26 
24.13 29.02 25.52 25.51 34.89 
17.08 22.39 22.02 24.60 30.04 
21.61 21.76 26.22 34.24 32.00 
21.33 25.39 25.06 27.68 33.06 
20.28 20.33 22.30 21.56 33.38 
24.37 24.33 20.74 34.79 33.06 
24.32 24.33 22.26 34.52 32.98 
25.13 29.2 27.26 45.74 36.80 
16.01 20.79 22.43 32.15 30.17 
21.381±3.182 24.720±3.S37 23.320±2.SS1 31.174±6.886 32.664±2.168 
l37 
(3) WSDl group 
I week 2 weeks 3 weeks 4 weeks 5 weeks 
22.81 19.24 23.5 26.65 26.16 
15.91 14.36 20.58 30.38 27.41 
20.31 17.77 21.19 21.35 24.71 
20.22 24.02 19.34 26.62 21.89 
27.68 20.99 19.27 21.69 27.42 
22.39 16.23 24.82 23.13 30.87 
20.79 22.79 23.07 29.59 32.47 
21.53 23.24 21.18 28.24 38.72 
21.65 24.42 22.52 36.59 27.87 
25.35 26.37 24.3 40.06 16.73 
21.864± 3.145 20.943±3.920 21.977±1.966 28.430±6.120 27.425±5.954 
(4) WSD2 group 
I week 2 weeks 3 weeks 4 weeks 5 weeks 
20.88 23.94 21.8 30.62 20.36 
21 18.97 23.77 28.64 33.65 
23.94 29.64 26.82 30.75 32.36 
18.15 12.59 21.04 19.88 28.65 
20.62 19.09 22.75 23.27 26.26 
16.02 23 .95 23.84 24.27 28.28 
22.21 20.2 19.08 25.32 25.75 
20.16 24.87 19.14 42.35 28.38 
22.04 22.31 24.44 39.8 27.32 
23.96 19.13 25.17 31.43 23.09 
20.898±2.441 21.469±4.584 22.785±2.535 29.633±7.106 27.410±3.932 
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(5) EEPI group 
1 week 2 weeks 3 weeks 4 weeks 5 weeks 
20.57 22.13 23.85 25 .18 38.66 
25.42 19.91 22.99 21.73 20.39 
23.04 24.1 23.14 24.53 26.44 
18.99 23.2 21.87 22.96 22.68 
20.Q9 21.41 25.26 22.76 26.55 
22.16 26.08 2l.l2 19.98 28.34 
17.65 19.42 18.03 24.59 26.24 
21.74 22.25 22.93 25.87 27.66 
15.32 22.78 22 .96 31.42 33.86 
20.75 20.16 29.08 29.59 36.58 
20.S73±2.836 22.144±2.048 23.123±2.832 24.861±3.470 28.740±S.871 
(6) EEP2 group 
1 week 2 weeks 3 weeks 4 weeks 5 weeks 
16.50 19.76 23 .02 27.61 29.20 
24.73 30.13 25.14 30.10 30.28 
20.43 20.04 27.30 27.70 27.77 
20.19 23.27 30.50 26.42 28 .15 
21.02 22.77 21.25 30.86 24.45 
16.79 20.54 2l.l1 23.14 20.14 
15.39 14.23 17.10 33.63 19.99 
15.11 12.86 2l.l1 30.95 30.20 
24.82 22 .11 28.35 32.70 31.33 
19.52 19.23 24.09 33.72 28.93 
19.4S0±3.S24 20.494±4.810 23.897±4.029 29.683±3.429 27.044±4.122 
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(7) Positive control group 
1 week 2 weeks 3 weeks 4 weeks 5 weeks 
21.81 29.70 22.84 17.55 25.42 
23.81 24.75 25.87 26.98 16.10 
20.45 22.39 22.50 24.03 23.26 
19.01 14.78 22.40 23.01 27.08 
24.66 26.19 23.52 22.39 29.87 
21.02 24.37 18.39 21.01 25.94 
23 .77 26.51 25 .02 38.47 25.97 
17.31 18.81 28 .91 37.48 31.60 
16.90 21.11 20.52 32.30 39.63 
21.70 23.24 23.03 28.31 27.14 
21.044±2.683 23.185±4.231 23.300±2.880 27.153±7.009 27.201±6.019 
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Table 2.2: Effects of propolis on the levels of HbAle, TG, Te, TP and ALB in rats 
with diabetes mellitus 
(1) Normal control group 
TG TC TP ALB 
HbAle (mmollL) (mmollL) (gIL) (gIL) 
0.04 0.46 1.06 54 27 
0.07 0.68 1.30 70 27 
0.04 0.73 1.27 69 32 
0.05 0.67 1.39 67 25 
0.04 0.67 1.52 83 35 
0.05 0.65 1.38 72 32 
0.05 0.73 1.91 71 34 
0.07 0.35 1.30 60 28 
0.04 0.53 0.91 65 33 
0.05 0.95 0.68 56 28 
0.050 ± 0.012 0.642 ± 0.165 1.272±0.34 66.700±8.51 30.100±3.48 
(2) Model control group 
TG TC TP ALB 
HbAle (mmollL) (mmollL) (gIL) (gIL) 
0.08 4.13 1.53 45 19 
0.07 2.49 1.25 46 21 
0.08 0.54 1.21 41 22 
0.08 8.55 1.84 41 20 
0.08 2.76 1.44 52 28 
0.07 4.90 1.31 44 23 
0.07 5.17 1.72 58 25 
0.07 3.43 1.49 43 20 
0.08 4.85 1.83 69 30 
0.07 2.85 1.18 55 24 
0.075 ± 0.005 3.967 ± 2.136 1.480±0.25 49.400±9.06 23.200 ±3.62 
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(3) WSDI group 
TG TC TP ALB 
HbAlc (mmoUL) (mmoIlL) (gIL) (gIL) 
0.08 1.40 1.60 54 25 
0.06 3.58 1.59 51 26 
0.06 5.01 1.96 63 28 
0.06 6.53 2.28 53 26 
0.09 1.67 1.36 57 28 
0.06 2.22 1.24 45 22 
0.Q7 1.70 0.98 47 21 
0.06 1.94 1.28 56 27 
0.07 3.99 1.44 59 26 
0.08 5.93 1.65 54 24 
0.069±0.01l 3.397 ± 1.903 1.538±0.37 53.900 ± 5.36 25.300 ±2.36 
(4) WSD2 group 
TG TC TP ALB 
HbAlc (mmoUL) (mmoUL) (gIL) (gIL) 
0.Q7 2.28 1.45 56 28 
0.05 1.83 1.05 46 18 
0.06 1.80 1.31 69 28 
0.06 1.53 0.96 49 20 
0.06 2.68 1.20 59 21 I 
0.08 0.95 1.01 56 25 
0.06 3.30 1.25 31 18 
0.Q7 1.82 1.63 55 27 
0.08 2.31 1.23 51 26 
0.Q7 2.24 1.47 49 22 
0.066±0.010 2.074± 0.646 1.256±0.22 52.100±9.86 23.300±3.97 
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(5) EEPI group 
TO TC TP ALB 
HbAie (mrnoVL) (mrnoVL) (gIL) (gIL) 
0.07 1.67 1.21 53 21 
0.06 0.93 1.13 62 27 
0.05 0.32 0.85 57 21 
0.07 2.18 1.15 55 26 
0.08 2.27 1.23 52 25 
0.06 2.45 1.41 47 25 
0.08 2.09 1.44 69 30 
0.07 2.93 1.36 41 21 
0.08 3.48 1.34 61 28 
0.08 1.11 0.94 42 17 
0.070 ± 0.01l 1.943 ± 0.955 1.206 ± 0.196 53.900±8.91 24.100±3.98 
(6) EEP2 group 
TO TC TP ALB 
HbAie (mrnoVL) (mrnoVL) (gIL) (gIL) 
0.07 1.81 1.21 56 24 
0.06 3.39 1.22 56 23 
0.05 1.58 1.19 57 25 
0.06 1.23 0.9 1 44 23 
0.06 1.36 1.11 48 24 
0.05 1.16 0.95 59 25 
0.08 3.09 1.25 55 23 
0.07 1.72 1.33 48 22 
0.07 1.80 1.58 70 25 
0.08 1.96 1.45 57 26 
0.065 ± 0.01l 1.910 ± 0.751 1.220±0.20 55.000±7.23 24.000 ± 1.25 
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(7) Positive control group 
TG TC TP ALB 
HbAlc (mmoUL) (mmoUL) (gIL) (gIL) 
0.07 1.95 1.59 58 25 
0.08 4.15 0.98 57 15 
0.08 4.91 1.88 56 25 
0.08 2.07 1.40 55 24 
0.06 4.47 1.50 58 25 
0.07 2.87 1.50 62 30 
0.07 6.98 2.00 70 25 
0.08 1.23 1.29 60 22 
0.07 2.37 1.59 51 20 
0.06 7.29 1.94 56 24 
0.072 ± 0.008 3.829±2.109 1.567 ± 0.313 58.300 ± 5.056 23.500±3.923 
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Table 2.3: Effects of propolis on the levels of FRV, CREA, BUN, VA and MDA in 
rats with diabetes mellitus 
(1) Normal control group 
FRU CREA BUN UA MDA 
(~ mollL) (~ moJIL) (mmoJIL) (~ mollL) (nmoJIL) 
70.33 57.52 4.80 135.48 9 
73.40 56.61 5.70 168.32 9 
71.15 63 .56 5.66 146.62 8 
75.77 54.22 5.56 183.86 10 
70.25 56.22 5.62 191.43 9 
83.36 71.29 6.37 155.73 10 
73.89 69.59 5.65 160.42 9 
73.11 61.34 5.96 129.28 8 
78.63 57.52 5.51 171.51 10 
63.75 56.39 5.58 151.50 11 
73.364 ± 5.27 60.426 ± 5.93 5.641±0.390 159.415 ± 19.917 9.300±0.95 
(2) Model control group 
FRU CREA BUN UA MDA 
(~ mollL) (~ mollL) (mmoIlL) (~ moJIL) (nmoIlL) 
97.63 66.12 17.63 202.34 29 
91.87 65.43 21.05 201.31 14 
92.66 60.77 17.94 214.35 11 
98.59 71.01 16.97 283.54 24 
111.46 71.41 11.12 245 .90 19 
121.75 67.6 16.17 218.39 17 
119.14 71.69 22.29 232.06 19 
85.52 58.61 21.66 218.73 17 
124.29 62.36 35.48 363.28 15 
104.94 76.59 18.41 200.70 16 
104.785±13.717 67.159±5.61 19.872 ± 6.357 238.060 ±50.762 18.100±5.15 
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(3) WSDI group 
FRU CREA BUN UA MDA 
(~ mollL) (~ moUL) (mmoUL) (~ mollL) (nrnollL) 
92.6 67.03 13.85 188.05 16 
106.36 63.84 19.38 244.76 14 
95.44 65.95 18.23 287.29 18 
97.02 60.26 13.36 224.06 20 
100.81 63.16 17.47 200.30 16 
80.90 66.86 14.18 158.82 13 
103.56 63.95 14.37 203.99 13 
89.38 69.93 14.46 240.34 15 
108.45 67.14 13.94 221.12 18 
92.20 67.60 17.42 278.77 15 
96.672 ± 8.415 65.572 ± 2.77 15.666 ± 2.202 224.750±39.734 15.800±2.30 
(4) WSD2 group 
FRU CREA BUN UA MDA 
(~ mollL) (~ mollL) (mmollL) (~ mollL) (nrnollL) 
80.36 69.41 19.39 199.14 13 
103.6 65.42 15.37 215.89 16 
121.15 76.96 26.6 214.25 14 
91.74 62.82 10.03 200.9 14 
84.97 66.23 17.85 204.56 13 
95.23 66.97 18.41 204.61 13 
66.5 67.82 13.59 188.73 17 
102.09 74.25 24.27 216.9 16 
105.96 66.86 12.33 220.65 16 
86.25 57.43 16.03 213.57 13 
93.785±15.376 67.417±5.46 17.387±5.138 207.920 ± 9.973 14.500±1.58 
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(5) EEPI group 
FRU CREA BUN UA MDA 
(p mollL) (p mollL) (mmollL) (p mollL) (runoIlL) 
90.76 67.64 19.31 201.63 16 
101.48 68.30 26.13 178.36 13 
100.61 66.69 14.25 170.81 10 
90.24 75.63 18.43 217.15 25 
82.70 68.56 16.43 184.31 17 
89.23 79.30 22.52 210.45 18 
110.19 60.71 12.58 260.96 25 
84.22 59.13 18.70 188.05 13 
95.43 54.33 24.49 244.43 18 
72.77 56.41 20.47 160.54 9 
91.763 ± 10.725 66.670±7.08 19.331±4.286 201.669 ±32.205 16.400 ± 5.50 
(6) EEP2 group 
FRU CREA BUN UA MDA 
(p mollL) (p mollL) (mmollL) (p mollL) (runollL) 
88.91 55.70 15.88 203.82 11 
85.14 62.82 21.04 226.96 12 
95.09 62.76 16.50 239.43 13 
91.41 64.98 21.11 186.47 12 
97.25 54.60 18.28 208.38 18 
91.10 59.80 16.84 206.28 11 
91.27 60.43 16.93 212.89 18 
104.04 53.36 21.10 236.88 12 
94.50 68.31 17.47 280.96 19 
106.65 61.51 15.93 213.91 15 
94.536±6.641 60.427±4.74 18.108±2.168 221.598 ± 26.243 14.100±3.14 
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(7) Positive control group 
FRV CREA BUN VA MDA 
(11 moVL) (11 moVL) (mmoVL) (11 mollL) (nmollL) 
93.00 62.42 14.28 260.66 19 
81.69 75.29 20.96 224.46 12 
98.89 57.97 18.75 241.81 15 
94.17 76.97 14.18 181.45 10 
98.37 55.59 13.69 222.31 12 
101.79 63.44 11.22 180.45 14 
108.30 70.38 19.31 244.12 21 
106.86 61.96 16.35 233.36 16 
99.45 67.51 20.56 224.35 16 
92.13 71.01 21.56 234.03 24 
97.465±7.741 66.254±7.158 17.086±3.615 224.700 ±25.733 15.900 ±4.358 
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Table 2.4: Effects of propolis on the levels of kidney weight/body weight in rats 
with diabetes mellitus 
(1) Normal control group 
Body weight (g) Kidney weight (g) Kidney weightlbody weight X 100 
333 1.3495 4.053 
305 1.0980 3.600 
335 1.3206 3.942 
337 1.2670 3.760 
310 1.1896 3.837 
331 1.1596 3.503 
345 1.2771 3.702 
345 1.2819 3.716 
338 1.2933 3.826 
371 1.2398 3.342 
33S.0±lS.4 1.2S±O.OS 3.73±O.21 
(2) Model control group 
Body weight (g) Kidney weight (g) Kidney wcightlbody weight X 100 
243 1.3667 5.624 
205 1.2656 6.174 
205 1.2237 5.969 
210 1.3590 6.471 
209 1.4057 6.726 
247 1.6653 6.742 
175 1.2838 7.336 
172 1.1443 6.653 
160 1.1163 6.977 
197 1.1914 6.048 
202.3±2S.4 1.30±O.16 6.47±O.S2 
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(3) WSDl group 
Body weight (g) Kidney weight (g) Kidney weightlbody weight X 100 
204 1.1789 5.779 
244 1.4414 5.907 
233 1.2854 5.517 
234 1.3127 5.610 
273 1.4363 5.261 
233 1.8425 7.908 
223 1.3045 5.850 
240 1.4909 6.212 
204 1.3365 6.551 
200 1.3120 6.560 
22S.S±22.3 1.39±O.IS 6.1l±O.76 
(4) WSD2 group 
Body weight (g) Kidney weight (g) Kidney weightlbody weight X 100 
242 1.4770 6.103 
241 1.4530 6.029 
212 1.3468 6.353 
296 1.5448 5.219 
270 1.7246 6.387 
283 1.7403 6.149 
256 1.5659 6.117 
191 1.4971 7.838 
265 1.0345 3.904 
157 1.2894 8.213 
241.3±43.2 1.47±O.21 6.23±1.21 
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(5) EEPI group 
Body weight (g) Kidney weight (g) Kidney weightlbody weight X 100 
221 1.3562 6.137 
210 1.4168 6.747 
200 1.2577 6.289 
258 1.4364 5.567 
226 1.4243 6.302 
219 1.5317 6.994 
228 1.0827 4.749 
243 1.4682 6.042 
217 1.3473 6.209 
195 1.2039 6.174 
221.7±lS.S 1.3S±O.14 6.12±O.62 
(6) EEP2 group 
Body weight (g) Kidney weight (g) Kidney weightlbody weight X 100 
236 1.4280 6.051 
201 1.3804 6.868 
238 1.2866 5.406 
245 1.3267 5.415 
289 1.6350 5.657 
230 1.5500 6.739 
186 1.1517 6.192 
218 1.1534 5.291 
158 1.3900 8.797 
204 1.0165 4.983 
22O.S±36.0 1.33±O.19 6.14±O.1l 
lSI 
(7) Positive control group 
Body weight (g) Kidoey weight (g) Kidoey weigbtlbody weight X 100 
235 1.4100 6.000 
221 1.5271 6.910 
225 1.4396 6.398 
287 1.4939 5.205 
242 1.5513 6.410 
240 1.5045 6.269 
186 1.1668 6.273 
283 1.5873 5.609 
205 1.3580 6.624 
197 1.2633 6.4 13 
232.1±33.4 I.43±O.13 6.21±O.49 
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Table 3.1: Changes in blood glucose in rats with induced diabetes mellitus and 
normal rats for eight weeks 
(1) 1 week 
Nonnal Model Postive 
WSD1 WSD2 EEPI EEP2 
control control control 
4.23 21.95 20.70 23.65 20.90 19.74 20.79 
4.72 22.07 24.56 21.56 22.08 21.26 20.75 
5.05 24.6 19.31 23.98 18.76 23.11 23.60 
4.30 20.00 23.46 21.56 24.01 19.69 20.81 
3.45 23.24 19.86 24.95 21.91 24.02 23 .27 
3.53 21.85 20.19 18.99 20.94 19.17 24.26 
3.43 21.56 22.60 18.55 21.34 23.37 22.55 
4.51 18.59 22.83 19.61 24.80 20.76 24.20 
2.45 24.10 19.00 24.01 24.97 24.01 19.45 
4.53 19.48 23.80 22.06 23.17 22.98 20.00 
3.16 20.70 24.31 20.26 19.47 22.98 23.90 
2.24 24.75 22.66 23.93 20.5 23 .66 19.83 
3.800± 21.908± 21.940± 21.926± 21.904± 22.062± 21.951 ± 
0.898 2.001 2.011 2.198 1.998 1.819 1.850 
(2) 2 weeks 
Nonnal Model Postive 
WSD1 WSD2 EEP1 EEP2 
control control control 
4.29 17.04 19.41 24.64 13.00 21.61 10.84 
5.29 23.44 24.08 22.32 19.07 22.10 21.91 
3.72 34.90 19.84 19.46 23.34 19.60 18.89 
5.18 20.60 24.34 20.82 29.05 14.79 18.54 
4.80 25.65 16.2 20.49 20.22 20.21 22 .16 
4.33 25.58 23 .27 17.74 18.88 20.66 19.42 
4.70 22.06 17.32 17.37 18.64 20.93 23.41 
4.06 19.64 22.33 18.14 19.90 13.49 13.88 
3.87 21.44 14.40 19.74 10.39 21.85 21.55 
3.77 17.29 13.66 23 .80 23.60 13.19 18.03 
3.64 21.60 21.21 17.74 17.39 20.80 20.09 
4.21 23.00 19.66 19.19 23.15 20.02 19.74 
4.322± 22.687± 19.643± 20.1 21 ± 19.719± 19.104± 19.038± 
0.561 4.717 3.633 2.406 4.928 3.287 3.571 
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(3) 3 weeks 
Nonnal Model Postive 
WSDI WSD2 EEPI EEP2 
control control control 
4.53 28.19 11.59 19.98 19.06 23.09 14.45 
4.54 20.47 21.83 18.97 18.86 22.98 22.21 
4.37 33.32 17.30 21.15 15.98 20.83 21.71 
4.12 24.74 18.80 16.53 24.42 19.37 14.88 
4.63 23.08 16.88 21.17 21.78 22.90 21.64 
5.36 24.08 20.41 15 .38 19.31 23.18 23.34 
5.14 16.12 16.69 16.03 17.77 22.89 24.68 
5.05 22.97 19.80 21.60 20.44 19.86 15.56 
3.65 20.72 17.88 16.73 13.04 21.13 17.Q4 
3.91 10.06 15.65 21.20 22.37 19.77 14.81 
3.62 25 .85 13.13 16.37 15.35 20.68 21.77 
4.63 19.74 19.51 16.06 20.32 21.01 12.35 
4.463± 22.445± 17.456± 18.431 ± 19.058± 21.474± 18.703 ± 
0.562 5.870 2.968 2.463 3.189 1.450 4.237 
(4) 4 weeks 
Nonnal Model Postive 
WSDI WSD2 EEPI EEP2 
control control control 
4.51 23.66 16.42 17.88 14.86 23.24 23.51 
4.63 25.03 20.10 16.18 15.98 20.36 19.17 
3.12 24.82 18.38 18.31 19.8 20.27 20.94 
3.82 24.22 17.13 15.44 20.25 21.60 17.24 
3.7 1 22.83 12.18 16.28 16.38 22.4 22.81 
4.32 20.32 15.D9 13.3 1 16.50 23.42 17.71 
3.97 19.73 16.02 16.19 17.79 21.36 23.01 
3.33 21.70 17.83 15.53 18.76 23 .60 19.00 
3.93 20.52 17.Q4 15.87 16.80 22.41 16.25 
3.19 22.3 17.64 18.04 20.64 20.26 16.21 
3.57 21.85 21.16 17.50 17.23 22.95 19.31 
4.12 23 .5 21.5 14.10 19.09 21.70 17.57 
3.852± 22.540± 17.541 ± 16.220± 17.840± 21.964 ± 19.394 ± 
0.495 1.774 2.609 1.545 1.849 1.232 2.613 
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(5) 5 weeks 
Nonnal Model Postive 
WSDI WSD2 EEP1 EEP2 
control control control 
3.31 22.04 11.35 20.56 18.68 20.42 18.18 
3.83 23.28 19.55 21.39 23.90 21.35 23.01 
3.87 24.77 22.81 21.58 19.22 28.83 23.10 
3.71 22.53 22.95 20.98 23.13 18.75 17.74 
3.18 23.68 26.27 21.94 18.35 15.82 22.52 
3.29 27.05 24.45 18.92 25.72 14.76 22.70 
4.08 27.02 11.30 20.61 19.78 18.93 23 .10 
3.06 23.40 20.52 20.69 25.62 28.96 17.23 
3.33 22.90 14.22 20.16 21.76 29.51 19.10 
2.67 19.71 17.00 20.38 21.89 13.70 14.99 
3.14 19.38 19.73 19.88 22.96 20.47 23.57 
3.64 26.15 20.48 18.9 21.77 20.61 15.01 
3.426± 23.493± 19.219± 20.499± 21.898± 21.009± 20.021 ± 
0.405 2.496 4.881 0.948 2.518 5.447 3.324 
(6) 6 weeks 
Nonnal Model Postive 
WSD1 WSD2 EEP1 EEP2 
control control control 
5.73 19.2 18.50 25 .24 21.54 20.33 15.95 
5.11 23 .62 22.02 21.48 23.77 26.20 20.75 
5.05 24.96 14.34 23.83 18.30 22.62 18.47 
4.6 23.52 22 .11 18.52 20.46 20.27 20.57 
4.02 23.05 18.70 15.97 8.05 22.52 18.19 
3.76 25.18 24.85 29.75 24.35 11.36 18.15 
3.96 34.04 13.87 21.43 24.65 25.49 16.87 
4.21 27.11 22.21 23.06 26.86 11.01 20.76 
3.77 25.19 16.07 19.33 12.43 27.87 20.97 
4.69 26.42 18.10 24.26 21.2 15.32 17.74 
4.22 27.22 16.06 22 .93 20.53 20.14 23 .00 
5.01 24.8 19.27 17.25 26.24 23.32 17.71 
4.511± 25.359± 18.842± 21.921 ± 20.698± 20.538± 19.094± 
0.622 3.480 3.431 3.810 5.578 5.468 2.070 
155 
(7) 7 weeks 
Nonnal Model Postive 
WSDI WSD2 EEP1 EEP2 
control control control 
5.22 24.01 10.48 21.13 22.86 29.30 19.30 
5.56 27.35 29.00 21.27 25.94 20.30 22.04 
4.82 28.21 19.02 27.02 32.13 25.87 24.33 
5.41 26.68 18.42 21.64 9.69 18.10 19.41 
4.36 27.58 15.39 23.65 12.40 26.63 22.14 
5.26 26.76 21.19 16.87 22.88 26.22 23.33 
4.76 28.56 14.39 9.15 9.57 29.48 23.41 
4.69 28.02 14.38 16.53 24.02 15.16 21.80 
4.57 25.6 9.55 22.51 20.97 29.79 18.69 
4.66 28.49 16.06 21.44 25.48 10.40 30.44 
4.60 28.86 21.80 20.03 23.56 26.95 20.19 
5.00 23.8 2U I 17.25 21.37 28.78 19.38 
4.909± 26.993± 17.599± 19.875± 20.905± 23.915± 22.038± 
0.376 1.716 5.410 4.507 6.899 6.396 3.241 
(8) 8 weeks 
Nonnal Model Postive 
WSD1 WSD2 EEP1 EEP2 
control control control 
4.27 21.85 15.57 24.45 21.75 20.25 15.16 
4.81 22.41 31.28 21.04 23.56 24.17 26.46 
3.80 28.17 21.00 24.2 15.80 24.74 26.02 
6.74 29.75 17.55 21.76 28.91 16.09 18.81 
5.88 24.82 14.98 36.59 12.28 24.99 22.27 
5.23 30.87 24.35 12.00 23.22 23.61 20.58 
5.28 31.77 11.72 17.43 19.10 26.99 21.91 
4.61 32.50 25.06 17.31 21.52 15.98 22.64 
4.92 27.70 17.72 15.10 19.71 28.75 22.34 
4.79 30.36 16.28 16.04 20.29 18.69 21.38 
5.61 25.14 18.29 20.31 27.63 22.71 17.03 
5.90 25.50 19.53 18.95 29.68 23.57 20.49 
5.153± 27.570± 19.444± 20.432± 2J.954± 22.545± 21.258± 
0.800 3.604 5.314 6.277 5.153 4.032 3.253 
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Table 3.2: Effect of propolis on the level of total cholesterol (TC), high density 
lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol 
(LDL-C), very low density lipoprotein cholesterol (VLDL-C) and 
triglycerol (TG) in rats with induced diabetes mellitus 
(1) TC 
Normal Model Postive 
WSDI WSD2 EEPI EEP2 
control control control 
2.06 1.59 1.71 1.76 2.20 2.19 1.48 
2.40 2.44 2.03 1.98 1.94 2.04 1.73 
1.94 2.82 1.75 2.13 1.86 2.26 2.24 
2.18 3.27 1.86 2.27 1.51 2.11 1.61 
2.03 1.99 1.44 1.87 2.5 1.91 2.16 
2.11 2.05 1.91 1.51 1.85 2.19 1.87 
2.16 2.07 2.17 1.74 1.59 2.03 1.97 
1.83 2.20 1.79 1.82 1.82 2.46 2.27 
1.99 2.69 2.09 1.95 2.30 2.02 1.86 
1.80 2.26 2.24 1.97 2.15 2.10 2.02 
1.76 2.24 1.79 1.47 1.97 2.05 1.74 
1.83 2.44 2.08 1.97 1.96 2.61 1.72 
2.007 ± 0.189 2.34± 0.44 1.91±0.23 1.870±0.23 1.971 ± 0.283 2.164±0.199 1.889±0.25 
(2) HDL-C 
Normal Model Postive 
WSDI WSD2 EEPI EEP2 
control control control 
0.84 0.81 0.82 0.89 0.82 0.80 0.94 
0.90 0.75 0.72 0.87 0.78 0.76 0.81 
0.92 0.76 0.80 0.95 0.74 0.90 0.98 
0.87 0.83 0.71 1.13 0.64 1.12 0.85 
0.97 0.86 1.06 1.02 1.20 0.81 0.91 
0.97 0.61 0.82 0.99 0.65 0.94 0.73 
1.03 0.86 0.89 0.67 0.66 0.83 0.76 
0.85 0.84 0.68 0.75 0.93 1.36 0.99 
0.93 0.88 1.06 0.97 0.95 0.72 0.90 
0.84 0.70 1.03 0.79 0.75 1.07 1.37 
0.82 0.88 0.75 0.90 1.32 0.82 0.89 
0.95 0.89 l.01 0.83 0.59 0.96 1.09 
0.908±0.068 0.81±0.09 0.86±0.14 0.898±0.13 0.836 ± 0.228 0.924±0.183 0.937±0.17 
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(3) LDL-C 
Nonnal Model Postive 
WSDI WSD2 EEPI EEP2 
control control control 
0.69 1.11 0.50 0.20 0.12 0.37 0.32 
0.33 1.65 0.70 0.54 0.33 0.55 0.15 
0.61 0.56 0.24 0.4 0.45 0.48 0.45 
0.44 0.42 0.25 0.52 0.31 0.28 0.53 
0.24 1.42 0.09 0.37 0.21 0.19 0.50 
0.52 0.53 0.19 0.27 0.04 0.41 0.22 
1.07 0.51 0.76 0.58 0.29 0.41 0.30 
0.35 0.93 0.39 0.48 0.40 0.42 0.23 
0.41 0.60 0.60 0.36 0.35 0.33 0.51 
0.45 0.69 0.38 0.49 0.52 0.43 0.50 
0.42 0.71 0.45 0.44 0.56 0.45 0.50 
0.39 0.68 1.13 0.60 0.45 0.39 0.37 
0.49l± 0.820± 0.475± 0.438± 0.34± 0.394 ± 0.381 ± 
0.22 0.39 0.29 0.115 0.16 0.09 0.127 
(4)VLDL-C 
Nonnal Model Postive 
WSDI WSD2 EEPI EEP2 
control control control 
0.43 1.24 1.39 1.07 1.45 1.27 0.55 
1.17 1.50 1.01 0.57 0.81 0.95 0.87 
0.31 1.30 1.29 1.08 0.94 1.43 0.09 
0.30 1.52 1.20 0.62 1.15 1.89 2.29 
0.82 1.19 0.89 0.48 1.49 1.31 0.75 
0.42 1.63 1.28 0.79 1.31 1.21 1.32 
0.06 1.73 0.52 0.99 1.14 1.49 1.11 
0.63 1.25 0.72 1.08 0.79 0.96 1.05 
0.65 1.69 0.43 1.35 1.02 0.95 0.55 
0.21 1.61 0.83 1.67 1.43 0.41 0.15 
0.32 1.58 1.38 0.66 0.9 0.47 0.68 
0.59 1.99 0.98 1.14 1.28 0.67 0.74 
0.494± 1.516± 0.994± 0.958± 1.14± 1.08± 0.847± 
0.30 0.24 0.33 0.35 0.25 0.44 0.58 
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(S)TG 
Nonnal Model Postive 
WSDI WSD2 EEPI EEP2 
control control control 
1.79 1.93 1.04 1.22 1.38 0.76 0.93 
1.10 1.23 0.99 1.06 1.18 1.57 0.86 
1.28 1.10 0.93 1.39 1.39 0.58 0.88 
1.04 1.47 1.54 1.54 0.73 1.15 0.61 
0.93 1.56 1.08 0.58 0.51 0.66 0.55 
0.93 0.82 1.33 1.19 0.81 0.80 0.59 
1.44 1.49 1.09 0.81 0.66 0.71 0.80 
1.49 1.63 1.08 0.85 0.99 1.26 1.20 
1.31 0.71 1.15 0.63 1.63 0.49 1.41 
1.75 1.07 1.44 0.78 0.90 0.49 0.94 
0.94 1.33 0.69 1.14 0.51 0.64 1.21 
0.88 1.34 1.66 0.78 0.74 0.55 0.96 
1.240± 1.306± 1.162± 1.000± 0.952± 0.805± 0.912± 
0.322 0.35 0.28 0.30 0.367 0.342 0.264 
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Table 3.3: Effects of propolis on the levels of FRU, SOD, MDA, NO and NOS in 
rats with induced diabetes mellitus 
(1) FRU 
Nonnal Model Postive 
WSDI WSD2 EEPI EEP2 
control control control 
250 295 216 235 269 279 190 
215 276 256 242 165 257 235 
202 291 219 285 214 294 271 
209 288 227 248 218 242 219 
219 289 184 201 221 277 267 
232 281 231 213 219 225 266 
233 292 223 218 188 286 241 
235 296 225 209 239 233 227 
227 295 223 247 204 243 258 
216 276 233 242 215 257 226 
237 289 213 221 214 250 231 
223 291 221 234 217 241 243 
224.833± 288.250± 222.583± 232.917± 215.250± 257.00± 239.500± 
13.456 6.969 16.407 22.686 25.060 22.197 23.567 
(2) SOD 
Nonnal Model Postivc 
WSDI WSDZ EEPI EEP2 
control control control 
160.956 128.765 151.445 151.445 148.519 136.447 110.475 
173.028 114.499 152.543 142.300 131.326 108.280 160.591 
160.956 110.840 145.592 138.642 128.765 139.374 159.493 
140.837 122.912 128.034 144.495 134.618 131.326 145.958 
145.227 114.499 155.469 140.105 136.447 109.011 146.690 
173.760 118.157 150.348 145.227 137.910 112.669 139.008 
143.398 103.890 124.375 143.763 147.056 136.813 136.447 
155.470 124.375 160.225 139.008 138.276 140.471 148.519 
164.980 108.646 138.642 151.811 145.227 143.398 155.469 
130.960 103.158 144.861 145.592 141.568 136.447 127.302 
139.374 113.767 115.230 149.982 107.182 108.280 131.692 
143.398 129.497 151.445 131.692 139.008 112.304 95.8422 
152.70± 116.078± 143.218± 143.67± 136.33± 126.24± 138.12± 
14.05 8.89 13.85 5.87 10.95 14.57 19.59 
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(3)MDA 
Nonnal Model Postive 
WSDI WSD2 EEPI EEP2 
control control control 
5.70 9.95 4.15 6.01 5.34 10.77 3.78 
5.74 12.17 4.74 6.33 4.25 5.04 5.42 
8.27 8.89 5.34 8.64 6.67 2.79 5.75 
3.60 6.40 4.59 7.42 4.04 8.59 5.37 
5.12 7.31 4.48 7.04 6.01 3.45 4.9 1 
5.57 10.07 4.71 5.07 7.25 3.67 4.83 
3.91 10.87 4.13 7.24 4.96 3.86 6.23 
8.01 7.14 4.79 3.26 4.96 8.70 9.97 
8.48 10.51 8.05 3.61 8.52 4.22 7.27 
4.18 7.05 6.88 6.85 8.41 4.65 2.27 
6.26 9.28 3.47 7.49 5.12 3.94 5.30 
2.96 10.04 3.07 6.70 6.73 8.36 4.09 
5.646± 9.145± 4.87± 6.306± 6.024± 5.67± 5.430± 
1.85 1.80 1.38 1.60 1.51 2.66 1.90 
(4) NO 
Nonnal Model Postive 
WSDl WSD2 EEPI EEP2 
control control control 
5.90 21.73 16.89 11.63 14.78 17.86 15.72 
4.01 15.94 16.03 15.29 13.81 20.14 22 .20 
6.32 18.49 14.61 11.82 35.94 16.62 21.36 
6.06 24.60 18.36 16.53 18.3 14.63 27.63 
6.15 23.01 15.10 15.54 12.53 15.41 7.65 
5.60 16.07 13.91 14.43 23.17 18.60 9.91 
6.61 17.51 14.34 16.36 23.04 16.93 8.34 
5.69 22.15 21.42 17.77 24.46 3.12 16.70 
4.05 16.69 15.48 22.69 2.44 16.48 3.54 
5.50 28.67 18.74 21.54 11.01 16.3 14.71 
4.43 14.08 16.34 22.84 9.75 18.72 15.1 2 
4.79 26.35 18.36 13.34 27.86 24.87 18.27 
5.43± 20.44± 16.63± 16.65± 18.091± 16.64± 15.10± 
0.89 4.65 2.22 3.90 9.19 5.03 6.89 
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(5) NOS 
Normal Model Postive 
WSD1 WSD2 EEP1 EEP2 
control control control 
5.097 18.970 4.955 8.636 11.892 11.326 12.741 
10.0517 16.988 4.813 14.723 11.750 10.193 9.060 
9.0607 13.733 9.485 14.015 9.768 9.202 12.033 
7.2207 18.263 12.033 8.636 12.033 11.042 13.024 
7.362 16.422 13.308 6.371 10.618 10.477 12.033 
9.344 12.741 13.874 8.636 9.060 12.741 14.157 
12.317 9.627 9.768 8.353 9.060 10.051 10.193 
8.494 11.326 10.193 14.865 9.485 8.777 10.759 
12.033 12.600 9.627 15.006 11.326 10.051 12.883 
8.919 13.308 12.175 11.892 12.175 8.636 13.449 
9.768 11.892 12.458 18.404 12.741 11.892 11.750 
12.600 11.892 6.371 18.121 11.892 10.476 8.494 
9.36±O.23 13.99±2.97 9.92±3.12 12.30±4.10 lO.98±1.32 lO.41±1.22 11.71 ±1.76 
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Table 4.1: Changes in blood glucose of diabetes mellitus and normal SD rats for 
five weeks 
Bee pollen group: 
1 week 2 weeks 3 weeks 4 weeks 5 weeks 
18.04 24.81 24.71 27.72 22.43 
25.16 20.56 21.82 32.28 27.9 
22 .89 16.92 20.63 30.78 34.15 
20.52 20.66 25.44 29.46 29.02 
19.24 22.55 25 .98 24.45 21.33 
25.8 18.76 24.1 34.02 25.55 
21.08 26.39 19.89 27.91 35.19 
16.37 25.85 22.21 25.73 25.51 
23 .9 19.47 24.22 21.7 21.91 
18.41 18.09 21.17 36.11 31.18 
21.141 ±3.204 21.406±3.344 23.017±2.137 29.016±4.439 27.417 ± 4.968 
(For the data of other groups see table 2.1) 
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Table 4.2: Effects of bee pollen and propolis on the levels of FRU, TG, TC, CREA, 
TP, ALB and MDA in diabetes mellitus SD rats 
Bee pollen group: 
FRU TO TC CREA TP ALB MDA 
102.30 2.94 1.26 69.30 54 25 13 
105.56 1.47 1.63 66.69 51 24 16 
103.44 2.29 0.91 89.07 64 23 15 
97.02 2.12 1.27 68.57 53 22 19 
73.00 1.02 1.37 80.60 49 24 19 
82.80 1.75 1.51 50.54 44 22 13 
103 .68 2.03 1.09 52.73 47 21 13 
86.14 2.69 1.82 51.10 56 23 14 
127.59 2.32 0.86 69.42 58 23 13 
92.20 3.54 1.92 63.28 54 24 12 
97.373 ± 15.06 2.217±0.73 1.364±0.36 66.130 ± 12.56 53.000±5.72 23.100±1.20 14.700±254 
(For the data of other groups see tables 2.2 and 2.3) 
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Table 4.3: Effect of bee pollen and propolis on body weight, kidney weight and 
kidney weight I body weight 
Bee pollen gronp: 
Body weight (g) Kidney weight (g) Kidney weightlbody weight 
203 1.1532 6.747 
242 1.4002 6.289 
232 1.2879 5.567 
233 1.3127 6.302 
272 1.4167 6.994 
231 1.7802 4.197 
223 1.3045 6.042 
238 1.4492 6.209 
202 1.3086 6.174 
200 1.2870 6.058 
227.6±22.1 l.3700±O.17 6.00±O.80 
(For the data of other groups see table 2.4) 
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Table 5.1: Effects of WSD and EEP on body weight, thymus index and adrenal 
gland index in FCA-induced arthritic rats 
(1) Model control group 
Weight of nonnal rats 
At the 19th day after injecting Freund's complete adjuvant 
(g) Thymus Adrenal Weight(g) 
index(mg/IOOg) index(mg/IOOg) 
212 268 145.19 14.93 
213 294 152.38 19.22 
210 288 136.18 13.23 
203 281 145.12 18.33 
199 238 193.95 19.87 
202 253 123.44 18.42 
203 258 187.98 19.88 
202 252 170.52 18.41 
205.5±5.3 266.5±19.7 156.8±25.0 17.8±2.4 
(2) Prednisone acetate group 
Weight of nonnal rats 
At the 19th day after injecting Freund's complete adjuvant 
(g) Thymus Adrenal Weight(g) 
index(mg/IOOg) index( mg/I OOg) 
212 309 174.47 13.85 
209 256 136.25 13.98 
201 270 117.41 15.85 
198 262 163.05 7.75 
199 281 117.Ql 13.20 
195 263 150.91 15.10 
197 275 134.80 12.33 
192 240 128.75 1l.21 
200.4±6.8 269.5±20.3 140.3±20.9 12.9±2.5 
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(3) WSD group 
Weight of nonnal rats 
At the 19th day after injecting Freund's complete adjuvant 
(g) Adrenal Weight(g) Thymus index(mg/100g) 
index(mg/ IOOg) 
213 291 145.22 18.25 
210 286 150.45 15.91 
206 292 148.70 13.18 
202 287 181.01 14.22 
207 308 137. 14 17.14 
205 303 173.56 18.98 
199 309 182.46 16.80 
196 276 157.68 19.02 
204.8±5.6 294.0±n.7 159.5± 17.3 16.7±2.1 
(4) EEP group 
Weight of normal rats 
At the 19th day after injecting Freund's complete adjuvant 
(g) Adrenal Weight(g) Thymus index(mg/l00g) 
index(mg/100g) 
224 309 156.15 17.96 
210 275 184.36 16.22 
201 279 165.52 14.44 
200 272 148.53 14.67 
207 314 161.21 16.56 
193 281 177.76 15.23 
199 292 168.66 16.23 
206 259 149.00 16.37 
205.0±9.4 285.1±18.8 163.9 ± 12.9 16.0±1.1 
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Table S.2: Effects of WSD and EEP on swelling of the right hind paw in 
FCA-induced arthritic rats (the primary affection) 
(1) Cub age before inflammation 
Model control Prednisone acetate WSD EEP 
0.95 0.90 1.00 1.05 
1.00 0.85 1.05 1.05 
1.00 1.05 1.05 0.90 
1.10 1.00 1.10 1.00 
1.00 1.05 0.90 1.10 
1.00 1.00 1.00 1.00 
1.01 ±0.05 0.98±0.08 1.02 ± 0.07) 1.O2±0.07 
(2) Cub age of right hind paw after inflammation (I day) 
Model control Prednisone acetale WSD EEP 
1.60 1.35 1.30 1.40 
1.45 1.35 1.45 1.35 
1.45 1.45 1.45 1.40 
1.35 1.25 1.30 1.40 
1.40 1.35 1.20 1.30 
1.30 1.45 1.30 1.35 
1.43±0.10 1.37±0.08 1.33±0.10 1.37 ± 0.04 
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(3) Cubage of right hind paw after inflammatiou (2 days) 
Model control Prednisone acetate WSD EEP 
1.95 1.75 1.65 1.60 
1.65 1.95 1.75 1.55 
2.05 1.55 1.75 1.55 
1.80 1.65 1.65 1.80 
1.90 1.65 1.80 2.00 
2.00 1.55 1.65 1.80 
1.89±O.15 1.68 ± O.15 l.71±O.07 1.72±O.18 
(4) Cub age of right hind paw after inflammation (3 days) 
Model control Prednisone acetate WSD EEP 
1.85 1.70 2.00 1.45 
1.85 1.55 1.65 1.65 
2.05 1.75 1.85 1.85 
1.70 1.65 2.00 1.80 
2.00 1.80 1.60 2.00 
1.60 1.65 1.70 1.80 
1.84±O.17 1.68±O.O9 1.80±O.18 1.76±O.19 
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(5) Cubage of right hind paw after inflammation (5 days) 
Model control Prednisone acetate WSD EEP 
1.60 1.45 1.75 1.85 
1.75 1.45 1.65 1.65 
1.90 1.45 1.90 1.65 
1.75 1.55 1.80 1.45 
1.55 1.65 1.60 1.70 
1.65 1.85 2.00 1.55 
1.70±O.13 1.57±O.16 1.78±O.15 1.64±O.14 
(6) Cubage of right hind paw after inflammation (7 days) 
Model control Prednisone acetate WSD EEP 
1.45 1.45 1.45 1.45 
1.65 1.40 1.50 1.35 
1.80 1.40 1.80 1.45 
2.00 1.40 1.40 1.60 
2.00 1.45 1.40 1.50 
2.00 1.55 1.55 1.45 
1.82±O.23 1.44±O.O6 1.52±O.15 1.47±O.O8 
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(7) Cub age of right hind paw after inflammation (9 days) 
Model control Prednisone acetate WSD EEP 
1.55 1.55 1.80 1.55 
1.75 1.55 1045 1.55 
2.00 lAO 1.50 1045 
1045 1.35 1.60 1.75 
1.95 1.35 1.50 1.75 
1.80 1.55 1.65 1.65 
1.7S±O.22 1.46±O.10 1.S8±O.13 1.62±O.12 
(8) Cub age of right hind paw after inflammation (11 days) 
Model control Prednisone acetate WSD EEP 
1.65 1.65 lAO 1.35 
1.55 1.80 1045 1.20 
1.70 1.55 1.35 1.35 
1.50 1045 1.35 1.60 
lAO 1.35 1.30 1.55 
1.60 1045 1.35 lAO 
1.S7±O.1l 1.S4±O.16 1.37±O.OS 1.41 ±O.lS 
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(9) Cubage of right hind paw after inflammation (13 days) 
Model control Prednisone acetate WSD EEP 
1.65 1.50 1.65 1.40 
1.65 1.45 1.40 1.45 
1.80 1.35 1.55 1.50 
1.75 1.35 1.70 1.55 
1.60 1.40 1.60 1.65 
1.75 1.55 1.75 1.55 
1.70±O.O8 1.43±O.O8 1.61 ±O.12 1.52±O.O9 
(10) Cub age of right hind paw after inflammation (16 days) 
Model control Prednisone acetate WSD EEP 
lAS 1.35 1.60 lAS 
1.50 1.55 1.35 lAO 
1.50 1.35 1.45 1.45 
1045 1.30 1.60 1.60 
1.55 1.20 lAO 1.60 
1.65 1.85 1.55 1.65 
1.52±O.O8 1.43 ± 0.23 1.49±0.11 1.53±O.10 
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(11) Cub age of right hind paw after inflammation (19 days) 
Model control Prednisone acetate WSD EEP 
1.75 1.65 1.95 1.55 
1.85 1.60 1045 1.65 
2.10 1.35 1045 1.85 
1.60 lAO 1045 1.55 
1.60 1045 1.50 1.75 
1.55 1.75 1.35 1.55 
1.74±O.21 1.53±O.16 1.53±O.21 1.65±O.13 
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Table 5.3: Effects of WSD and EEP on swelling of left hind paw (the secondary 
affection) 
(1) Cub age before inflammation (ml) 
Model control Prednisone acetate WSD EEP 
0.95 0.90 1.05 1.00 
0.95 0.85 1.05 0.95 
1.05 1.05 1.00 0.90 
1.05 1.05 1.00 1.l0 
1.00 1.00 1.00 1.20 
1.00 1.00 1.l0 0.90 
1.OO±0.04 0.98±0.08 1.03±0.04 1.01 ±0.12 
(2) Cubage before inflammation ofleft hind paw (1 day) 
Model control Prednisone acetate WSD EEP 
1.00 1.00 1.00 1.05 
1.05 0.90 1.05 0.90 
1.20 1.00 1.20 0.90 
1.10 0.90 1.00 1.00 
0.90 0.95 0.95 1.05 
1.00 1.05 1.05 1.00 
1.O4±0.10 0.97±0.06 1.04±0.08 0.98 ± 0.07 
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(3) Cubage before inflammation ofleft hind paw (2 days) 
Model control Prednisone acetate WSD EEP 
0.90 1.00 1.10 0.85 
1.00 0.95 1.10 1.10 
1.15 0.85 1.10 1.05 
1.20 0.95 0.80 1.00 
1.20 1.05 0.90 1.00 
1.00 0.85 0.90 1.10 
1.08±O.13 O.94±O.O8 O.98±O.13 1.02±O.O9 
(4) Cub age before inflammation ofleft hind paw (3 days) 
Model control Prednisone acetate WSD EEP 
1.05 1.20 1.15 0.95 
1.25 1.10 1.15 1.00 
1.25 1.05 1.10 1.05 
0.90 1.10 0.90 1.20 
1.00 1.15 0.80 1.00 
0.80 1.20 0.80 0.80 
1.O4±0.18 1.l3±O.O6 O.98±O.17 1.00±O.13 
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(5) Cub age before inflammation ofleft hind paw (5 days) 
Model control Prednisone acetate WSD EEP 
1.10 1.20 1.15 0.95 
1.20 1.00 1.10 1.00 
1.15 1.00 1.15 1.00 
1.00 1.25 1.30 1.20 
0.95 1.10 1.00 1.00 
1.10 1.05 0.70 0.90 
1.08±0.09 1.10±0.10 1.07±0.20 1.01 ±0.10 
(6) Cubage before inflammation ofleft hind paw (7 days) 
Model control Prednisone acetate WSD EEP 
1.05 1.15 1.15 1.00 
1.05 0.95 1.30 1.00 
1.30 1.00 1.05 1.l5 
1.50 1.10 0.95 1.00 
1.20 1.00 0.90 0.70 
lAO 1.20 0.85 1.00 
1.2S±0.18 1.07±0.10 1.03±0.17 0.98 ± 0.IS 
176 
(7) Cub age before inflammation ofleft hind paw (9 days) 
Model control Prednisone acetate WSD EEP 
1.10 1.15 1.35 1.20 
1.30 1.15 1.35 1.15 
1045 1.15 1.05 1.25 
1.00 1.25 1.00 1.20 
1.15 1.15 1.00 1.35 
1.20 1.05 1.10 1.20 
1.20±O.16 1.15±O.O6 1.14±O.17 l.22±O.O7 
(8) Cub age before inflammation ofleft hind paw (11 days) 
Model control Prednisone acetate WSD EEP 
1.15 lAO 1.30 1.00 
1.30 1.20 1.20 1.05 
1.20 1.20 1.05 1.20 
1.10 1.30 0.90 1.10 
1.00 1.10 1.00 1.05 
1.00 1.05 0.95 1.15 
1.13±O.12 1.21±O.13 l.07±O.lS l.O9±O.07 
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(9) Cub age before inflammation of left hind paw (13 days) 
Model control Prednisone acetate WSD EEP 
lAO 1.05 1.25 1.20 
1.30 1.25 l.l0 1.05 
l.l5 1.00 1.15 1.30 
1.00 1.00 1.25 lAO 
1.10 1.00 1.05 1.30 
1.20 1.30 l.l5 1.05 
1.19±O.14 1.10±O.14 1.16±O.OS 1.22±O.14 
(10) Cub age before inflammation of left hind paw (16 days) 
Model control Prednisone acetate WSD EEP 
0.95 l.l0 1.05 0.90 
1.00 0.90 1.25 0.95 
1.00 0.95 0.90 1.05 
1.10 0.95 1.00 1.30 
1.00 0.90 1.00 1.15 
1.05 0.85 1.00 1.10 
1.02±O.OS O.94±O.O9 1.03±O.12 1.0S±0.14 
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(11) Cub age before inflammation ofleft hind paw (19 days) 
Model control Prednisone acetate WSD EEP 
1.25 1.25 1.25 1.15 
1.25 1.25 1.25 1.00 
l.30 1.15 1.15 l.35 
1.45 1.00 1.25 1.25 
1.20 1.25 1.25 1.25 
l.35 1.00 1.20 l.30 
1.30±O.O9 1.15±O.12 1.23±O.O4 1.22±O.13 
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Table S.4: Effects of WSD and EEP on the levels of PGE2, IL-2, IL-6 and IFN""Y in 
the extravasate of FCA-induced arthritis rats 
(1) Normal control group 
PGEz 11.-2 (pg) IL-6 (pg) JFN- Y (pg) 
0.009 22.00 110 820 
0.010 22.70 80 860 
0.004 21.00 110 660 
0.022 25 .50 130 660 
0.012 10.80 100 690 
0.Dl1 16.50 110 710 
0.011 ±0.006 19.75±5.27 106.67 ± 16.33 733.33 ± 85.71 
(2) Model control group 
PGE, IL-2 (pg) 11.-6 (pg) IFN- Y (pg) 
0.050 10.70 90 570 
0.031 22.70 176 570 
0.063 11.50 106 760 
0.051 9.30 170 590 
0.042 9.40 120 600 
0.044 10.50 170 650 
0.047±0.011 12.35±5.14 138.67±37.80 623.33±73.12 
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(3) Prednisone acetate group 
PGE, IL-2 (pg) IL-6 (pg) IFN- Y (pg) 
0.017 12.50 60 630 
0.029 12.50 40 590 
0.028 25.00 80 500 
0.026 17.50 50 590 
0.046 19.00 106 590 
0.034 16.50 60 620 
O.030±0.010 17.17±4.67 66.00±23.66 586.67 ± 45.90 
(4) WSD group 
PGE, IL-2 (pg) IL-6 (pg) IFN- Y (pg) 
0.034 12.50 70 660 
0.035 9.80 90 690 
0.042 9.20 80 820 
0.036 12.00 90 620 
0.027 22.50 60 580 
0.030 21.50 80 800 
0.034 ± 0.005 14.58±5.89 78.33 ± 11.69 695.00 ± 96.69 
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(5) EEP group 
PGE, IL-2 (pg) IL-6 (pg) IFN- y (pg) 
0.040 17.80 80 520 
0.021 12.50 60 510 
0.027 10.30 80 570 
0.024 12.50 110 560 
0.026 20.70 110 610 
0.019 17.80 90 620 
0.026±0.007 15.27±4.06 88.33 ± 19.41 565.00 ± 45.06 
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Table 6.1: Effects of propolis on celiac capillary leakage in mice induced by acetic 
acid 
Nonna1 control Prednisne acetate WSD EEP 
0.600 0.557 0.571 0.446 
0.626 0.561 0.465 0.541 
0.544 0.547 0.328 0.606 
0.736 0.457 0.422 0.501 
0.673 0.586 0.626 0.546 
0.535 0.427 0.518 0.542 
0.739 0.492 0.643 0.511 
0.517 0.573 
0.6213±0.088 0.5181 ± 0.060 0.5104±0.114 0.5333 ± 0.048 
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Table 6.2: Effects of propolis on Carrageenan-induced hind paw oedema in rats 
(1) Normal paw cubage (ml) 
Model control Dexamethasone acetate WSD EEP 
0.95 1.20 1.20 1.30 
0.90 1.00 1.20 1.20 
0.85 1.15 1.00 1.30 
0.55 0.95 1.10 1.00 
1.10 1.25 1.25 1.30 
0.80 1.20 1.15 1.20 
1.00 0.90 1.00 1.30 
0.75 1.20 1.00 1.45 
O.863±O.169 1.106±O.135 1.113±O.103 1.256±O.129 
(2) Oedema degree (1 h) 
Model control Dexamethasone acetate WSD EEP 
0.10 0.20 0.15 0.00 
0.15 0.25 0.15 0.15 
0.20 0.20 0.05 0.15 
0.35 0.45 0.20 0.25 
0.00 0.05 0.05 0.30 
0.15 0.05 0.10 0.20 
0.45 0.50 0.00 0.15 
0.10 0.15 0.25 0.10 
O.188±O.146 O.231±O.167 O.119±o.o84 O.163±O.092 
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(3) Oedema degree (2 b) 
Model control Dexamethasone acetate WSD EEP 
0.50 0.20 0.25 0.15 
0.40 0.40 0.20 0.25 
0.65 0.45 0.35 0.35 
0.85 0.40 0.15 0.35 
0.65 0.10 0.15 0.20 
0.65 0.05 0.10 0.35 
0.55 0.45 0.45 0.05 
0.50 0.15 0.45 0.15 
O.S94±O.137 O.27S±O.167 O.263±O.138 O.231±O.113 
(4) Oedema degree (3 b) 
Model control Dexamethasone acetate WSD EEP 
0.50 0.15 0.20 0.25 
0.60 0.20 0.35 0.30 
0.65 0.15 0.45 0.35 
0.90 0.50 0.35 0.40 
0.70 0.20 0.10 0.40 
0.65 0.05 0.30 0.30 
0.70 0.25 0.45 0.15 
0.75 0.05 0.55 0.25 
O.681±O.116 O.194±0.143 O.344±O.14S O.300±O.O85 
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(5) Oedema degree (4 b) 
Model control Dexamethasone acetate WSD EEP 
0.75 0.25 0.20 0.05 
0 .65 0.10 0.35 0.20 
0.80 0.45 0.25 0.10 
1.00 0.35 0.30 0.25 
0.65 0.15 0.15 0.00 
0.85 0.30 0.45 0.05 
0.65 0.25 0.10 0.35 
0.80 0.45 0.15 0.05 
O.769±O.122 O.288±O.127 O.244±O.118 O.131±O.122 
(6) Oedema degree (5 b) 
Model control Dexamethasone acetate WSD EEP 
0.45 0.05 0.20 0.15 
0.45 0.05 0.30 0.10 
0.55 0.05 0.25 0.20 
0.85 0.25 0.15 0.40 
0.40 0.05 0.20 0.25 
0.65 0.00 0.25 0.15 
0.85 0.10 0.35 0.15 
0.65 0.00 0.35 0.10 
O.606±O.176 O.O69±O.O80 O.256±O.O23 O.188±O.O99 
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(7) Oedema degree (6 b) 
Model control Dexamethasone acetate WSD EEP 
0.45 0.05 0.05 0.10 
0.50 0.10 0.30 0.20 
0.65 0.10 0.40 0.10 
0.80 0.15 0.10 0.35 
0.45 0.10 0.15 0.20 
0.50 0.15 0.15 0.10 
0.55 -0.10 0.05 0.10 
0.45 0.10 0.20 0.15 
O.S44±O.124 O.O81±O.O80 O.175±O.122 O.163±O.O88 
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Table 6.3: Effects of propolis on pleurisy extravasate and leucocyte counts in rats 
(1) Normal control group 
Extravasate WEC Lymphocyte Neutrophils 
(mI) (X 10'. L· l ) (%) (%) 
0.10 5.80 45.00 55.00 
0.10 6.00 42.00 58.00 
0.10 5.80 46.00 54.00 
0.10 9.60 52.00 48.00 
0.10 6.00 41.00 59.00 
0.10 3.80 53.00 47.00 
0.10 15.00 51.00 49.00 
0.10 4.20 49.00 51.00 
O.IO±O.OO 7.03±3.66 47.38±4.57 52.63±4.57 
(2) Model control group 
Extravasate WEC Lymphocyte Neutrophils 
(mI) (X 10' • L· l ) (%) (%) 
2.10 33.20 8.00 92.00 
2.50 20040 17.00 83.00 
1.70 37.00 12.00 88.00 
2040 21.40 15.00 85.00 
1.70 39.80 23.00 77.00 
1.70 32.80 13.00 87.00 
1.80 24.20 18.00 82.00 
L99±O.35 29.83±7.77 15.14 ± 4.81 84.86 ± 4.81 
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(3) Prednisone acetate group 
Extravasate WBC Lymphocyte Neutrophils 
(mI) (X \0' • L-l ) (%) (%) 
1.70 18.00 26.00 74.00 
1.60 28.90 30.00 70.00 
1.60 27.00 31.00 69.00 
2.10 24.90 38.00 62.00 
2.20 21.70 33.00 67.00 
1.30 29.50 35.00 65.00 
1.20 24.40 20.00 80.00 
1.50 35.60 9.00 91.00 
1.40 20.80 27.00 73.00 
1.62±O.34 25.64±5.31 27.67±8.77 n .33±8.77 
(4) WSD group 
Extravasate WBC Lymphocyte Neutrophils 
(mI) (X 10'. L- l ) (%) (%) 
1.50 19.70 32.00 68.00 
1.50 14.00 21.00 79.00 
0.90 37.80 19.00 81.00 
0.90 15.20 29.00 71.00 
1.00 23.75 20.00 80.00 
0.70 21.95 29.00 71.00 
l.O8±O.34 22.07±8.58 25.00±5.62 75.00±5.62 
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(5) EEP group 
Extravasate WBC Lymphocyte Neutrophils 
(mI) ( X 10' • L-I) (%) (%) 
2.10 39.00 28.00 72 .00 
1.20 22.30 26.00 74.00 
1.90 27.90 21.00 79.00 
1.70 20.10 18.00 82.00 
1.00 30.70 33.00 67.00 
1.40 31.15 13.00 87 .00 
1.70 19.20 15.00 85.00 
2.00 23.35 32.00 68.00 
0.90 38.40 27 .00 73.00 
1.54±O.44 28.01 ± 7.42 23.67±7.25 76.33 ± 7.25 
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Table 6.4: Effects of propolis on the levels of total protein, NO and PGE2 in the 
pleurisy extravasate in rats 
(1) Normal control group 
Protein (gIL) NO (umoVL) PGEz (OD) 
5.00 3.72 0.003 
3.28 5.60 0.007 
3.24 9.10 0.005 
4.28 3.50 0.004 
2.67 6.20 0.004 
2.69 8.60 0.001 
3.S3±0.93 6.12±2.36 0.004 ± 0.002 
(2) Model control group 
Protein (gIL) NO (umoIlL) PGE,(OD) 
18.52 28 .28 0.193 
23.79 24.43 0.233 
24.89 35.99 0.194 
28.73 28.65 0.192 
18.92 33.52 0.182 
21.50 43.09 0.169 
22.73±3.89 32.33±6.68 0.194±0.021 
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(3) Positive control control group 
Protein (gIL) NO (umol/L) PGE,(OD) 
7.48 10.30 0.054 
12.30 22.78 0.075 
6.96 10.24 0.068 
12.37 11.96 0.126 
5.31 17.07 0.066 
13.05 16.95 0.066 
9.58±3.37 14.88±4.95 0.076±0.025 
(4) WSD group 
Protein (gIL) NO (umol/L) PGE,(OD) 
14.04 26.30 0.162 
14.40 19.51 0.189 
8.80 29.65 0.056 
14.82 28.79 0.068 
12.13 23.59 0.044 
17.67 23.06 0.027 
13.64±2.97 25.15±3.83 0.091 ± 0.067 
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(5) EEP group 
Protein (gIL) NO (urnoVL) PGE,(OD) 
11.96 16.16 0.118 
14.44 29.10 0.Q28 
17.42 18.52 0.040 
17.74 22.30 0.030 
13.16 12.94 0.071 
24.86 22.46 0.033 
16.60±4.65 20.25±5.67 0.053 ± 0.035 
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Table 6.5: Effects of propolis on the leucocyte count and lung index in rats with 
of acute lung injury 
(1) Normal control group 
WBC Neutrophils Lymphocyte 
Lung index (X 10'· L· ') ('!o) ('!o) 
0.9215 4.20 13 .00 87.00 
0.7748 4.00 11.00 89.00 
0.8466 6.00 16.00 84.00 
0.8858 6.00 30.00 70.00 
0.7763 7.80 9.00 91.00 
0.8274 4.80 24.00 76.00 
O.84±O.O6 5.47 ± 1.43 17.17±8.18 82.83±8.18 
(2) Model control group 
WBC Neutrophils Lymphocyte 
Lung index (XIO'. L·
'
) ('!o) ('!o) 
1.3666 11.20 52.00 48.00 
1.4835 12.00 61.00 39.00 
1.3094 10.80 56.00 44.00 
1.6376 10.60 62.00 38.00 
1.4013 9.60 51.00 49.00 
1.3876 12.00 69.00 31.00 
1.43±O.12 11.03±O.92 58.50±6.83 41.50±6.83 
194 
(3) Dexamethasone acetate group 
WBC Neutrophils Lymphocyte 
Lung index ( X 10' . L-l ) (%) (%) 
1.4216 6.00 31.00 69.00 
1.5349 5.60 73.00 27.00 
1.2209 4.80 68.00 32.00 
1.0008 3.80 56.00 44.00 
1.5379 7.00 33.00 67 .00 
1.1479 4.40 16.00 84.00 
1.31 ±O.22 5.27±l.16 46.17±22.83 53.83 ± 22.83 
(4) WSD group 
WBC Neutrophils Lymphocyte 
Lung index (X 10'. L- l ) (%) (%) 
1.2605 5.60 45.00 55 .00 
0.8308 6.40 28.00 72.00 
1.3123 5.20 47.00 53.00 
1.6152 6.20 53.00 47.00 
0.8353 7.00 22.00 78.00 
1.3171 6.20 25.00 75.00 
1.20±O.31 6.10 ± O.63 36.67±13.19 63.33 ± 13.19 
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(5) EEP group 
WBe Neutrophils Lymphocyte 
Lung index (XIO'· L· I ) (%) (%) 
1.3171 13.60 17.00 83.00 
1.3868 9.80 15.00 85.00 
1.0374 12.00 27.00 73.00 
1.3802 10.80 23.00 77.00 
1.0268 12.60 12.00 88.00 
0.7071 6.80 40.00 60.00 
L14±0.27 10.93±2.43 22.33 ± 10.23 77.67 ± 10.23 
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Table 7.1 : Effects of propolis solutions on tbe leucocyte count and lung index of 
acute lung injury in rats 
(See Table 6.5) 
Table 7.2: The activation ofNF-KB p65 in lung determines immuno-histochemically 
Normal control Model control Dexamethasone WSD EEP 
204 633 397 344 386 
226.5 655 402.5 289.5 345.5 
184 613 378 416 328.5 
189.5 664 362 369.5 301 
201 614 445 348 367 
149 660 356 315.5 280.5 
214 617 447.5 391 331 
174.5 630.5 404 301 246 
192.81±24.26 635.81 ±21.16 399.00±34.16 346.81 ±44.12 323.19 ± 45.86 
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Table 8.1 : Blood TC and TG (mmol/L) changes of hyperlipidemic rats for six weeks 
(1) Normal control group 
zero week 2nd week 4th week 6th week 
TC TG TC TG TC TG TC TG 
1.56 0.76 1.89 2.20 1.68 1.08 2.04 1.62 
1.92 1.03 1.60 1.73 0.98 0.96 1.49 1.44 
2.66 0.85 2.19 1.57 1.59 1.19 3.36 1.27 
2.17 0.77 2.18 1.45 1.50 1.18 2.55 1.56 
2.46 1.63 2.23 1.67 1.55 1.27 2.80 1.74 
2.01 1.40 1.79 1.36 1.47 1.69 2.56 1.17 
1.96 1.20 2.08 1.92 1.88 1.51 3.03 1.32 
2.23 1.13 1.86 2.23 1.54 0.82 2.70 1.95 
1.92 1.12 2.01 2.29 1.44 0.82 3.32 1.79 
2.01 1.09 1.78 1.94 1.44 1.14 2.44 1.42 
2.09±O.31 l.lO±O.27 1.96±O.21 1.84±O.33 I.SI±O.23 1.17±O.28 2.63±O.S7 I.S3±O.2S 
(2) Model control group 
zero week 2nd week 4'" week 6th week 
TC TG TC TG TC TG TC TG 
2.04 1.27 3.67 2.71 3.97 1.16 5.15 1.51 
2.00 0.56 3.61 3.27 3.91 1.61 5.83 2.82 
1.99 1.52 4.18 1.90 5.28 2.12 6.00 3.21 
2.48 0.83 3.35 2.23 5.52 1.58 7.94 2.85 
2.25 0.82 3.08 2.27 4.62 1.40 6.76 2.53 
2.19 0.90 4.06 3.11 4.34 2.56 7.51 4.38 
2.17 0.74 3.50 1.97 4.46 2.04 5.91 5.11 
1.72 1.14 3.02 1.99 3.56 1.48 4.77 2.27 
2.55 1.12 3.09 2.38 3.19 0.88 6.01 4.67 
2.20 1.21 3.96 3.61 3.56 1.84 4.80 2.58 
2.16±O.24 I.OI±O.29 3.SS±O.42 2.S4±O.60 4.24±O.76 1.67±O.49 6.07±1.07 3.19±1.l6 
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(3) Xuezhikang group 
zero week 2nd week 4th week 6'h week 
TC TG TC TG TC TG TC TG 
2.26 1.16 3.87 3.81 4.30 0.78 5.42 1.81 
2.32 1.09 3.07 2.42 2.66 1.04 5.05 2.04 
2.23 1.29 3.10 2.80 2.70 0.84 5.44 1.33 
2.15 1.10 3.51 2.65 4.00 1.32 5.63 1.57 
2.02 0.86 4.12 3.29 4.57 0.91 6.34 1.95 
2.00 1.12 3.50 2.44 2.40 1.20 2.48 1.09 
2.24 1.41 3.57 2.22 2.74 0.90 2.01 1.50 
2.05 1.02 4.03 4.00 3.21 0.80 2.90 0.92 
2.02 1.30 3.44 1.49 3.20 0.98 2.67 1.53 
2.14 1.15 4.01 3.82 3.48 0.74 4.22 1.53 
2.14±O.12 1.15±O.16 3.62±O.38 2.89±O.82 3.33±O.74 O.95±O.19 4.22±1.57 1.53±O.35 
(4) WSDl group 
zero week 2nd week 4th week 6th week 
TC TG TC TG TC TG TC TG 
1.87 1.01 3.77 2.32 3.41 1.07 4.93 3.11 
2.20 1.62 2.96 2.39 3.39 1.10 5.06 2.23 
1.93 1.87 3.28 2.60 4.46 1.70 5.34 3.74 
2.13 1.87 2.97 3.30 3.14 1.70 4.25 2.69 
2.40 0.86 3.64 3.29 3.81 1.67 5.22 1.96 
1.74 0.93 3.78 3.37 4.69 1.26 4.99 1.50 
2.31 1.07 3.42 3.08 3.26 0.84 4.98 2.46 
1.95 1.18 3.30 2.73 3.45 0.75 4.79 3.20 
2.06 1.45 3.38 3.06 3.39 1.70 4.41 1.74 
2.59 0.99 3.71 2.59 4.11 1.65 4.12 2.5\ 
2.12±O.30 1.29±O.39 3.42±O.31 2.87±O.39 3.71±O.54 l.34±O.38 4.81±O.41 2.51±O.70 
199 
(5) WSD2 group 
zero week 2nd week 4th week 61h week 
TC TG TC TG TC TG TC TG 
1.91 1.61 3.46 2.07 3.41 1.07 3.29 1.60 
1.77 0.65 3.84 2.57 3.39 1.\0 4.37 0.95 
1.90 1.23 2.95 2.37 4.46 1.70 3.92 0.74 
2.26 1.57 3.83 4.47 3.14 1.70 4.94 1.\9 
2.38 1.56 3.01 2.65 3.81 1.67 4.18 1.56 
1.83 1.23 3.12 2.06 4.69 1.16 4.07 3.17 
2.16 0.96 3.76 2.65 3.26 0.94 3.74 1.43 
2.39 1.18 3.74 4.02 3.45 0.95 5.43 1.63 
1.78 0.97 4.14 2.34 3.39 1.70 3.92 2.32 
2.38 0.65 2.63 1.82 4.11 1.65 3.87 2.46 
2.08±O.26 1.16±O.36 3.45±O.49 2.70±O.86 3.35±O.70 1.36±O.34 4.17±O.62 1.71±O.74 
(6) EEPI group 
zero week 2nd week 4'h week 6th week 
TC TG TC TG TC TG TC TG 
2.25 1.29 3.46 2.25 3.77 1.47 4.64 1.53 
2.18 1.\7 3.57 2.95 4.19 1.27 4.75 1.64 
2.66 1.27 3.51 2.39 2.83 0.77 4.07 0.82 
2.32 0.83 3.89 3.60 3.12 1.04 3.55 1.40 
2.11 1.34 3.31 2.07 3.58 1.63 3.75 1.98 
1.79 0.78 2.96 1.70 2.71 1.17 3.36 0.71 
2.17 0.86 3.19 3.25 3.14 1.20 4.18 0.54 
1.95 1.05 3.33 2.83 2.43 0.71 2.85 0.99 
2.40 1.21 3.79 2.36 3.52 1.27 4.58 0.68 
2.04 1.09 4.16 2.84 3.14 0.92 4.18 1.60 
2.19±O.24 1.09±O.20 3.52±O.35 2.62±O.57 3.24±O.53 1.15±O.29 3.99±O.61 1.19±O.50 
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(7) EEP2 group 
zero week 2"" week 4'" week 6th week 
TC TG TC TG TC TG TC TG 
1.84 0.96 3.21 2.89 3.66 1.19 4.27 1.80 
1.92 0.91 3.95 2.14 3.36 1.02 5.01 1.66 
1.82 1.30 3.43 2.40 3.12 1.01 3.46 1.53 
1.87 0.81 3.57 2.09 3.14 1.24 4.56 1.19 
2.24 1.51 3.55 2.97 3.53 1.29 4.17 1.10 
1.98 1.15 3.39 2.75 3.79 1.68 4.84 1.61 
2.24 1.39 3.60 3.15 3.77 0.87 3.13 0.82 
2.21 0.64 2.91 2.24 2.93 1.12 3.18 0.76 
2.01 0.81 3.08 3.01 2.63 0.83 2.80 1.76 
1.86 1.18 4.41 2.90 3.42 1.02 3.82 1.02 
2.00±O.17 1.07±O.28 3.51±O.43 2.65±O.40 3.34±O.38 1.13±O.24 3.92±O.77 l.33±O.39 
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Table S.2: Effects of propolis on HDL-C, LDL-C and AS in hyperlipidemic ratss 
(1) Normal control group 
HDL-C (mmollL) LDL-C (mmollL) AS 
2.67 1.27 0.58 
1.37 0.82 0.47 
2.64 0.93 0.66 
2.17 0.93 0.58 
2.73 1.28 0.30 
1.62 1.29 0.64 
2.36 1.33 0.51 
2.33 1.34 0.69 
1.95 0.91 0.83 
2.13 0.80 1.03 
2.20±O.4S l.O9±O.23 O.63±O.20 
(2) Model control group 
HDL-C (mmollL) LDL-C (mmollL) AS 
1.56 2.43 2.30 
0.76 2.49 6.67 
1.51 2.54 2.97 
1.29 3.66 5.16 
1.32 3.75 4.12 
1.52 4.00 3.94 
1.17 2.55 4.05 
0.98 2.58 3.87 
1.01 3.02 4.95 
1.31 2.28 2.61 
1.24±O.26 2.93±O.64 4.06±1.30 
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(3) Xuezhikang group 
HDL-C (mrnol/L) LDL-C (mrnollL) AS 
1.56 2.30 2.57 
0.76 2.35 2.50 
1.51 2.97 2.33 
1.29 2.46 1.76 
1.32 2.96 2.35 
1.52 1.15 1.03 
1.17 0.80 2.07 
0.98 1.39 3.26 
1.01 1.25 3.93 
1.33 1.96 1.88 
1.25±O.26 1.96±O.77 2.37±O.80 
(4) WSDl group 
HDL-C (mrnoUL) LDL-C (mrnollL) AS 
1.47 2.44 2.18 
1.05 2.56 1.84 
1.17 2.73 2.79 
1.77 2.25 2.00 
1.55 2.43 2.73 
2.13 2.56 2.01 
1.61 2.24 2.30 
1.01 2.34 2.07 
1.34 2.48 1.51 
1.46 2.00 1.86 
1.46±O.34 2.40±O.21 2.13±O.39 
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(5) WSD2 group 
HDL-C (mmol/L) LDL-C (mmollL) AS 
1.18 1.31 1.15 
1.50 1.91 2.26 
0.93 1.85 1.88 
1.62 2.16 2.53 
1.12 2.16 1.42 
1.56 2.18 2.36 
2.58 1.91 1.94 
1.26 2.63 2.72 
1.89 2.41 1.39 
1.67 1.76 2.62 
1.S3±O.47 2.O3±O.37 2.03±O.S6 
(6) EEPl group 
HDL-C (mmoIlL) LDL-C (mmollL) AS 
1.46 2.09 2.18 
3.17 2.37 2.26 
0.85 1.32 3.79 
1.54 0.86 1.31 
1.52 1.66 1.47 
1.07 1.09 2.14 
1.36 1.10 2.07 
-
0.74 0.90 2.75 I 
1.43 1.92 2.20 
0.80 1.39 4.23 
1.39±O.70 1.47±O.S2 2.44±O.93 
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(7) EEP2 group 
HDL-C (mmollL) LDL-C (mmollL) AS 
0.80 1.74 4.34 
1.68 2.57 1.98 
1.14 0.93 2.04 
1.30 1.95 2.51 
1.27 1.90 2.28 
1.10 2.48 3.40 
1.25 0.99 1.50 
1.68 1.38 2.12 
2.02 0.74 2.12 
1.36 1.52 1.84 
1.36±O.35 1.62±O.63 2.41±O.84 
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Table 8.3: Effects of propolis on body weight, liver weight, liver index, TC and 
TG in liver, GPT and GOT in serum of hyperlipidemic rats 
(1) Normal control group 
TC TG GPT GOT Body weight Liver weight 
Liver index (mmoUL) (mmollL) CUlL) (UIL) (g) (g) 
0.44 1.16 26 38 394 7.92 1.97 
0.44 1.20 32 36 371 7.02 1.88 
0.26 1.02 29 51 398 6.94 2.29 
0.23 0.92 26 33 301 9.02 2.37 
0.31 0.89 35 66 339 8.81 2.73 
0.23 0.92 28 45 372 6.24 1.98 
0.35 1.27 25 36 353 7.93 1.83 
0.29 1.01 35 50 339 8.34 2.37 
0.44 1.25 27 38 362 7.14 2.28 
0.34 1.14 34 49 355 8.11 1.88 
O.33±O.O8 1.08±O.14 29.7±3.9 44.2±lO.1 358,4±28.4 7.75±O.89 2.16±O.29 
(2) Model control group 
TC TG GPT GOT Body weight Liver weight 
Liver index 
(mmoUL) (mmoUL) (UIL) (UIL) (g) (g) 
2.56 3.63 63 58 419 17.80 4.47 
1.71 2.35 62 70 430 17.94 3.48 
1.47 2.05 47 85 449 15.25 3.70 
2.31 3.43 88 81 433 17.33 4.31 
2.11 3.18 86 73 448 14.72 3.91 
2.18 3.26 72 53 472 16.65 3.76 
1.37 1.92 71 89 404 15.65 3.89 
2.31 3.12 70 62 475 17.57 3.11 
2.36 3.20 63 72 401 15.03 3.60 
2.04 2.90 70 71 448 16.22 3.23 
2.04±O,40 2.90±O.59 69.2±11.9 71.4±1l.5 437.9±25,4 16,42±1.21 3.75±O,43 
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(3) Xuezhikang group 
TC TG GPT GOT Body weight Liver weight 
Liver index (mmol/L) (mmollL) (UIL) (UIL) (g) (g) 
2.31 2.40 43 66 380 10.86 2.96 
2.29 3.26 52 60 417 13.46 2.92 
0.93 1.81 45 45 406 11.81 2.97 
2.88 3.83 42 89 376 10.21 2.46 
1.45 1.98 40 31 451 11.45 2.66 
1.80 3.09 27 58 394 10.74 3.01 
1.95 2.61 25 71 402 11.89 2.42 
0.75 2.26 25 40 461 11.57 2.44 
1.92 2.27 31 59 410 11.02 3.32 
1.92 2.61 39 58 411 10.05 2.34 
1.82±O.64 2.61±O.62 36.9±9.4 57.7±16.4 410.8±27.3 1l.31±O.98 2.75±O.33 
(4) WSDl group 
TC TG GPT GOT Body weight Liver weight 
Liver index (mmol/L) (mmollL) (UIL) (UIL) (g) (g) 
1.13 2.12 69 40 458 17.75 3.72 
2.07 3.07 50 45 471 14.71 3.66 
1.77 2.87 62 41 412 14.76 3.21 
1.58 2.04 64 54 481 17.70 2.87 
1.35 2.41 74 46 428 13 .66 3.91 
1.46 2.62 52 44 380 15.32 3.57 
2.40 3.65 43 38 452 13 .79 3.36 
1.16 2.02 56 41 386 14.92 4.50 
1.24 1.94 54 45 412 16.61 3.22 
2.12 2.35 40 36 462 15.40 3.56 
1.63±O.44 2.51±O.55 56.4±lO.9 43.0±5.1 434.2±35.7 15.46±1.45 3.56±O.45 
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(5) WSD2 group 
TC TG GPT GOT Body weight Liver weight 
Liver index (mmollL) (mmollL) (OIL) (UIL) (g) (g) 
1.49 2.17 37 33 413 16.43 3.44 
1.22 1.64 53 34 388 16.33 3.48 
1.49 2.49 53 35 429 15.31 3.70 
1.17 2.07 55 41 415 17.82 4.42 
1.56 2.91 50 78 400 14.72 3.96 
1.46 2.Q4 48 32 435 13.18 3.76 
1.75 2.71 38 28 419 15.65 3.89 
1.56 2.85 30 47 425 14.26 3.11 
1.32 1.99 43 41 467 14.49 3.60 
1.02 1.97 56 42 397 14.66 3.18 
1.40±O.22 2.28±O.43 46.3±8.9 41.1±14.2 418.8±22.5 15.29±1.32 3.65±O.39 
(6) EEPI group 
TC TG GPT GOT Body weight Liver weight 
Liver index (mmollL) (mmollL) (OIL) (OIL) (g) (g) 
1.26 1.79 33 34 435 13.99 3.51 
1.10 2.05 43 32 406 11.79 3.55 
1.86 2.18 26 42 390 15.03 3.04 
1.26 2.09 32 39 413 14.17 2 .88 
1.30 1.68 35 47 408 13.11 3.41 
1.25 2.25 47 33 409 14.92 3.46 
2.09 3.13 32 37 424 14.35 3.96 
2.01 3.05 35 31 409 13.55 3.60 
1.72 3.01 36 26 380 14.05 3.40 
2.12 2.66 34 35 428 14.56 3.16 
1.60±O.40 2.39±O.53 35.3±5.9 35.6±6.0 410.2±16.6 13.95±0.96 3.40±0.3\ 
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(7) EEP2 group 
TC TG GPT GOT Body weight Liver weight 
Liver index (mmoIlL) (mmollL) (UIL) (UIL) (g) (g) 
1.76 2.27 21 31 440 14.23 2.55 
0.95 1.99 38 33 373 10.97 3.40 
1.62 2.74 41 35 443 13.88 3.11 
1.94 2.30 41 34 365 13.21 2.48 
2.13 2.31 40 36 43 1 11.19 2.75 
1.62 2.06 34 32 408 11.56 3.13 
1.82 3.28 33 55 428 12.19 3.38 
2.01 2.16 34 54 367 11.69 3.40 
1.22 2.49 31 38 404 11.85 3.04 
1.67 2.40 27 38 407 12.60 3.04 
1.67±O.36 2.40±O.38 34.0±6.S 38.6±8.7 406.6±29.7 12.34±1.12 3.03±O.34 
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Table 8.4: Effects of propolis on MDA, SOD and NO in serum and MDA in livers 
of hyperlipidemic rats 
(1) Normal control group 
MDAin liver MDA in serum SOD NO 
(nrnollmg prot) (nrnollrnL) (NO/rnL) (UmoIlL) 
174.87 6.88 130.6 8.43 
169.21 8.49 134.7 7.86 
200.36 8.30 125.4 7.04 
198.31 8.45 127.9 11.27 
166.90 7.75 127.5 6.25 
171.43 10.15 125.7 9.73 
161.2 8.04 123.6 6.61 
189.24 8.31 135.4 9.48 
177.61 8.85 141.7 4.29 
190.63 7.42 141.5 7.02 
179.9±13.7 8.26±O.88 131.4±6.6 7.80±2.0 
(2) Model control group 
MDAinliver MDA in serum SOD NO 
(nmollmg prot) (nrnollrnL) (NO/rnL) (UmoIlL) 
207.12 9.39 115.5 14.75 
253.46 10.31 144.0 10.05 
236.41 14.10 113.4 18.49 
234.50 12.12 121.3 18.02 
232.14 12.08 110.8 10.56 
245.63 11.75 121.7 12.22 
219.45 11.38 116.8 22.18 
239.62 11.39 119.9 11.92 
233 .61 11.21 116.4 18.34 
223.37 11.49 116.2 18.42 
232.S±13.2 1l.S2±1.23 119.6±9.2 lS.S±4.1 
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(3) Xuezhikang group 
MDAin liver MDAinserum SOD NO 
(nmoVmg prot) (nmoVmL) (NU/mL) (UmoVL) 
236.12 10.43 120.2 16.89 
235.70 14.81 121.5 22.31 
213.60 12.43 130.0 19.31 
246.10 14.60 123.3 25.08 
217.30 14.11 117.8 20.02 
203.54 12.59 114.4 20.44 
231.01 12.40 100.3 18.56 
245.20 11.30 118.0 23.90 
213.17 11.58 109.5 26.27 
189.43 11.58 110.0 20.20 
22S.3±17.6 12.S8±1.48 116.S±8.4 21.3±3.0 
(4) WSDl group 
MDAin liver MDAin serum SOD NO 
(nmoVmg prot) (nmoVmL) (NU/mL) (UmoVL) 
236.12 11.45 116.5 20.06 
235 .70 12.31 128.2 19.04 
213.60 12.66 96.7 13.78 
246.10 12.31 117.8 15.83 
217.30 10.54 112.0 15.03 
203.54 10.87 110.7 13.87 
231.01 14.10 125.6 13.83 
245.20 12.45 104.8 12.34 
213.17 8.63 139.6 11.76 
189.43 11.70 114.1 27.44 
223.1±18.7 11.70±1.47 116.6±12.2 16.3±4.7 
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(5) WSD2 group 
MDAin liver MDAinserum SOD NO 
(nmoVrng prot) (nmoVrnL) (NU/rnL) (UrnoVL) 
203.56 9.46 120.4 18.41 
213.45 14.26 119.5 23 .04 
189.10 12.56 119.2 16.47 
229.30 9.95 131.5 22.05 
226.31 12.03 118.3 17.61 
198.32 14.11 123.2 13.62 
224.16 7.88 124.6 19.71 
239.40 11.31 129.1 18.09 
183.45 12.42 123.2 11.99 
201.11 10.53 125.0 20.04 
210.8±18.6 1l.45±2.04 123.4±4.3 18.1±3.4 
(6) EEPI group 
MDAin liver MDAinserum SOD NO 
(nmoVrng prot) (nmoVrnL) (NU/rnL) (UrnoVL) 
237.81 9.66 101.4 6.49 
213.45 10.41 130.6 23.76 
228.90 12.89 121.6 14.58 
212.45 12.16 122.5 12.90 
226.30 11.70 128.7 14.41 
237.89 7.98 122.1 14.84 
189.31 10.87 127.9 14.03 
197.2 10.62 122.4 25.58 
223.41 9.64 122.5 15.97 
169.31 9.50 118.3 19.47 
213.6±22.3 10.54±1.45 121.8±8.1 16.2±5.5 
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(7) EEP2 group 
MDAin liver MDAinserum SOD NO 
(nmollmg prot) (nmollmL) (NU/mL) (UmoliL) 
213 .5 9.99 102.7 18.41 
214.21 10.22 125.8 19.48 
188.47 10.5 121.6 16.47 
239.12 11.89 122.5 11.82 
229.4 12.02 121.8 17.61 
212.31 12.24 122.1 12.62 
193.70 11 .26 125.1 19.71 
224.13 10.19 122.4 18.09 
207.23 13.21 131.9 12.49 
227.35 11.28 119.1 20.34 
214.9±lS.8 1l.28±1.06 121.S±7.S 16.7±3.2 
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Table 9.2: Effects of propolis extracts on S180 tumor growth in mice 
Average tumor weight (g) 
Model control 95% EEP 80% EEP 
1.2796 0.5487 0.4102 
1.2303 0.5489 0.4322 
1.3069 0.4879 0.4189 
1.2563 0.5973 0.4356 
1.3120 0.6833 0.4008 
1.2341 0.5392 0.4129 
1.2794 0.5484 0.3861 
1.2572 0.5873 0.4097 
1.2383 0.5480 0.4109 
1.2302 0.4870 0.4036 
WSD 
0.2488 
0.2375 
0.2309 
0.2580 
0.2433 
0.2429 
0.2451 
0.2344 
0.2422 
0.2434 
1.262±0.031 0.558 ± 0.057 0.412±0.014 0.243 ± 0.008 
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Table 9.3: Effects of propolis extracts on the weight of granuloma in mice 
Weight of granuloma (mg): 
Model control Prednisone acetate WSD 80%EEP 
34.91 20.58 20.11 24.76 
33.05 20.61 21.29 25.90 
34.96 22.92 20.96 23.74 
35.06 22.54 21.34 22.89 
34.45 22.45 19.70 25.56 
37.58 20.91 21.04 23.81 
32.57 19.81 22.53 28.97 
35.55 19.70 22.65 24.41 
34.82 21.09 22.81 25.69 
34.01 20.67 19.91 24.93 
34.11 21.44 20.64 20.09 
35.79 21.32 21.77 26.85 
34.738±1.300 21.170±1.030 21.229 ± 1.058 24.800 ± 2.180 
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Table 9.4: Effects of propolis solutious on edema of the right hind paw of rats 
induced by Carrageenan. 
(See table 6.2) 
Table 9.5: Effects of propolis on pleurisy extravasate and leucocyte counts in rats 
(See table 6.3) 
Table 9.6: Effects of propolis on the levels of total protein, NO and PGE2 in the 
pleurisy extravasate in rats 
(See table 6.4) 
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